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Chapter  
1.1 
 
 
 
Introduction to the thesis 
 
 
 
In 1892, Arnold Pick described the first patients with a clinical syndrome that is currently 
named frontotemporal dementia (FTD).1 He emphasised the focal aspect of cortical 
atrophy in his patients, to this day the hallmark of this disorder. Following a detailed 
description of the neuropathological changes by Alois Alzheimer in 1911,2 including the 
argyrophilic neuronal inclusions later known as Pick bodies, the term Pick’s disease was 
introduced in 1926.3 Over the years, many different names have been used to describe 
this clinical and pathological entity: frontal lobe dementia,  dementia of non-Alzheimer 
type, dementia of frontal lobe type, Pick’s disease, and others. In 1994, the term FTD 
was introduced to describe the clinical syndrome associated with focal frontotemporal 
degeneration,4 with semantic dementia and primary progressive aphasia being 
recognised as clinical variants of FTD.5 Typical features of this syndrome, which often 
presents with a presenile onset, are progressive behavioural changes and language 
disturbances. FTD can be caused by a number of neuropathological substrates, 
including Pick’s disease, which is currently defined by the presence of argyrophilic Pick 
bodies.6 
In 1994, a genetic-epidemiological study on FTD was started at the Erasmus MC of 
Rotterdam. The main research questions addressed in this study are the estimation of the 
prevalence of FTD in the Netherlands, the clinical aspects of the temporal variant of 
FTD, and further elucidation of the genetic and other risk factors involved in the 
aetiology of FTD. 
Chapter 1.1 
4 
After an introduction to FTD in general (chapter 1.2) and familial FTD in particular 
(chapter 1.3), epidemiological findings are presented in chapter 2. Results of the 
genetic-epidemiological study are given in chapter 2.1, concerning a total of 245 FTD 
patients identified between January 1994 and June 2002. Emphasis is placed on the 
prevalence of FTD in the province Zuid-Holland, results of genetic analyses, and 
pathological findings in a subgroup of 40 autopsied patients. In chapter 2.2, a case-
control study is reported regarding medical and environmental risk factors of sporadic 
FTD, in which 80 patients with sporadic FTD were compared with 124 age, sex, and 
surrogate informant matched controls. In chapter 3 characteristics of patients with the 
temporal variant of FTD are explored. Chapter 3.1 reports on the presence of complex 
compulsive behaviour in patients with the temporal variant of FTD, while in chapter 3.2 
the apolipoprotein E genotype is related to the distribution of atrophy in a group of 111 
FTD patients. The role of the tau gene in familial FTD is investigated in chapter 4. Two 
novel tau mutations are reported (chapters 4.1 and 4.2), with detailed description of the 
clinical features, neuropathology, biochemical analyses and functional studies. In 
chapter 4.3 we investigated the co-occurrence of amyloid pathology in a subgroup of 
FTD patients with tau mutations, while in chapter 4.4 we measured the levels of tau and 
amyloid protein in cerebrospinal fluid of nine FTD patients with tau mutations. Finally, in 
chapter 5.1 a large pedigree of FTD patients is presented which shows genetic linkage 
to the tau containing region on chromosome 17, but no mutations in the tau gene. 
Neuropathologically, this family is characterised by tau-negative, ubiquitin-positive 
inclusions, suggesting a different aetiology of FTD in this family compared with families 
with tau mutations. In the last chapter the main findings of this study are presented and 
the possible implications are discussed.   
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Chapter  
1.2 
 
 
Frontotemporal dementia 
 
 
 
 
 
 
Abstract 
Frontotemporal dementia (FTD) is a neurodegenerative disorder characterised by 
progressive behavioural disturbance, aphasia, and a decline in frontal cognitive 
functions. Frontotemporal atrophy on CT and MRI, as well as hypoperfusion of the 
frontal brain regions on single-photon emission computed tomography (SPECT), are 
characteristic findings. Neuropathological examination reveals deposition of abnormally 
phosphorylated tau protein in neurons and glialcells in a number of the sporadic and 
familial cases, while aspecific changes with neuronal loss, spongiosis and gliosis are 
found in the remaining cases. A familial form with an autosomal dominant pattern of 
inheritance is seen in about 20 percent of patients. Mutations in the tau gene have been 
identified in a number of these FTD families, with deposition of abnormal tau protein in 
affected brain regions. Presymptomatic DNA-testing is now available for relatives of 
patients with tau mutations, and must only be considered after extensive genetic 
counselling. 
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rontotemporal dementia (FTD) is a neurodegenerative disorder, characterised 
by progressive behavioural changes and disturbance of language and frontal 
functions. Memory problems are not prominent at the initial stage. Clinical 
discrimination of FTD from the much more common Alzheimer’s disease has 
been facilitated due to the introduction of clinical criteria according to the Lund-
Manchester Groups.1 A correct diagnosis is important, as the clinical presentation and 
course of the disease require a different approach to both patient and partner than in 
Alzheimer’s disease.2 
The prevalence, aetiology, and clinical and pathological heterogeneity of FTD have 
been the object of extensive research over the past few years. Primary progressive 
aphasia (PPA) and semantic dementia (SD) can be differentiated from FTD clinically, but 
show similar neuropathological characteristics, suggesting a common cause. Therefore, 
in this chapter we will use the term FTD to describe all clinical variants of this 
neuropathological spectrum. The identification of the responsible genetic defect for the 
hereditary form of FTD has led to more insight into the pathophysiological background 
of a whole group of neurodegenerative disorders, the tauopathies. Furthermore, 
presymptomatic testing is now available, and it is important that extensive genetic 
counselling is offered to all at-risk individuals.  
 
Prevalence and familial clustering of FTD 
The prevalence of FTD is estimated to be 10 to 20 percent of all presenile dementias.3 
In 1998, a preliminary epidemiological study of FTD in the Netherlands estimated the 
prevalence of FTD to be 1 per 100.000 at the age 50 to 60 years, and 3 per 100.000 
at age 60 to 70 years.4 Subsequent research has shown that the prevalence of FTD is 
probably 2 to 3 timer higher than previously suspected (chapter 2.1). It probably 
concerns 25 to 50 new patients every year. PPA and SD are substantially less common, 
although exact figures are not known. A familiar form of FTD with an autosomal 
dominant pattern of inheritance is seen in about 20% of patients, with dementia also 
being present in affected relatives at a similar age and with a similar clinical 
manifestation.5 
 
Clinical symptoms 
The disease usually starts between age 40 to 60 years, with a clear peak in incidence 
between ages 50 to 60. The disease duration varies between 5 to 15 years.1,6 Typical is 
the onset with disinhibited behaviour. Roaming, impatience and gluttony are also 
important symptoms.  
F 
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Table 1. Clinical criteria for FTD, PPA en SD1 
 
 
Features common to all clinical syndromes 
 
• Insidious onset and gradual progression* 
• Onset before 65 years 
• Positive family history of similar disorder in first degree relatives 
• Motor neurone disease 
 
Core diagnostic features per clinical syndrome:* 
 
- Frontotemporal dementia  
• Early decline in social interpersonal conduct 
• Early decline in regulation of personal conduct 
• Early emotional blunting 
• Early loss of insight 
 
- Primary progressive aphasia 
Non-fluent spontaneous speech with at least one of the following:  
• Agrammatism 
• Phonemic paraphasias 
• Anomia 
 
- Semantic dementia 
• Language disorder characterised by: 
- progressive, fluent, empty sponaneous speech 
- loss of word meaning (impaired naming and comprehension) 
- semantic paraphasias, and/or 
• Perceptual disorder charachterised by: 
- prosopagnosia (impaired recognition of faces) 
- associative agnosia (impaired recognition of objects) 
 
Diagnostic exclusion criteria 
 
• Abrupt onset with ictal events 
• Head trauma related to onset 
• Early, severe amnesia 
• Spatial disorientation 
• Logoclonic, festinant speech with loss of train of thought 
• Myoclonus 
• Corticospinal weakness 
• Cerebellar ataxia 
• Choreoathetosis 
 
* Criteria necessary for diagnosis 
Chapter 1.2 
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However, other executive and behavioural modalities that may not be regarded as 
suspect for FTD, can be affected.7-10 Initiative loss with self-neglect and diminished 
attention for surroundings are often the only initial symptoms, and may be unjustly 
interpreted as a depression. Other patients show obsessive-compulsive behaviour with 
continuous specific activities (making jig-saw puzzles, counting, collecting) or fixation on 
certain ideas.7 Schizophrenia may be considered as an initial diagnosis, until cognitive 
decline becomes evident and the correct diagnosis is made.8,9 Artistic talent, such as 
remarkable drawing or painting efforts, may arise in some patients with bitemporal 
atrophy.10 Diminished emotional response to major life-events (death of a close relative, 
birth of grandchild) may sometimes lead to painful situations for spouses and unjustly 
lead to a referral for psychotherapy. 
Within the recently defined clinical consensus criteria (Table 1), the decline in social and 
personal conduct, emotional bluntness, and loss of insight are obligatory features for the 
diagnosis FTD.1 PPA is characterised by non-fluent spontaneous speech, with 
agrammatism, phonemic paraphasias and naming difficulties,1,11 while a fluent, but 
empty spontaneous speech with loss of comprehension, semantic paraphasias and 
perceptual agnosia  is seen in patients with SD.1,12 
 
Psychometric evaluation 
The pattern of cognitive disturbances characteristic for FTD has become clear over de 
past decade.6 Insufficient attention, lack of self-control and impulsive behaviour upon 
formal testing are typical features of frontal dysfunction. A decreased wordfluency 
(naming of animals etc.), diminished abstract thinking (concrete thinking or inability to 
explain proverbs), as well as mental inflexibility are prominent in the early stages of the 
disease. The relatively intact orientation and memory functions, and the spared visuo-
spatial abilities help differentiate FTD from Alzheimer’s disease.  
 
Imaging 
Focal atrophy of the frontal and temporal lobes is characteristic for this disorder (Figure 
1),1 and is usually most severe frontally. The atrophy is asymmetric in about 30% of 
patients and increases dramatically within a few years. Temporal atrophy predominates 
in patients with SD and PPA, and is more often asymmetric (up to 70%).11,12  Structural 
imaging (CT or MRI) is still normal at presentation in about 10% of patients. Clinical 
experience has taught us that hypoperfusion of the frontotemporal cortex using Single 
Photon Emission Computed Tomography (SPECT) is seen in FTD patients at the earliest 
stage.13 
Introduction to FTD 
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Figure 1. Brain of a FTD patient with focal frontal atrophy   
 
 
Neuropathological classification of FTD 
Neuronal loss, gliosis and spongiosis of the superficial layers of the frontotemporal 
cortex are characteristic for FTD, as well as PPA and SD. These changes may vary in 
distribution and severity over the frontal or temporal cortices. Neuropathologically, FTD 
may be divided into three subtypes regarding the presence and type of deposition of 
abnormally phosphorylated tau protein:14-17  
- Pick’s disease: is a histopathological diagnosis that may only be made in the 
presence of numerous tau protein-containing Pick bodies in the cortex, hippocampus 
and different subcortical nuclei. This group also comprises about 20% of the total FTD 
group (Figure 2A)14 
- Familiar FTD with tau pathology:  present in about 15-20% of cases and 
characterised by deposition of abnormally hyperphosphorylated tau protein in neurones 
(ranging from pretangles, to neurofibrillary tangles and Pick-like bodies) and 
occasionally in the glial cells (Figure 2B).15-17  
- FTD without tau deposition: is seen in about 60% of cases. It often concerns 
sporadic cases, but familial cases without detectable tau mutations have been described. 
In some cases ubiquitin-positive inclusions are found in the second layer of the 
frontotemporal cortex and dentate gyrus of hippocampus (Figure 2C).14,16  
The interrelation between the clinical, neuropathological and genetic findings is 
schematically represented in Figure 3. 
Chapter 1.2 
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Figure 2. Neuropathology in FTD 
 
A. Classical Pick’s disease with Pick bodies. B. Tau pathology in a FTDP-17 brain 
(S320F mutation). C. FTD with ubiquitin-positive inclusions (Immunohistochemistry with 
AT8 tau antibody in A and B, ubiquitin antibody in C). 
 
Genetic factors 
Since 1998, numerous different mutations have been found in the gene for the 
microtubule-associated protein tau in patients with familial FTD;18-24 this protein is of 
importance to the stability of neuronal cells. Genotype-phenotype studies have shown 
that the onset age in most tau mutations is between 40 and 60 years, although specific 
mutations may lead to a more severe phenotype with onset ages of around 30 years.21,22 
The presence of early parkinsonism, epileptic seizures, and corticobasal degeneration is 
also associated with specific mutations.21-23 The genetic cause for a number of FTD 
families without tau mutations still remains unclear, as tau-negative, ubiquitin-positive 
inclusions are the only characteristic neuropathological feature.5,23,25 A single family of 
Danish descent has shown genetic linkage to a locus on chromosome 3.26 Future 
research will be focussed on the identification of different genetic loci and the 
responsible genetic defect on chromosome 3. 
Because the tau deposits are considered to play a central role in the aetiology, the term 
“tauopathy” was introduced. Abnormal deposition of tau protein is also found in brains 
of patients with other neurodegenerative disorders, such as Alzheimer’s disease, 
Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration. These disorders 
differ neuropathologically by the distribution and type of tau deposition. The responsible 
genetic factors and pathophysiological mechanisms behind these disorders are not yet 
fully understood, although genetic studies have shown that the tau gene is probably also 
implicated in the pathogenesis of  PSP.27 
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Figure 3. Relationship between clinical manifestation of FTD, autosomal 
dominant inheritance, and tau deposition at neuropathology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. Sporadic forms of FTD without tau pathology. B. Sporadic FTD with tau-positive Pick 
bodies (Pick’s disease) C. Hereditary forms of FTD with tau pathology (FTDP-17 patients 
with mutations in the tau gene). D. Hereditary forms of FTD without tau pathology 
(familiar FTD with or without ubiquitin positive inclusions). E. Other tauopathies with 
autosomal dominant inheritance, such as rare cases of familial PSP. F. Other sporadic 
neurodegenerative disorders with tau pathology, such as Alzheimer’s disease and PSP. 
 
Genetic counselling and presymptomatic testing 
The identification of the responsible genetic defect in a number of families with  FTD has 
enabled presymptomatic testing in at-risk relatives. Many family members have been 
aware of the hereditary character of the disease and their personal risks for many years. 
Fear of developing the disease and preoccupation with onset of the first symptoms may 
become a constant preoccupation for these at-risk individuals.28  Sometimes relatives of 
FTD patients want to know the risk of an hereditary form of FTD in order to make 
important life decisions.  When asked as to the hereditary nature of the disorder, a well-
informed family history is essential. Information on diseases, cause of and age at death 
of all first and, if possible, second degree family members must be obtained. If a familiar 
form of FTD is suspected, it is important to refer both patient and family to a centre for 
clinical genetics or to a neurological centre with expertise in neurogenetic disorders. 
  FTD 
 
 A 
 
 
 
       D            B 
               C 
 
                E        F 
 
 
Autosomal 
dominant  
disorders 
Tau 
Pathology  
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Patient management 
There are currently no therapeutic options for patients with FTD, only pharmaceutical 
intervention for disturbing behavioural problems is possible. Over the past years, the 
burden for caregivers has been the focus of much research.29,30 The severity of 
behavioural problems of FTD patients appears to lead to a considerable increase of the 
burden for caregivers (usually the spouse), with education, ability to express emotions, 
social structure and the premorbid relationship with the patient as important 
determinants. Family members of FTD patients often have an exceptional need for 
accurate information on this relatively rare disorder, as well as advice regarding the best 
way to approach the behavioural problems of the patient. A common problem is the 
total lack of insight and refusal of care by the patient, to the despair of the family. 
Hopefully, future research will characterise the specific problems of caregivers, making 
interventions and practical solutions possible to diminish the caregiver burden. 
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Abstract 
The identification of tau mutations in frontotemporal dementia and parkinsonism linked 
to chromosome 17 (FTDP-17) has revealed invaluable information regarding the role of 
the tau protein in neurodegenerative disease. Over the past year, several new mutations 
have been identified, and experimental studies have provided more insight into the 
mechanism of neurodegeneration due to tau mutations and possible interactions with 
amyloid pathology. Extensive clinical and pathological variation is seen in patients with 
different types of mutations, as well as in patients with the same mutation. Mutations 
may be found in patients with frontotemporal dementia (FTD), parkinsonism, progressive 
supranuclear palsy (PSP) , and corticobasal degeneration, justifying mutation analysis in 
familial cases of these disorders. Genetic heterogeneity exists in FTD, because a number 
of FTDP-17 families have neither tau mutations nor tau pathology. Genetic linkage has 
been found in familial FTD (chromosome 3), FTD with amyotrophic lateral sclerosis 
(9q21-q22), and FTD with inclusion body myopathy (9p13.3-p12). Tau deposits may 
consist of mainly mutated protein, or of mutated and wild-type protein in equal amounts, 
depending on the mutation. Recent animal studies show that amyloid-β deposition may 
accelerate formation of neurofibrillary tangles. Hopefully, the identification of 
responsible genetic defects and associated proteins will be helpful in improving our 
understanding of the role of the tau protein in the common neurodegenerative process 
of frontotemporal degeneration. 
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n less than one decade, familial frontotemporal dementia (FTD) has emerged as a 
distinct clinical disease entity, with pathological and genetic heterogeneity. 
Although the common pathological substrate consists of neuronal loss, spongiosis, 
and gliosis in the frontal and temporal cortices, further classification of FTD into 
different pathological subtypes can be made by means of immunohistochemical (anti-
tau and anti-ubiquitin antibodies) and biochemical techniques.1  
The term ‘frontotemporal dementia and parkinsonism linked to chromosome 17’ (FTDP-
17) was proposed at a consensus meeting in Ann Arbor in 1996 in order to include the 
clinical and pathological spectrum of 13 large families with significant linkage to 
chromosome 17q21-22.2 After the identification of mutations in the tau gene in some of 
these families in 1998,3-5 many novel tau mutations have been found in predominantly 
smaller families over recent years.6-9 All of these families have in common the 
accumulation of hyperphosphorylated tau protein in neurones or glial cells, or both, in 
frontal and temporal cortices, as well as subcortical structures. However, genetic 
heterogeneity still exists in FTD families with linkage to chromosome 17q21-22, because 
a number of these families show neither tau mutations nor tau deposition on 
neuropathological assessment, suggesting that there may be a second gene involved 
that is located close to the tau gene.10 Genetic heterogeneity is further emphasised by 
the identification of three other genetic loci by linkage analysis in FTD families with 
variable phenotypes but without tau pathology: one on the pericentromeric region of 
chromosome 311 and another two on chromosome 9.12,13  
 
Tau mutations in FTDP-17  
The tau protein is considered to play an important role in assembly and stabilisation of 
microtubuli in axons. Six different isoforms are produced from the single tau gene by 
alternative splicing of exons 2, 3 and 10. Three isoforms contain three amino acid 
repeats, encoded by exons 9, 11, and 12, whereas the inclusion of the amino acid 
repeat encoded by exon 10 gives rise to the other three isoforms, which have four 
repeats. Tau gene mutations can be distinguished into two distinct types. In the first type, 
missense mutations in exon 9, 10, 11, 12, and 13 reduce the ability of the tau protein 
to bind to microtubuli and some also enhance the rate of heparin-induced assembly of 
tau into filaments. In the second type of mutation, the effect of the intronic and some 
coding mutations in exon 10 is at the messenger RNA level, resulting into a change of 
the ratio of tau isoforms of three amino acid repeats to those of four amino acid 
repeats. From November 2000 until Februari 2002, eight new tau mutations have been 
identified; the most important pathological and biochemical findings in these mutations 
are summarised in Table 1.14-22 
I 
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The frequency of tau gene mutations has been studied in different populations of FTD 
patients, with diagnoses made according to more or less strict criteria. A genetic-
epidemiological study conducted in the Netherlands revealed tau mutations in 17.6% of 
patients,23 whereas the prevalence was 13.6% in an autopsy-verified series of FTD 
patients,24 and only 5.9% in a referral series from the USA.25 The P301L mutation is the 
most common missense mutation.23,25,26 Some investigators have suggested that a 
selection bias might have skewed the results of the Dutch study, resulting in 
overrepresentation of familial cases. However, in a follow-up study (chapter 2.1), the 
percentage remained above 10% after the identification of novel mutations (S320F and 
L315R), as well as known mutations (G272V, P301L, and R406W) in patients identified 
since the previous publication. Tau mutations are mostly found in patients with a positive 
family history for dementia, being present in 10 to 50% of such patients.1,23,25,27 The 
presence of tau pathology in familial FTD cases  increases this prevalence to nearly 
100%. Although most authors agree that nearly all cases of familial FTD with tau 
pathology exhibit tau mutations, rare forms of familial FTD with tauopathy, but no tau 
mutations have been described.28  
As a result of the identification of tau mutations, genetic testing in individuals who are 
at-risk for FTD has become available. Preliminary studies indicate that only a minority of 
such individuals request genetic testing, which is not surprising in view of the fact that 
preventive interventions and treatments are still lacking.29,30 Unfavourable test results 
have had considerable impact on life, marriage, and family planning; however, they 
may also lead to relief of uncertainty on the other hand. An important observation by 
Geschwind et al. is that asymptomatic carriers of the P301L mutation already showed 
alterations in frontal executive and attentional tasks decades before the predicted onset 
of dementia.31 Because those alterations did not correlate with age, this frontal executive 
dysfunction is probably already determined at the developmental stage. 
 
Phenotypic variation in tau mutations 
Deposition of hyperphosphorylated tau is the pathological hallmark of FTDP-17 with tau 
mutations. Several novel mutations in the tau gene have extended the clinical and 
pathological phenotype of FTDP-17. Phenotypic variation is large between families with 
different mutations, but also within families with the same mutation.  
Although mutations are mainly found in patients with classical FTD, the identification of 
tau mutations in patients with Progressive Supranuclear Palsy (PSP),18,19,32 Corticobasal 
Degeneration (CBD),17,33 and dementia with epilepsy34 justifies tau mutation analysis in 
hereditary forms of related disorders. Clinical features of PSP were observed in patients 
with the silent S305S mutation, the intron mutation at the +11 position, and in two 
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siblings homozygous for the ∆N296 mutation.18,19,32 Interestingly, two family members, 
both of whom were heterozygous for the ∆N296 mutation, suffered from mild, late-onset 
Parkinson’s disease (PD).18 The co-occurrence of mental retardation in patients with 
+11 intron mutation suggests an additional effect of this tau mutation or of the 
concomitant silent P301P polymorphism.19 Resemblance to CBD in the P301S mutation 
is based on clinical features,33 but also on neuropathological features in the novel 
N296N mutation.17 The latter mutation is characterised by degeneration of pyramidal 
tracts, tau-positive coiled bodies in oligodendroglia, and threads with pretangles in 
subcortical nuclei, and functional studies have shown that the primary effect of this silent 
mutation in exon 10 is probably overproduction of four amino acid repeat isoforms of 
tau. 
The genetic background of Pick’s disease, which is characterised by Pick bodies that 
consist mainly of tau isoforms with three amino acid repeats, has also been extended by 
the identification of several novel tau mutations (K257T, S320F, E342V, K369I, and 
G389R).14-16,21,22,35 The similarity to sporadic Pick’s disease is supported by similar 
staining patterns with tau-antibody 12E8 in K257T, S320F, and K369I mutations, as 
well as increased levels of three amino acid repeat tau isoforms in K257T brain.14 A few 
of these mutations also exhibit altered levels of specific tau isoforms in the sarkosyl-
soluble fraction (a decrease in 3R0N and 4R2N in S320F22 and an increase of 4R0N in 
E342V16) suggesting a possible effect of these mutations on either the alternative splicing 
of amino terminal inserts or selective degradation of specific isoforms. 
 
Related sporadic tauopathies 
In order to appreciate the role of tau protein in the pathophysiology of 
neurodegeneration in FTDP-17,  it is worthwhile studying other related sporadic 
disorders with tau pathology,  such as PSP, CBD, and Pick’s disease. Homozygosity of 
the extended H1 haplotype of the tau gene has been significantly associated with both 
PSP and CBD.36-38 Although a recent study showed that tau deposition in PSP consists 
mainly of  tau isoforms with four amino acid repeats, the ratio of four-repeat to three 
repeat tau did not appear to be influenced by the H1 haplotype.39 A novel tauopathy, 
which is also characterised by selective deposition of four repeat tau, has been 
described in a sporadic case of FTD.40 The tau pathology in this case differs from PSP 
and CBD by the presence of severe cortical pathology, which consisted of dense 
globular tau-positive inclusions in neurons and glia cells, and the absence of neuropil 
threads and abundant astrocytic plaques. Although the pathology is similar, it can be 
distinguished from FTD due to intron mutations by the negative family history, a very late 
age at onset, and the absence of both parkinsonism and tau mutations.40  
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Another type of tauopathy is suggested by the observation of profound and selective 
reduction in all six soluble tau isoforms in different cortical regions in some cases of 
Dementia Lacking Distinctive Histology (DLDH) and in a FTDP-17 family (HDDD2) that 
lacked mutations in the tau gene.41 The normal expression of tau messenger RNA in 
these cases indicates that there is either a defect in post-transcriptional regulation of tau 
messenger RNA or increased degradation of the tau protein. In our opinion the loss of 
tau in DLDH still requires confirmation in other studies.42   
 
Biochemical experiments and animal models 
In-vitro studies have shown that several tau mutations result in reduced binding and 
polymerisation of the tau protein with microtubuli, which is supposedly important for the 
normal function of the neuronal cytoskeleton.43 Studies in living cells transfected with 
mutant complementary DNA and expressing mutant P301L or V337M tau protein44 
confirmed those findings by showing reduced bundling of microtubuli and higher 
proportion of tau protein in the soluble fraction as compared with wild-type protein.44  
Studies with site-specific antibodies against mutant P301L tau have shown that tau 
deposits in P301L brains consist mainly of mutant P301L tau protein.45,46 Furthermore, 
the mutant P301L tau is strikingly decreased in the soluble fraction, and levels appear to 
be inversely correlated with the extent of tau pathology. In contrast to this, tau deposits 
in brains of patients with the R406W mutation consist of equal amounts of highly 
phosphorylated wild-type and R406W mutant tau.47 Although the underlying 
pathophysiological mechanism in these mutations is not yet understood, a change in the 
conformation or in the degradation of mutant tau protein may explain the different 
observations in those studies.   
Expression of human tau with the P301L mutation in transgenic mouse lines leads to tau 
filament formation, neuronal loss, and gliosis in brain stem, cerebellar nuclei and spinal 
cord.48-50 These mice show limb weakness and behavioural changes. Amyotrophy 
reflects loss of motor neurones in the anterior horns. Tau filaments are selectively formed 
in oligodendrocytes throughout the brain and spinal cord in the transgenic mouse line 
expressing mutant G272V tau.51 Neuronal loss with filamentous tau aggregation in 
hippocampus, as is observed in the transgenic mouse expressing mutant V337M human 
tau, appears to be correlated with impaired recognition of location on standard 
behavioural tests.52 Although transgenic mouse studies have major limitations in the 
choice of a specific promotor, different levels of expression, and the expression of only a 
single tau isoform, which explains some of the observed differences, they provide 
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invaluable information regarding the pathophysiological mechanisms of neuro-
degeneration. 
The possible interaction between amyloid-β protein (the major constituent of diffuse and 
neuritic plaques) and tau pathology in Alzheimer’s disease, and in a few FTDP-17 cases 
is also very interesting.53,54 The absence of high numbers of plaques in a series of 54 
FTD patients (six of whom had tau mutations) by Mann et al.55 does not support the idea 
that tau pathology leads to amyloid-β deposition.55 However, inversely, amyloid-β 
deposition promotes neurofibrillary tangle formation in double mutant (tau/amyloid 
precursor protein) mice,56 as well as in P301L mice injected with amyloid-β-42 fibrils.57 
Interestingly, the neurofibrillary tangles in P301L mice did not appear in the cortex at the 
site of amyloid-β-42  injection, but rather in the amygdala from which neurones project 
to the injection site. Gotz et al.57 propose that this anatomical separation is consistent 
with amyloid-β-42 induced axonal damage, and possibly with impaired axonal transport 
of tau. 
 
Other types of hereditary FTD 
There are at least three types of pathology in familial FTD.1 The first is characterised by 
tau deposition in neurons or glialcells, or both, in patients with tau mutations. The 
second is characterised by the presence of cytoplasmic ubiquitin-positive, tau-negative 
inclusions and dystrophic neurites in frontal and temporal cortices, and 
hippocampus.10,58,59 One large Dutch family presented with a clinical presentation 
similar to that observed in patients with FTDP-17 due to tau mutations, except for a 
older and broader range of age at onset.10 Genetic analysis showed strong evidence for 
linkage to chromosome 17q21-22, in the absence of identified mutations in the tau 
gene. The presence of a few intranuclear ubiquitin-positive inclusions, which have also 
been observed in some sporadic cases of FTD and motor neurone disease,60 may be a 
neuropathological marker, although the role of ubiquitin in the aetiology of this FTD 
subtype is not evident. Familial ubiquitin-positive FTD constitutes at least 20% of the total 
group of hereditary FTD,1 but most families are too small for significant linkage and 
further genetic analyses are awaited.59 In the third type of pathology, a group of families 
show neither tau-positive or ubiquitin-positive neuronal inclusions, and are collectively 
called dementia lacking distinctive histology (DLDH).1,61,62  
Hereditary FTD in some families is associated with amyotrophic lateral sclerosis, and this 
form has shown linkage to a genetic locus on chromosome 9q21-q22.12 On the basis 
of available pathological findings in these families, tau pathology is absent or only 
sparse. Hereditary FTD associated with inclusion body myopathy and Paget’s disease is 
linked to another locus on chromosome 9 (i.e. 9p13.3-p12).13 
2  
Finally, linkage to the pericentromeric region on chromosome 3 has been found in a 
single large FTD family of Danish descent.11 We expect that the identification of the 
responsible genetic defects and the associated proteins in familial FTD forms may prove 
to be helpful in improving our understanding of the role of tau protein in the common 
neurodegenerative process of frontotemporal degeneration. 
 
Conclusion 
 
Increasing numbers of tau gene mutations are being found in FTD families, as well as in 
some patients with clinical features of PSP and CBD, justifying genetic analysis of the tau 
gene in familial forms these disorders. The diversity of tau mutations has revealed 
invaluable information regarding the role of tau protein in FTDP-17 in particular, but 
also in neurodegeneration in general. Although the site of the mutation correlates to 
some extend with the morphological and biochemical characteristics of the tau deposits, 
it is still unclear which other genetic or environmental factors determine the phenotypic 
variation. Hopefully, the identification of novel mutations, both in the tau gene and in yet 
to be discovered genes, will be helpful in improving our understanding of the process of 
frontotemporal neurodegeneration. 
 
2
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Chapter  
2.1 
 
Frontotemporal dementia in the Netherlands;  
patient characteristics and prevalence estimates 
from a population-based study 
 
Abstract 
Since 1994, a population-based study of frontotemporal dementia (FTD) in the 
Netherlands aims to ascertain all patients with FTD and first prevalence estimates based 
on 74 patients were reported in 1998. Here, we present new prevalence estimates after 
expansion of our FTD population to 245 patients, with emphasis on the prevalence in 
the province Zuid-Holland where the main study centre is located. All neurologists and 
physicians in nursing homes received a yearly postal enquiry about suspected FTD 
cases. FTD was diagnosed in 245 patients according to the Lund-Manchester criteria, 
supported by neuroimaging and neuropsychology. Tau mutation analysis was performed 
in a subgroup of 154 patients (63%), and 40 out of 98 patients (41%) who died during 
follow-up came to autopsy during the course of the study. The prevalence of FTD in the 
province Zuid-Holland was 3.6 per 100.000 at age 50 to 59 years, 9.4 per 100.000 at 
age 60 to 69, and 3.8 per 100.000 at age 70 to 79. The average age at onset of the 
245 patients (51% female) was 57.6±9.0 years. Dementia in one or more first-degree 
family members was found in 43% of patients and mutation analysis of the tau gene 
showed mutations in 34 patients (19 P301L, five L315R, four G272V, four R406W, one 
∆K280, one S320F), all with a positive family history (14% of the total population, 32% 
of patients with a positive family history). Pathological findings in the 40 autopsied 
patients consisted of dementia lacking distinctive histology in 22%, FTD with ubiquitin-
positive inclusions in 33%, Pick’s disease in 15%, and tauopathy in the remaining 30% 
of patients, with tau mutations identified in more than half of the latter patients. We 
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conclude that the prevalence of FTD in the Netherlands is higher than previously 
reported, confirming that FTD is more common than expected. The finding of tau 
mutations in 32% of patients with a positive family history for dementia justifies mutation 
screening in FTD patients with a positive family history, while tau mutations in non-
familiar cases are rare.  
 
rontotemporal dementia (FTD) has become increasingly recognised by 
clinicians and pathologists as a major cause of dementia over the last decade. 
Reliable clinical criteria for the diagnosis FTD have been established,1,2 and 
several pathological subtypes are now distinguished using immuno-
histochemical techniques.3,4 The identification of mutations in the Microtubule-
associated protein tau gene has led to a new classification of familial FTD, in which 
subclasses show specific pathological features.5 The frequency of tau mutations varies 
considerably in different FTD populations, ranging from zero to 18%.6-10 Although the 
number of different tau mutations is still increasing, some FTD families show neither tau 
pathology nor tau mutations, and may be distinguished by typical ubiquitin-positive 
inclusions, emphasising genetic heterogeneity.5,11-13  
Since 1994, a population-based study aims to ascertain all patients with FTD in the 
Netherlands. Preliminary results indicated a maximal prevalence of 2 per 100.000 
inhabitants at age 60 to 69.14 However, a recent study in the Cambridge area of the 
United Kingdom (UK) found a substantially higher prevalence of 15 per 100.000 
inhabitants aged 45 to 64 years.15 Although FTD is known to occur at older age, the 
prevalence of FTD in patients older than 65 has not yet been investigated. In the current 
study, we describe a large cohort of FTD patients ascertained between January 1994 
and June 2002 in the Netherlands, and present estimates of the prevalence of FTD at 
different ages, the frequency of tau mutations, and the distribution of different 
pathological subtypes. We also attempted to evaluate the proportion of misdiagnosis 
and non-referral by looking at all patients with a neuropathological diagnosis 
compatible with FTD, autopsied during the same period at the Netherlands Brain Bank 
(NBB). 
 
Patients and Methods 
 
Study design and diagnosis 
A complete ascertainment of patients with FTD in the Netherlands was attempted from 
January 1994 until June 2002.14 All hospital-based neurologic and psychiatric practices 
(n=183) and physicians in psychogeriatric hospitals or nursing homes (n=269) received 
F 
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a yearly postal enquiry about all suspected FTD cases, irrespective of their family history. 
Additionally, we visited four university medical centres specialised in dementia in June 
2002 (P.S., W.v.G, H.P.K, F.V.) and reviewed medical records (including 
neuropsychological evaluation and hard copies of neuroimaging) of all suspected FTD 
patients examined after 1994 to assess whether they fulfilled the criteria for probable 
FTD. The diagnosis FTD was based on the criteria of Lund and Manchester,1,2 and 
included (1) a progressive behavioural disorder with insidious onset; (2) affective 
symptoms; (3) speech disorder; (4) preserved spatial orientation and praxis and (5) 
selective fronto-temporal atrophy (computed tomography [CT] or magnetic resonance 
imaging [MRI]) or selective fronto-temporal hypoperfusion (single photon emission 
computed tomography [SPECT] with 99mTc-hexamethyl propyleneamine oxime 
[HMPAO]). Consensus about the clinical diagnosis between research physician, 
neurologist, and neuropsychologist was obtained, and in case of uncertain diagnosis, 
the final decision was made based on supplementary clinical, neuropsychological, and 
neuroimaging data later in the course of the disease. 
Spouses and first-degree relatives assisted in obtaining detailed clinical history on the 
onset and evolution of the disease, with emphasis on frontal symptoms, speech and 
spatial functions, as well as memory problems. The age at onset was defined as the age 
at which the first symptom compatible with the diagnosis FTD was observed by a close 
relative or caretaker. The duration of the disease was determined in all patients who 
died during the course of the study. A positive family history was defined as at least one 
first-degree relative with dementia before the age of 80. An autosomal dominant pattern 
of inheritance was considered present if at least three affected individuals (including the 
proband) over two or more generations were identified, and through genealogical 
research we attempted to link these familial cases in order to determine the number of 
individual families. The pattern of cerebral atrophy on CT or MRI was evaluated, and 
patients were classified according to the predominance of either frontal or temporal 
atrophy as described previously.16 Left-right asymmetry was considered to be present if 
there was at least one grade difference.  
Tau mutation analysis was performed in a subgroup of 154 patients (63%). Mutation 
analysis for 90 patients was previously described.7 For another 50 cases all 11 coding 
exons of the tau gene, including flanking intronic sequences, were amplified from 
genomic DNA. Sequence analysis was performed on exons 1, 2, 3, 4, 5, 7, 9, 11, and 
13. For the remaining 14 patients only exons 9 to 13 of the tau gene were sequenced 
by our clinical testing laboratory. The possibility of post-mortem examination was 
discussed with relatives of patients who died during follow-up. In collaboration with the 
NBB, all brains that became available for autopsy were processed for routine staining, 
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including Bodian silver staining, as well as immunohistochemistry with tau (AT8, 1:40, 
Innogenetics, Ghent, Belgium) and ubiquitin (1:500, Dako, Glostrup, Denmark) 
antibodies as described previously.12 The NBB complies with all relevant ethical and 
legal guidelines regarding obtaining consent from autopsy, anonymity of the donors and 
the collection use and transport of tissue samples as well as the safety procedures of 
working with human post-mortem tissues.17 The study was approved by the Medical 
Ethics Committee of the Erasmus Medical Centre of Rotterdam. Informed consent for 
participation (including DNA-studies) was obtained from the spouse or a first-degree 
relative of each patient. 
 
Prevalence estimates  
Point prevalence estimates for the Netherlands were calculated for the 1st of January of 
each year between 1995 and 2000 to evaluate consistency of ascertainment over the 
years. Subsequently, age-specific prevalences were calculated for 10 year periods for 
the chosen census day, 1st of  January 1998, for both the Netherlands and the province 
of Zuid-Holland, in which the main study centre is located. The number of patients with 
FTD resident in the appropriate target area and alive on the census day, was divided by 
the total number of inhabitants in the same area. Information about population size was 
derived from the Central Bureau for Statistics in the Netherlands. The 95% confidence 
intervals (CI) were calculated using a recommended method for small numbers with 
Confidence Interval Analysis (CIA) software.18 Differences across groups were compared 
using Student’s t-test and Chi-square test when appropriate. Differences in prevalence 
ratios between different target areas, as well as between the present study and published 
studies, were compared using the recommended method for unpaired samples 
(Newcombe) with CIA software.18 
 
Evaluation of accuracy of prevalence estimates 
In order to assess the accuracy of our prevalence estimates, we looked at all patients 
autopsied at the NBB during the course of the study, who had a neuropathological 
diagnosis compatible with FTD. Firstly, we evaluated the proportion of autopsied 
patients with a clinical diagnosis other than FTD, in order to assess the proportion of 
misdiagnosis of FTD by primary physicians. Secondly, we looked for autopsied patients 
with a clinical diagnosis of FTD, to determine if non-referral by the primary physician 
occurred in our study. Subsequently, we evaluated what effect correction for the 
proportion of non-referral would have on our prevalence estimates. 
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Results 
 
Demographic and clinical features 
During the entire study period a total of 245 patients (125 women, 120 men) with 
probable FTD were identified according to the Lund-Manchester criteria. FTD patients 
referred by neurologists and psychiatrists (n=135) were examined at the out-patients 
clinic, the remaining patients were seen at nursing-homes (n=110). The mean duration 
of symptoms at ascertainment was 3.6±2.5 years in the former group, and 6.0±3.2 
years in the latter group. The average age at onset was 57.6±9.0 years, with a broad 
range from 33 to 80 years. Fifty-four patients (22%) were older than 65 years at onset of 
symptoms. Ninety-eight patients died during the course of the study, after a mean 
duration of symptoms of 7.9±3.6 years (range 2 to 19 years). The family history was 
positive for dementia in 105 of patients (43%). Forty-nine of these patients (20%) had an 
autosomal dominant pattern of inheritance, and genealogical research showed that they 
came from 18 independent families. The information on affected family members was 
too limited to determine whether there was a true familiar form of FTD in the remaining 
56 patients (23%). Symptoms of motor neurone disease (MND) developed during the 
course of the illness in 11 patients (4%), six of whom had a positive family history for 
either dementia or amyotrophic lateral sclerosis. Parkinsonism early in the course of the 
disease, was present in 34 patients (14%), whereas most patients developed a hypo-
kinetic-rigid syndrome later in the course of the disease. Predominantly temporal atrophy 
on neuroimaging was seen in 97 (40%), which was asymmetric in 70 patients (72%). In 
patients with frontotemporal atrophy, asymmetry was seen in only 27% of patients. 
 
Prevalence estimates 
The estimated overall prevalence of FTD in the Netherlands climbed from 0.9 per 
100.000 in 1995 to 1.1 per 100.000 in 1997, and remained stable thereafter (Figure 
1). A total of 174 patients were alive and suffering from FTD in the Netherlands on the 
1st of January 1998, our census day, resulting in an overall prevalence of 1.1 per 
100.000 inhabitants (95% confidence interval (CI): 1.0 to 1.3). The overall prevalence 
in the province Zuid-Holland was at least twice as high, namely 2.7 per 100.000 
inhabitants (95% CI: 2.1 to 3.5), based on 55 patients. Because there is no evidence 
that familial aggregation in Zuid-Holland is more common, this difference is most likely 
due to underascertainment in regions further away from the main study centre. The age-
specific prevalence in Zuid-Holland, summarised in Table 1, was highest in patients 
aged 60 to 69 (9.4 per 100.000 inhabitants). The prevalence of FTD at age 45 to 64 
was 4.0 (95% CI: 2.8 - 5.7) per 100.000 inhabitants based on 31 patients. 
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Figure 1. Overall prevalence estimates in the Netherlands on the 
1st of January for subsequent years during the course of the study 
 
 
 
Table 1. Age-specific prevalence estimates of FTD on 1st January 1998 
 
       Patients   Population         Prevalence* (95% CI) 
      
30 to 39 years       1     556.346    0.2 (0.03 – 1.0) 
40 to 49 years       6     488.269    1.2 (0.6 – 2.7) 
50 to 59 years       14     391.154    3.6 (2.1 – 6.0) 
60 to 69 years       26     276.581    9.4 (6.4 – 13.8) 
70 to 79 years      8     212.754    3.8 (1.9 – 7.4) 
 
Total population   55     2.043.949   2.7 (2.1 – 3.5) 
 
* per 100.000 inhabitants 
1995    1996   1997   1998   1999   2000
0
0.5
1.0
*
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At the NBB we identified 50 patients autopsied after January 1st 1994, with a 
pathological diagnosis compatible with FTD. Thirty-three (66%) patients had been 
ascertained in the current study, whereas 17 (34%) had not been not referred. Although 
the diagnosis FTD had been considered during life in nine of these 17 patients (18%), 
including two from Zuid Holland which had not been referred to our centre. The 
remaining eight patients (16%) had been diagnosed with other disorders, most 
frequently Alzheimer’s disease. Assuming that the proportion of misdiagnoses is similar 
throughout the Netherlands, correction for a non-referral of 34% would increase the 
prevalence of FTD at ages 45 to 64 years in Zuid-Holland (based on 31 and 52 
patients respectively) from 4.0 to 6.7 per 100.000 inhabitants (95% CI: 5.1 to 8.8). 
 
Genetic studies 
Tau mutation analysis was carried out in a subgroup of 154 (63%) patients (Table 2). 
Missense mutations in the tau gene were identified in 34 patients (19 P301L, five L315R, 
four G272V, four R406W,  one ∆K280, one S320F). Through genealogical research we 
were able to link a large number of these 34 patients, and reduce the number of 
independent families to 10 (three P301L, two L315R, one G72V, two R406W, one 
∆K28, and one S320F). The frequency of tau mutations was 14% of the total FTD 
population, 32% in patients with a positive family history for dementia, and 56% of the 
independent autosomal dominant families (10 out of 18). Mutation analysis in the 
remaining 120 patients did not reveal any tau mutations. Of the 48 patients with a 
positive family history for dementia but no tau mutations upon sequencing, nine came 
from two large FTD pedigrees with ubiquitin-positive, tau-negative inclusions and 
significant linkage to chromosome 17q21-22.12,19 Another six patients were from 
unrelated FTD families with a clear autosomal dominant pattern of inheritance, but too 
small for informative linkage analysis. Tau screening was also negative in the remaining 
72 patients, all of whom had a negative family history of dementia. 
 
Pathological findings 
Brain autopsy was performed in 40 out of 98 (41%) patients, who died during the 
course of the study (16% of the total population). This group consisted of nine (22%) 
patients with the pathological diagnosis Dementia Lacking Distinctive Histology (DLDH), 
13 (33%) patients had ubiquitin-positive inclusions in neurons of the second layer of the 
frontotemporal cortex and dentate gyrus of the hippocampus (FTD-MND type), and 18 
(45%) patients showed tauopathy (tau mutations in seven, sporadic Pick’s disease in six, 
other tauopathy without tau mutations in three, other tauopathy without tau mutation 
screening in two patients). 
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Table 2. Family history, autosomal dominant forms of FTD and tau 
mutation analysis in 245 FTD patients 
 
           Number*  Analysis   Mutations 
 
Total patient group      245   156 (64%)  34 (14%) 
Sporadic form       140   72 (515)   0 
Total positive family history    105    82 (78%)   34 (32%) 
-  autosomal dominant      49 (18)  49 (100%)  34 (69%) 
  - P301L       19 (3) 
  - L315R       5 (2) 
  - G272V       4 (1) 
  - R406W       4 (2) 
  - ∆K280       1 (1) 
  - S320F       1 (1) 
  - No mutation**     15 (8) 
-  possible familial FTD     56    33 (59%)   0 
* Number between brackets is number of independent families. 
** Nine patients from two FTDP-17 pedigrees with ubiquitin-positive inclusions12,19 
  
 
Discussion 
 
The present population-based study, consisting of the largest series (n=245) of FTD 
patients reported so far, showed a maximum prevalence of 9.4 per 100.000 at age 60 
to 69 years in the province Zuid-Holland of the Netherlands. Prevalence estimates for 
the Netherlands as a whole were a factor two lower, probably due to 
underascertainment in regions further away from the study centre. An age at onset 
higher than 65 years was found in 22% of patients. The family history was positive for 
dementia in 43% of patients (n=105), and tau mutation screening showed mutations in 
32% of these patients(n=34), 14% of the total population. Pathology in 40 patients who 
died during follow-up, showed DLDH in 22%, FTD with ubiquitin-positive inclusions in 
33%, Pick’s disease in 15%, and tauopathy in the remaining 30% of patients. 
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The highest prevalence of 9.4 per 100.000 emphasises that FTD is much more common 
than previously considered. This was also apparent in the only other study on the 
prevalence of FTD in the UK, where a prevalence of 15 per 100.000 was found at ages 
45 to 64.15 In the current study, the maximum prevalence estimate in patients aged 45 
to 64 was 4.0 per 100.000, significantly lower than in the UK study. The lower 
prevalence estimate in the Netherlands may be explained by methodological differences 
between the two studies. One limitation of the present study in this respect is the 
possibility of underascertainment due to misdiagnosis by the primary specialist, which 
was not a problem in the UK study as all patients with dementia were clinically 
evaluated. In the autopsy series of the NBB, 34% of patients had not come to our 
attention, either due to misdiagnosis or non-referral by the primary specialist. A 
correction for a non-referral proportion of 40% would increase the prevalence of FTD at 
ages 45 to 64 in Zuid-Holland from 4.0 to 6.7 per 100.000 inhabitants, still 
considerably lower than in the UK study. Other factors which may contribute are the 
ethnic background of the population. The population of Zuid-Holland consists for a 
considerable part (10%) of non-Caucasian ethnic groups, which do not have the same 
risk of FTD as Caucasians do. In the current study, over 99% of patients were indeed of 
Caucasian origin. In contrast, Ratnavalli explicitly mentioned that ethnic minorities were 
underrepresented in the Cambridge study population.15 
An important observation of the present study was that 22% of our patients had an age 
at onset higher than 65 years (63% between ages 65 and 70, and 37% after the age of 
70). Interestingly, two of the four original patients described by Arnold Pick had an age 
at onset of 69 and 73 years.20 However, van Mansvelt in his large literature review of 
Pick’s disease emphasised its presenile onset.21 The older age at onset in a subgroup of 
patients has not been given much attention in more recent literature, although the 
frequency in several studies varied from 10% up to 44% in a pathologically confirmed 
series by Giannakopoulos.22-27 
A positive family history was present in 43% of Dutch FTD patients, similar as reported 
previously.14 These patients have proven (tau mutation) or convincing autosomal 
dominant inheritance of FTD in 20%, whereas the pattern of inheritance could not be 
determined in the remaining patients due to small pedigrees or limited information on 
affected family members. Tau mutations were seen in 14% of Dutch patients, similar to 
the 18% percent reported in our previous study of 90 FTD patients7 and to 14% in the 
stringently diagnosed Manchester series described by Houlden.6 However, most other 
studies show fewer tau mutations, with percentages in Sweden, U.S.A. and Japan of 
zero, 6% and 8% respectively.8-10 As also observed in series from France and Northern 
America,9,28 the most common tau mutation in the Netherlands was P301L (19 patients), 
Chapter 2.1 
38 
which may be due to a founder effect in these populations. The absence of intronic 
splice-site mutations appears to be common on the European Continent , in contrast to 
the U.K. where mainly intronic mutations downstream of exon 10 are found.6,9,28 
More than half of the pathologically confirmed cases did not have deposition of 
hyperphosphorylated tau in affected brain regions, as also reported in other 
pathological series.4,29 DLDH was the diagnosis in 22% and FTD with ubiquitin-positive 
inclusions in 33% of these cases. MND was present in only three of 13 cases with 
ubiquitin-positive inclusions. Tauopathy was found in 45% of our patients, which is quite 
a high percentage compared with other series,3,4,30 although the frequency of classical 
Pick’s disease, diagnosed in 15% of our patients, varies considerably in different studies, 
ranging from 8 to 35%.3,4,30-32 The cause of tauopathy in five other patients (two with a 
positive family history) has to be elucidated in the future. Boeve et al. recently presented 
a similar family characterised by tauopathy, but extensive sequencing of the tau gene 
also did not reveal a tau mutation.33 It may be that a gene other than the tau gene is 
responsible for the extensive tauopathy in these familial cases.  
In conclusion, frontotemporal dementia is more common in the Netherlands than we 
previously reported, with a maximum prevalence at ages 60 to 69. As nearly a quarter 
of patients had an age at onset of higher than 65, more attention should be paid to FTD 
at older ages in epidemiological studies. The presence of tau mutations in 32% of 
patients with a positive family history justifies tau mutation analysis in familial cases of 
FTD.   
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Medical and environmental risk factors for 
sporadic frontotemporal dementia;  
a retrospective case-control study 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
We performed a retrospective case-control study with 80 sporadic FTD patients and 124 
age, sex, and surrogate informant matched control subjects, regarding various medical 
and environmental risk factors. Firstly, head trauma was associated with an odds ratio of 
3.3 (95% confidence interval: 1.3 to 8.1). Although we cannot exclude that recall bias 
accounts for part of the observed association, the frontal lobes are known to be 
especially vulnerable to head trauma. Secondly, thyroid disease was associated with a 
2.5 times increased risk of FTD (95% CI: 0.9 to 7.9), unfortunately not statistically 
significant due to limited power. As altered thyroid hormone levels have also previously 
been observed in FTD, future studies will be important to confirm this observation. 
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rontotemporal dementia (FTD) is a neurodegenerative disorder with a 
predominantly presenile onset of behavioural changes and cognitive decline.1 
Since the identification of mutations in the tau gene in familial forms of FTD, 
there is increasing interest in genetic factors which may predispose to the 
disease. About sixty percent of FTD patients do not have a family history for dementia 
and are considered to be sporadic cases. Genetic factors, such as apolipoprotein E 
genotype and the H1-haplotype of the tau gene, have been inconsistently associated 
with the sporadic form of FTD.2-4 To our knowledge, no studies have been reported to 
date addressing non-genetic risk factors for FTD, in contrast to other neurodegenerative 
disorders such as Alzheimer’s disease, Parkinson’s disease, and progressive 
supranuclear palsy. The identification of new risk factors for sporadic FTD may help us 
understand which mechanisms underlie the aetiology of sporadic forms of FTD. 
Therefore, we performed a retrospective case-control study with 80 patients with 
sporadic FTD and 124 age, gender, and surrogate informant matched controls, 
regarding possible medical and environmental risk factors. 
     
Methods 
 
Cases 
Cases were identified through our nation-wide study on FTD in the Netherlands between 
January 1994 and January 2002. The diagnosis FTD was based on the criteria of Lund 
and Manchester,1 and included (1) a progressive behavioural disorder with insidious 
onset; (2) affective symptoms; (3) speech disorder; (4) preserved spatial orientation and 
praxis and (5) selective fronto-temporal atrophy (CT/MRI) or selective fronto-temporal 
hypoperfusion (SPECT) on neuroimaging. The method of case-ascertainment has been 
described previously.5 The age at onset was defined as the age at which the first 
symptom compatible with the diagnosis FTD was observed by the surrogate informant. 
Cases were considered to have a sporadic form of FTD if there were no first-degree 
relatives with dementia with an onset before the age of 70, nor a tau mutation identified 
upon mutational analysis. 
 
Controls 
For each case, one or two controls were identified through either the nursing-home 
where the patient resided or the general practitioner. In order to avoid selection-bias, 
co-operating physicians were asked to recruit persons who would be willing to answer a 
verbatim questionnaire as a surrogate respondent regarding a family member (spouse, 
parent, or sibling) with current age (± 5 years) and sex matched to that of the patient. 
F 
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These family members then served as surrogate informant matched controls. An 
exclusion criterion was that the controls were not suffering from clinically diagnosed 
dementia. Furthermore, as all patients were of Caucasian origin, only Caucasian 
controls were included. 
 
Data collection 
Because many of our FTD patients were in late stages of the disease and unreliable as 
historians due to language difficulties, the information was collected from a close 
relative of the patient, the surrogate informant. Only spouses, offspring, and siblings 
were questioned, as information from more distant relatives is unreliable. A structured 
verbal interview was obtained by one of the investigators from the surrogate informant of 
both cases and controls. A risk factor was considered positive only if it preceded the date 
of onset of FTD in the matched case. The investigators were blinded to the information 
available from the medical records of the FTD patients to avoid information bias. The 
level of education (divided into three categories: (1) primary school only, (2) secondary 
school or lower/intermediate professional education, and (3) higher professional 
education or university) was registered, as was employment or hobbies associated with 
exposure to chemicals, pesticides or insecticides. Questions regarded history of the 
medical problems (Table 1), and smoking and alcohol consumption (Table 2). Head 
trauma was studied extensively and was positive if it was followed by severe headache, 
nausea, blurred or double vision, dizziness, memory loss or loss of consciousness. 
Severe head trauma was present only if the trauma was followed by loss of 
consciousness. We also collected information on the practice of sports associated with 
chronic head trauma (i.e. boxing, football). Thyroid problems were positive if confirmed 
by a specialist or prescription of thyroid-related medication by a general practitioner. 
Smoking was measured in pack-years, i.e. the average number of cigarette packs 
smoked per day times the number of years the individual smoked. Alcohol consumption 
was measured in drinks per day and considered mild-to-moderate if individuals used 
between one to three drinks per day, and severe if more than three drinks per day, for a 
period of at least 10 years. 
 
Statistical analysis 
Statistical procedures were performed using Statistical Package of Social Sciences (SPSS) 
software. Differences between cases and controls were analysed using Chi-square test 
for categorical variables and T-test for continuous data. Variables with a p-value lower 
than 0.05 were evaluated in a multivariate analysis in which these variables were studied 
simultaneously. Conditional logistic regression was used to determine odds ratio’s 
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adjusted for age, sex, and surrogate respondent relationship, with each case with it’s 
control(s) classified as a stratum. 
 
Results 
 
The 80 patients had a mean age of  64.3±9.4 years, while the 124 controls were on 
average 62.5±10.2 years (p=0.2). All cases and controls were Caucasian. The 
surrogate respondent was a spouse for 54 cases (67%), an off-spring for 22 cases 
(28%), and a sibling for four cases (5%). The level of education in both cases and 
controls was similar. Cases did not practice (contact) sports associated with chronic 
head trauma, or had employment/hobbies associated with exposure to chemicals, 
pesticides or insecticides more regularly than control subjects. Regarding history of 
medical problems, both head trauma and thyroid disease showed a p-value lower than 
0.05.  
 
Table 1. History of medical problems of cases and controls 
 
          Sporadic FTD  Controls    P-value 
          n=80     n=124 
 
Hypertension       11 (14%)    18 (15%)    n.s.* 
Diabetes Mellitus     5 (6%)     3 (2%)     n.s. 
High cholesterol      6 (8%)     7 (6%)     n.s. 
Myocardial infarction    0      3 (2%)     n.s. 
Stroke         0      0      n.s. 
Meningitis/encephalitis    0      0      n.s. 
Seizures        0      1 (1%)     n.s. 
Head trauma       19 (24%)    10 (8%)    p=0.002 
- with loss of consciousness  5 (6%)     3 (2%)     n.s.. 
Thyroid disease      11 (14%)    6 (5%)     p=0.03 
Headache, > once a month  20 (25%)    25 (20%)    n.s. 
Migraine        12 (15%)    9 (7%)     n.s. 
Herpes Zoster      4 (5%)     7 (6%)     n.s. 
Cold sores       30 (38%)    3 (26%)    n.s 
Severe influenza      5 (6%)     9 (7%)     n.s. 
 
* n.s. = not significant (p<0.05) 
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With conditional logistic regression, only head trauma remained a significant 
independent risk factor for FTD and was associated with a odds ratio of 3.3 (95% 
confidence interval: 1.3 to 8.1). The time between head trauma and onset of dementia 
spanned several decades in some FTD patients. Head trauma followed by loss of 
consciousness was also more frequent in FTD patients, but was too infrequent to be a 
significant risk factor. Thyroid disease was associated with an odds ratio of 2.5 (95% CI: 
0.9 to 7.9) using conditional logistic regression (p=0.09). Smoking and alcohol 
consumption were not associated with higher or lower risks of FTD.  
 
Table 2. Smoking and alcohol use in cases and controls 
 
Sporadic FTD Controls   P-value 
           n=80     n=124 
 
Smoking:                    n.s.* 
 Never         32 (40%)    53 (43%) 
 < 20 pack years      27 (34%)    45 (36%) 
 ≥ 20 pack years      21 (26%)    26 (21%) 
 
Alcohol consumption:                n.s. 
 < 1 drink per day     28 (35%)    55 (44%) 
 1 to 3 drinks per day    46 (58%)    60 (48%) 
 > 3 drinks a day     6 (8%)     9 (7%) 
 
* n.s. = not significant (p<0.05) 
 
 
Discussion 
 
To our knowledge, this is the first case-control study regarding medical and 
environmental risk factors in patients with sporadic FTD. Head trauma was associated 
with a 3.3 fold increased risk of FTD in cases compared to controls and thyroid disease 
with a 2.5 fold increased risk (not statistically significant using conditional regression 
analysis). Neither smoking or alcohol use was associated with FTD, nor exposure to 
chemicals, pesticides or insecticides, which have been implicated in related disorders 
such as Parkinson’s disease and progressive supranuclear palsy. 
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Numerous difficulties arise in identifying risk factors for disorders such as FTD. 
Prospective studies, needed to establish a causal relationship between an exposure and 
a disease, are unfortunately not viable for rare disorders such as FTD. The problem with 
case-control studies, however, is that relevant exposure takes place before the onset of 
the disease, and unless the information is documented for both patients and controls in 
a standardised way (i.e. registers, medical records), we are dependent on retrospective 
information, which is subject to recall bias and may lead to false positive results. We 
opted for a design with surrogate informants, because the demented patients were 
unable to give accurate information, and the information we wished to collect was not 
completely available from registers or medical records. Unfortunately, information is 
often lost with this design, resulting in reduced statistical power. However, if information 
regarding exposure is collected uniformly in cases and controls, information bias will not 
be major problem.   
Head trauma, associated with a 3.3 times increased risk of FTD in the current study, has 
also been associated with Alzheimer’s disease in several case-control studies, although 
this has not been confirmed in prospective studies.6;7 Head trauma followed by loss of 
consciousness, a measure for more severe traumatic brain injury, also appeared to be 
more frequent in FTD patients, although this difference was not significant due to the 
fact that it was a very uncommon occurrence. The frontal lobes are especially sensitive 
to head trauma and experimental animal models and post-mortem studies have shown 
axonal damage and dysfunction, mostly localised in the frontal lobes, following even 
mild traumatic brain injury.8 However, we cannot exclude that recall bias plays a role in 
the observed association, as surrogate informants may be more prone to remember 
head trauma in patients than controls, as a possible cause of their dementia. 
Thyroid disease was associated with a 2.5 fold increased risk of FTD, although the 
association did not reach significance using conditional logistic regression. It is well 
known that thyroid problems can lead to cognitive disturbance and even dementia, but 
thyroid disease may also be associated with FTD specifically. First of all, experimental 
studies have shown that splicing of juvenile and adult tau mRNA variants is regulated by 
thyroid hormone9 and Pick’s disease, one of the tauopathies, is a common cause of the 
clinical syndrome of FTD. Secondly, a study regarding thyroid hormone levels in different 
dementia syndromes showed that abnormalities were rather common in FTD (38%).10 
Therefore, thyroid problems may play a role in the aetiology of sporadic FTD, and 
further studies will be important to evaluate this association. 
Smoking and alcohol consumption have also been extensively studied in different 
neurodegenerative disorders. Smoking has been found to be protective regarding 
Parkinson’s disease11 and harmful regarding risk the of Alzheimer’s disease,12 but in the
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 current study neither effect was found. Also in contrast to the current study, light to 
moderate alcohol consumption (one to three drinks per day) has been shown to have a 
protective effect in Alzheimer’s disease,13 but not in Parkinson’s disease.14 A possible 
explanation why these risk factors were not identified in the current study, may be that 
the clinical syndrome of FTD is caused by number of different neuropathological 
substrates, such as Pick’s disease, Dementia Lacking Distinctive Histology, and FTD with 
ubiquitin inclusions.15 It is probable that these different neuropathological subtypes arise 
through different pathophysiological mechanisms and contrasting effects of risk factors 
may be diluted in a mixed group of patients. Because it is currently impossible to predict 
the neuropathological subtype of FTD based on clinical grounds, it will be important to 
conduct similar retrospective studies in patients with pathological verification of the 
disease. 
In conclusion, the search for risk factors for sporadic FTD will be difficult, but may 
nevertheless be of importance in both the elucidation of the pathophysiological 
mechanisms leading to disease, as in the search for therapeutic opportunities and 
preventive interventions. Therefore, we hope that future research will place more 
emphasis on the resolution of this problem.  
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Chapter  
3.1 
 
Complex compulsive behaviour in the temporal 
variant of frontotemporal dementia 
 
 
Abstract 
As metabolic and structural changes in frontotemporal-subcortical pathways have been 
reported in patients with obsessive-compulsive disorders, we investigated the correlation 
between complex compulsive behaviour (CCB) and the distribution of atrophy in a group 
of 90 patients with frontotemporal dementia (FTD). CCB was defined as complex, 
intentional, and time consuming repetitive behaviour, which was distinguished from 
simple compulsive behaviour (SCB), such as verbal and motor repetitions and utilisation 
behaviour. Cortical atrophy on CT and/or MRI was semiquantitatively assessed in 
frontal, temporal, parietal and occipital regions, and the pattern of atrophy was 
compared between patients with and without CCB or SCB. Linear measures were used 
to establish the presence of caudate atrophy (bicaudate ratio) and ventricular 
enlargement (bifrontal ratio). CCB was reported in 18 (21%) and SCB in 53 (61%) FTD 
patients. Frontotemporal atrophy was present in 64 patients (74%), and predominant 
temporal atrophy in 23 (26%). The pattern of atrophy was asymmetric in 25 patients 
(29%). Logistic regression analysis showed that temporal lobe atrophy (p<0.005), as 
well as asymmetry of atrophy (p<0.05) were independently associated with CCB, after 
adjusting for age at onset, gender, duration of symptoms at the time of imaging, severity 
of atrophy, and bicaudate and bifrontal ratio. No relationship was found between the 
presence of SCB and the distribution of atrophy, although patients with SCB tended to 
have more caudate atrophy (p<0.1). Temporal lobe atrophy appears to mediate CCB 
in patients with FTD, especially if asymmetry of atrophy is present. Future studies with 
quantitative and volumetric measurements of the cortical and subcortical structures may 
further clarify the aetiology of CCB in FTD. 
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rontotemporal dementia (FTD) is a neurodegenerative disorder of 
predominantly presenile onset, characterised by progressive behavioural 
changes and cognitive decline. Several investigators have paid attention to 
specific behavioural symptoms or cognitive changes and have tried to 
correlate them to the distribution of atrophy or hypoperfusion.1-3 Temporal lobe 
pathology in FTD has been associated with language difficulties4,5 and facilitation of 
visual and musical talents6,7 when the left lobe is affected, and psychiatric disturbances 
when the right lobe is affected.2,4 Snowden et al. divided FTD patients into three clinical 
subtypes and found distinct patterns of hypoperfusion in each subtype: the disinhibited 
subtype was associated with orbitofrontal hypoperfusion on SPECT, the apathetic 
subtype with dorsolateral hypoperfusion of the frontal lobe, and the stereotypic subtype, 
which is characterised by the presence of complex compulsive behaviour, with both 
striatal and temporal hypoperfusion.8  
Repetitive behaviour shows a spectrum of complexity, with complex compulsive 
behaviour (CCB) at one end of the spectrum, and simple motor and verbal repetitions at 
the other end. CCB is frequently reported in patients with FTD, and consists of  a time-
consuming preoccupation with certain ideas or activities. It often occurs at an early 
stage of the disease, and is useful in distinguishing FTD from Alzheimer’s disease.9,10 As 
metabolic and structural changes in orbitofrontal-subcortical pathways have been 
reported in patients with both idiopathic and acquired obsessive-compulsive disorders,11-
16 the occurrence of CCB in FTD is pathophysiologically interesting.  
Here, we address the correlation between CCB and the distribution of atrophy in a 
group of 90 patients with FTD, ascertained from a genetic-epidemiological study in the 
Netherlands.   
 
Methods 
 
Patients were recruited in the Netherlands between January 1994 and June 1998; the 
method of ascertainment has been reported previously.17 The mean age at onset of the 
disease was 54.8 ± 8.4 ( ± standard deviation) years; the mean duration of illness 4.9 ± 
2.9 years. A positive family history for dementia was present in 34 (39%) patients. The 
clinical diagnosis was established according to the criteria of the Lund and Manchester 
groups18,19 by two independent neurologists blinded to family history. The core 
diagnostic features of FTD are (1) an insidious onset and gradual progression, (2) an 
early decline in social interpersonal conduct, (3) an early impairment in regulation of 
personal conduct, (4) early emotional blunting, and (5) early loss of insight.19 The 
diagnosis was supported by neuroimaging and neuropsychological evaluation at 
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ascertainment and/or by review of previous neuropsychological reports when testing was 
no longer possible at time of ascertainment. Fifteen patients had tau gene mutations 
(G272V, P301L, R406W, and ∆K280),20 and the clinical diagnosis was confirmed by 
neuropathological examination in an additional 12 patients who died during follow-up. 
The Medical Ethics Committee of the University Hospital of Rotterdam approved the 
study and the spouse or a first-degree relative of each patient gave informed consent for 
participation. 
The investigators asked for the presence of repetitive behaviour in all patients in an 
interview with a primary caregiver or close family member. Repetitive behaviour was 
divided into simple compulsive behaviour (SCB; repetitive motor or verbal actions and 
environmentally dependant behaviour which is not internally generated) and complex 
compulsive behaviour (CCB; complex, intentional, and time-consuming (more than 1 
hour a day) behaviour, resulting in an interference with regular daily routines). In the 
absence of clear clinical criteria for CCB, a descriptive characterisation of the type of 
CCB was attempted. The anxiety component, which is characteristic of patients with 
obsessive-compulsive disorder as defined by the DSM-IV,21 is difficult to assess in 
patients with FTD as they show limited insight and do not perceive their behaviour as 
irrational or excessive, especially after the early stage of their disease.  
Computed tomography (CT) and magnetic resonance imaging (MRI) scans were 
evaluated by two reviewers blinded to clinical symptoms and family history. 
Frontotemporal atrophy on CT and/or MRI was present in 87 patients (31 men and 56 
women). The remaining three patients did not have any atrophy on structural imaging, 
but showed anterior hypoperfusion on single-photon emission computed tomography 
(SPECT) scanning and were not included in further analyses. The extent of regional 
cortical atrophy in frontal, temporal, parietal, and occipital lobes of both hemispheres 
was semiquantitatively rated according to the four-point scale of Scheltens22 into no, 
mild, moderate, and severe atrophy. The severity of atrophy was defined as the score of 
the region which was most severely affected (no sum-score). A distinction was made 
between patients with predominance of temporal atrophy (temporal atrophy more severe 
than frontal atrophy), and patients with frontal or frontotemporal atrophy. Left-right 
asymmetry was considered to be present if there was at least one grade difference 
between analogous regions of the left and right hemisphere (Figure 1). Caudate atrophy 
and ventricular enlargement were estimated by means of linear ratios: the bicaudate 
ratio (BCR), defined as the intercaudate distance divided by the distance between the 
inner tables of the skull at the intercaudate line, and the bifrontal ratio (BFR), defined as 
the bifrontal distance divided by the distance between the inner tables of the skull at the 
CCB in the temporal variant of FTD 
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bifrontal line.23 Consecutive scans (with an interval of at least 6 months) were available 
in 34 patients. 
The neuroradiological features of patients with and without CCB were compared using 
the Student’s t or chi-square test, and Fisher's exact test was used when appropriate. The 
determinants of CCB were analysed by multiple logistic regression. The critical level for 
statistical significance was set at p<0.05 for all tests. In 20 patients both CT and MRI 
scans, made within a six month interval, were available. There was good agreement for 
assessment of the distribution of atrophy, as established by both CT and MRI (kappa 
value: 64%, p<0.001). The correlation between the linear ratios measured in CT and 
MRI was higher than +0.95 (p<0.001) for both measures, and a paired t-test revealed 
no statistically significant differences between the means. Therefore, both CT and MRI 
scans were used to determine the distribution of atrophy and to measure the linear ratios 
in this study, and no further distinction was made. 
 
Figure 1. Neuroimaging examples. 
 
 
 
A. T1-weighted Magnetic Resonance Imaging (MRI) of FTD patient with CCB showing 
asymmetric temporal atrophy: severe atrophy of the right temporal lobe (including the 
amygdala) and moderate atrophy of the left temporal lobe. B. MRI of a patient without 
CCB showing mild symmetric atrophy of the frontal lobes. 
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Results 
 
Complex compulsive behaviour 
CCB was present in 18 (21%) patients with FTD. It often presented at an early stage of 
the disease and diminished in complexity with progression of the illness. CCB consisted 
of visual compulsive preoccupation in four patients: ritualistic completion of jigsaw 
puzzles in two patients, copying embroidery patterns in detail by one patient, and 
production of hundreds of identical drawings in another patient. Other manifestations of 
CCB were a preoccupation with certain ideas (health, religion, financial status and 
environment), and coercive behaviour directed at family members who did not adhere to 
these ideas. Extreme fixation to daily routines was also a common feature, as was 
repetitive checking behaviour (time, locks, clothing) and arranging of objects in a 
particular order. The demographic data, compulsive features, and distribution of atrophy 
of patients with CCB are listed in table 1. SBC, including both verbal and motor 
repetitions and utilisation behaviour, was present in 53 (61%) of patients.  
The age at onset was significantly lower in patients with CCB: 50.9 ± 9.4 compared to 
56.1 ± 7.7 years (p=0.02). Duration of illness, gender distribution, and the percentage 
of patients with a positive family history were similar in both groups. There was no 
difference in duration of symptoms at time of imaging between patients with and without 
CCB (2.9 ± 1.7 years for patients with CCB, and 3.2 ± 1.8 years for patients without 
CCB). The demographic and radiological features of patients with and without CCB are 
shown in Table 2. 
 
Type of atrophy 
Frontotemporal atrophy was seen in 64 patients (74%): mild in 23 (36%), moderate in 
32 (50%), and severe in 9 (14%) patients. Temporal atrophy was seen in 23 patients 
(26%): mild in 9 (39%), moderate in 12 (52%), and severe in 2 (9%). The severity of 
atrophy did not differ between patients with frontotemporal and temporal atrophy 
(p=0.8). Patients with temporal atrophy never showed more than mild atrophy of the 
frontal lobes. Asymmetry of atrophy was present in 25 (29%) of patients, and was more 
frequent in patients with temporal atrophy (p=0.004). Patients with asymmetric atrophy 
showed more severe atrophy than patients with symmetric atrophy (p=0.02). The 
distribution of atrophy did not change over time in 31 out of 34 patients (91%) of whom 
consecutive scans were available. Both ventricular enlargement (BFR) and bicaudate 
atrophy (BCR) were most prominent in patients with frontotemporal atrophy (p=0.014 
and p=0.009 respectively). The average duration of symptoms at time of neuroimaging 
was 3.1 ± 1.8 years. The distribution and severity of atrophy are shown in Table 3. 
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Correlation between atrophy and compulsive behaviour 
CCB was associated with atrophy of the temporal lobe: 12 out of 18 patients (67%) with 
CCB had temporal atrophy, compared to 11 of 69 patients (16%) without CCB 
(p<0.001).  Asymmetry of atrophy was also associated with CCB: 11 of 18 patients 
(61%) with CCB had asymmetric atrophy, compared to 14 of 69 patients (20%) without 
CCB (p=0.001). The left-right distribution of atrophy was not associated with the 
occurrence of CCB, and there were no differences between the two groups in severity of 
atrophy, caudate atrophy (as estimated by the BCR), or ventricular enlargement (BFR). 
SCB was present in 53 (61%) patients: 9 (17%) with predominant temporal atrophy, and 
44 (83%) with  frontotemporal atrophy, which did not differ from patients without SCB. 
Although patients with SCB tended to have a more caudate atrophy (mean BCR: 0.25) 
than patients without (mean BCR: 0.23), this difference did not reach significance 
(p=0.1). 
 
Table 2. Demographic data and imaging features of patients with and 
without CCB* 
 
CCB    no CCB 
               (n=18)   (n=69) 
 
Demographic data: 
Age at onset (years ± SD)**     50.9±9.4   56.1±7.7 
Duration of illness (years)     4.3±2.3   5.2±3.0 
Men/women (number)      10/8    21/48 
Positive family history      6 (33%)   28 (41%) 
Neuroimaging features: 
Frontotemporal distribution:** 
- Frontotemporal atrophy   6 (33%)   58 (84%) 
- Temporal atrophy     12 (67%)   11 (16%) 
Asymmetry*         11 (61%)   14 (20%) 
Left/right sided atrophy      6/5    6/8 
Moderate to severe atrophy     12 (67%)   43 (62%) 
BCR (mean)         0.23    0.25 
 
* The remaining three patients had normal structural imaging. 
** significant difference (p<0.05). 
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Table 3. Distribution and severity of atrophy in total patient population 
 
Mild     Moderate     Severe 
 
Temporal: 
- asymmetric    2 (17%)    8 (66%)     2 (17%) 
- symmetric     7 (64%)    4 (36%)     0  
 
Frontotemporal: 
- asymmetric    2 (15%)    7 (54%)     4 (31%) 
- symmetric     21 (41%)    25 (49%)      5 (10%) 
 
 
Logistic regression analysis showed that both temporal atrophy (p=0.004), as well as 
asymmetric atrophy (p=0.02) were significantly and independently associated with CCB. 
Patients with temporal atrophy had a 7.1 (95% confidence interval (CI): 2.0 – 25.7) fold 
increased risk of developing CCB, and patients with asymmetry of atrophy a 5.4 (95% 
CI: 1.4 – 20.6) fold increased risk. Multivariate logistic regression analysis with age at 
onset, duration of the symptoms at the time of imaging, gender, severity of cortical 
atrophy, BCR, and BFR as covariates, showed that only age at onset had an additional 
significant contribution to the model (p=0.03, odds ratio 0.9, 95% CI: 0.8 - 1.0). 
However, since age at onset did not have an impact on the odds ratios for temporal and 
asymmetric atrophy, it was not a confounder.  
 
Discussion 
 
This study describes the occurrence of complex compulsive behaviour (CCB) in 21% of 
patients from a large population-based study of 90 patients with FTD. Visual compulsive 
behaviour, preoccupation with certain ideas, repetitive checking, counting, and extreme 
fixation to specific activities and times are manifestations of this behaviour. CCB was 
independently associated with both temporal atrophy and asymmetric atrophy, after 
adjusting for age at onset, duration of symptoms at time of imaging, and severity of 
atrophy. The caudate nuclei did not appear to be involved in the development of CCB in 
our patients.  
This study confirms that CCB is a common feature in patients with FTD, which differs 
from observations in Alzheimer’s disease patients.9 CCB often occurs at the initial stage 
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of the disease and is followed by more elementary motor or verbal repetitions at a later 
phase. The higher frequencies of repetitive behaviour of up to 80% reported by some 
other investigators are probably due to the inclusion of these simple repetitions and 
utilisation behaviour in their studies.24,25  It will be interesting to investigate whether the 
manifestations of CCB in FTD differ qualitatively from compulsive behaviour observed in 
idiopathic and acquired obsessive-compulsive disorders. It has been suggested that 
serotonin may play a role in the aetiology of idiopathic obsessive-compulsive disorders, 
because of the anti-obsessional effect of selective serotonin reuptake inhibitors (SSRIs).26 
That serotonin may also be involved in the pathogenesis of behavioural disturbances in 
patients with FTD is supported by the finding of reduced levels of post-synaptic serotonin 
in post-mortem studies of FTD patients.27,28 Furthermore, a partial treatment response to 
SSRIs was found in a small sample of FTD patients with behavioural symptoms which 
included compulsions,29 although further studies are needed to verify this effect.  
Isolated atrophy of the left temporal lobe was described for the first time by Arnold Pick 
in a patient with a progressive language disorder and dementia.30 The profile of 
language deficits in FTD patients has more recently been denoted as primary 
progressive aphasia and semantic dementia.31,32  The frequency of temporal atrophy in 
the present study (26%) is similar to that in a large review of cases of Pick’s disease 
(17%) from literature.33 The asymmetric pattern of temporal atrophy, in the present as 
well as in other studies, is a distinctive feature of FTD compared to Alzheimer’s disease 
and other neurodegenerative conditions, and may determine the clinical picture of 
FTD.25,33-35 Right-sided temporal atrophy has been associated with characteristic 
psychiatric symptoms, such as psychosis, mania, and bizarre affect,2,4 whereas 
emergence of artistic (musical) talent can be a clinical manifestation of left temporal 
lobe involvement.6,7 
Temporal atrophy on neuroimaging is significantly correlated with CCB in the present 
study, and has also been mentioned in association with striatal atrophy in a number of 
FTD cases with compulsions by Snowden et al.8 It is well known that structural and 
functional changes of striatum (caudate nucleus and globus pallidus) are associated with 
repetitive behaviour,11,13,15,36-38 in analogy to findings in Gilles de la Tourette’s disease  
and Huntington’s disease.39 However, several case reports have suggested that frontal 
and temporal regions may contribute independently to the development of compulsive 
behaviour, based on the presence of isolated frontal or temporal lesions (infarctions, 
arachnoid cysts) or epilepsy in patients with acquired obsessive-compulsive 
disorders.12,14,36,40,41 A possible mechanism might be that these lesions disrupt the 
frontotemporal-limbic-subcortical nuclei circuitry involved in the suppression of 
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compulsive thoughts and behaviour in normal subjects.12,14 However, we do not have an 
explanation for the association between asymmetric temporal atrophy and CCB. Both 
left and right temporal lobes were equally often affected, and no difference in the quality 
of CCB was observed in patients with left and right sided pathology.  
In the present study, CCB was not associated with caudate atrophy. Our findings  are 
consistent with observations of Snowden et al. of a small number of FTD patients that 
temporal lobe disease appears to be associated with more complex compulsive 
behaviour, whereas severe striatal disease is linked to more elementary compulsive 
behaviour.8 It is possible that the amygdala, located in the medial temporal lobe, is 
involved in the development of CCB in our patients with temporal atrophy. Recent 
findings of reduced volumes and increased metabolism of limbic structures, including 
the amygdala, in patients with idiopathic obsessive-compulsive disorder, support this 
hypothesis.12,42  
One limitation of the present study is the lack of a formal and quantitative assessment of 
CCB by means of questionnaires.43,44 However, lack of insight of patients with FTD 
prevents them from describing distress and anxiety associated with their compulsions. 
Therefore, conventional questionnaires are not useful in assessment of severity of CCB in 
FTD. Another limitation of this study is that quantitative volumetry of temporal lobes and 
adjacent limbic structures could not be carried out owing to unavailability of coronal 
MRI in most patients. However, a recent study showed that visual assessment of medial 
temporal lobe atrophy is both quicker and more accurate than volumetry in 
differentiating Alzheimer’s disease patients from controls.45,46 In analogy, we suggest that 
visual assessment of cortical atrophy, if performed by a single rater,22 is both reliable 
and as accurate as volumetry. Furthermore, it has been shown that the BCR is a good 
indicator of caudate atrophy,23 although volumetric measurements will be needed in 
future studies of FTD patients with CCB to exclude involvement of the caudate nuclei. 
In summary, we have observed CCB in 21% of our FTD patients. Most patients with 
CCB have asymmetric temporal atrophy, and logistic regression analysis confirmed that 
both temporal atrophy and (to a lesser extent) asymmetric atrophy were independently 
associated with the risk of developing CCB. Limbic structures of the temporal lobe, for 
example the amygdala, might be involved in the inhibition of compulsive impulses, 
leading to compulsive behaviour when damaged. Elementary motor and verbal 
compulsions (SCB) were not associated with temporal atrophy.  
Future quantitative neuroimaging and functional MRI studies in FTD patients will help 
clarify the distinct contributions of the different anatomical regions to the development of 
CCB. 
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lthough the apolipoprotein E4 (apoE4) allele has consistently been 
associated with Alzheimer’s disease and other types of dementia in many 
studies,1 its association with frontotemporal dementia (FTD) is controversial. 
After our report in 1997 of increased apoE4 allele frequencies in sporadic 
FTD and its effect on the age at onset,2 other studies of cases of FTD with pathological 
confirmation or tau mutations did not confirm this effect.3-5 However, recently it has been 
shown that semantic dementia, the temporal variant of FTD, may be associated with 
higher frequencies of the apoE4 allele.6 Therefore, we have genotyped apoE in our 
expanded FTD patient population and have assessed whether patients with 
predominance of temporal atrophy have higher frequencies of the apoE4 allele. 
 
 
Methods 
 
Patients were ascertained through a clinico-epidemiological survey of patients with FTD 
in the Netherlands.2 We identified 111 patients with the diagnosis probable FTD, 
established according to the Lund and Manchester criteria. Thirteen of the patients had 
an autosomal dominant form (defined as at least three affected family members in two 
generations) of FTD, with tau mutations identified in 10 (P301L, G272V, R406W and 
∆K280), and were excluded from further analyses. Predominant temporal atrophy, 
semiquantitatively assessed on CT and/or MRI, was found in 31 (32%) patients, whereas 
frontal atrophy with or without temporal atrophy was present in 67 (68%) patients. Nine 
of the 31 patients (29%) with temporal atrophy fulfilled the criteria for semantic 
dementia, and four patients (13%) showed severe problems in language 
comprehension, although the diagnosis semantic dementia could not be definitely 
established due to incomplete or inconclusive neuropsychological testing. The remaining 
18 patients (58%) showed mainly decreased spontaneous speech and wordfinding 
difficulties. The clinical diagnosis of FTD was pathologically confirmed in all 17 patients 
who came to autopsy (five of whom had predominant temporal atrophy). Non-demented 
control subjects (n=561) were taken from the Rotterdam study.7 All patients and controls 
were genotyped for the apoE allele as described by Slooter et al.1 Both genotype 
frequencies and apoE4 allele frequencies were calculated for each group and 
compared with non-demented controls using a chi-square test.  
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Results 
 
Six per cent of the 98 patients with sporadic FTD had the apoE4/E4 genotype, 
compared with 2.3% of non-demented controls (p=0.04). This genotype was present in 
9.7% of patients with the temporal variant of FTD (p=0.01, compared with non-
demented controls), compared with only 4.5% in patients with frontotemporal atrophy 
(p=0.5). Genotype frequencies of heterozygote E4 (E4/*) and homozygote E4 (E4/E4) 
carriers are summarised in table 1. The frequency of the apoE4 allele in all patients with 
sporadic FTD was 21.9%, compared to 15.3% in the non-demented controls (p=0.02). 
In patients with temporal atrophy the apoE4 allele frequency was as high as 29.0% 
(p=0.004), whereas in the patients with frontotemporal atrophy only 18.7% (p=0.3) of 
alleles was apoE4. No association between ApoE4 and the age at onset, nor the 
duration of symptoms, was found in the overall group, nor in the subgroups.  
 
 
Table 1. Frequency of apoE genotypes and E4 alleles in different groups 
 
 
 
 
 
 
 
 
 
 
†: E4/E4 = E4 homozygotes, E4/* = E4 heterozygotes, No E4 = all other genotypes. 
 
 
Conclusion 
 
Our results show that the apoE4 allele frequency is increased in patients with the 
temporal variant of FTD compared with non-demented controls. Although a biological 
hypothesis justifying such an association is still lacking, the effect of the apoE4 allele on 
the predominance of temporal atrophy compared with frontal atrophy has also been 
observed in patients with Alzheimer’s disease.8 To verify the association between the 
Group                Patients        Genotype (%)†    Alleles  
E4/E4  E4/*   No E4  %E4     P-value 
Non-demented controls  561  2.3  26.0  71.7  15.3  ref. 
Sporadic FTD     98   6.1  31.6  62.3  21.9  0.02 
-    Temporal atrophy   31   9.7  38.7  51.6  29.0  0.004 
-    Frontotemporal atrophy 67   4.5  28.4  67.1  18.7  0.3 
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apoE4 allele and the temporal variant of FTD, a large study with pathological 
confirmation of the clinical diagnosis of FTD is required to exclude admixture of patients 
with Alzheimer’s disease. However, in all 17 patients who were autopsied in our series, 
including five patients with temporal atrophy, the clinical diagnosis was 
neuropathologically confirmed. This shows that the clinical criteria according to the Lund 
and Manchester groups, when combined with neuroimaging and psychometric 
evaluation, are highly accurate. We conclude that the association we previously found 
between the apoE4 allele and sporadic FTD may be due to a selective increase of this 
allele in patients with the temporal variant of FTD. 
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A novel tau mutation (S320F) causes a 
tauopathy with inclusions similar to those in 
Pick’s disease 
 
 
 
 
 
 
Abstract 
Mutations in the tau gene cause familial frontotemporal dementia and parkinsonism 
linked to chromosome17. In this article, we describe a novel missense mutation, S320F, 
in the tau gene in a family with presenile dementia. To our knowledge, it is the first 
mutation to be described in exon 11 of tau. The proband died at age 53, after a disease 
duration of 15 years, and autopsy revealed a neuropathological picture similar to Pick’s 
disease. Recombinant tau protein with the S320F mutation showed a greatly reduced 
ability to promote microtubule assembly, suggesting that this may be the primary effect 
of the mutation. 
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he identification of different types of mutations in the tau gene in familial 
frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-
17), and the association of these mutations with a spectrum of filamentous 
tau pathology, has established the important role of the tau gene in causing 
neurodegeneration.1-3 The primary effect of intronic and some coding region mutations 
in exon 10 is at the mRNA level, resulting in a change in ratio of 3- to 4-repeat tau 
isoforms. By contrast, most missense mutations reduce the ability of mutant tau to 
interact with microtubules and other molecules, and some also stimulate the in vitro 
assembly of tau into filaments. 
In this article, we report a novel missense mutation (S320F) in tau in a family with 
presenile dementia. It constitutes the first known mutation in exon 11 of tau.  
Experimentally, the S320F mutation resulted in a markedly reduced ability of tau to 
promote microtubule assembly. 
 
Subject and Methods 
 
Clinical history of the proband 
The proband, a travelling salesman, presented at age 38 with complaints of mild 
memory problems and spatial disorientation. Neuropsychological examination, 
computerised tomography and electroencephalography, were normal at this time. Nine 
years later, at age 47, memory problems and naming difficulties had evidently 
worsened. Furthermore, he had become introverted, mentally inflexible, and 
disinterested. Psychometric evaluation revealed fluent aphasia, word finding difficulties, 
impairment of comprehension, and abstract thinking. Extrapyramidal signs and motor 
neurone disease were absent. Magnetic resonance imaging of the brain showed 
moderate bilateral temporal atrophy. The patient died at age 53 years. The proband’s 
mother also died with a similar dementing illness at age 53 years. Neither her parents 
(ages at death, 57 and 90 years), nor any of her seven siblings were reported to have 
developed dementia.  
 
Immunohistochemistry 
Immunohistochemistry with phosphorylation-dependent (AT8, AT180, AT270, PHF1, 
MC1, and 12E8 [1:500, donated by P. Seubert, Elan Pharmaceuticals, San Francisco, 
Ca]), and phosphorylation-independent tau antibodies (BR01, Tau 2) was performed, as 
well as with antibodies directed against ubiquitin, β-amyloid, α-synuclein, and αB-
crystallin, as described previously.4 
 
T 
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DNA extraction and mutational analysis 
Genomic DNA of the proband was extracted, and exons 9 to 13 of tau were amplified 
and sequenced as described.5 Exon 11 of tau was also sequenced from the genomic 
DNA of a healthy maternal uncle of the proband (aged 84), as well as 50 control 
individuals. 
 
Tau extraction, immunoblotting and electron microscopy 
Sarkosyl-soluble and -insoluble tau was extracted, dephosphorylated, and analysed as 
described previously,6 and incubated with BR01 tau antibody (1:2,000). The ratio of 
soluble 3- to 4-repeat tau was assessed using Image Master 1D elite software 
(Amersham Pharmacia Biotech, United Kingdom). Dispersed filaments from the sarkosyl-
insoluble fraction were processed for electron microscopy and immunolabelled with tau-
antibodies BR01 and AT8, as described previously.6 
 
Microtubule assembly 
Site-directed mutagenesis was used to change S320 to phenylalanine in the 3-repeat 
381 and 4-repeat 412 amino acid isoforms of human tau (numbering of 441 amino 
acid isoform of human tau), expressed from cDNA clones htau37 and htau46, 
respectively. Wild-type and mutant tau proteins were expressed in Escherichia coli 
BL21(DE3), purified, and incubated with bovine brain tubulin as described previously.7 
Assembly into microtubules was monitored over time by change in turbidity at 350 nm.  
 
Results 
 
Sequencing of the proband’s genomic DNA showed a C to T transition in exon 11 at the 
second base position of codon 320 (TCC to TTC), which results in the substitution of 
serine by phenylalanine (S320F). This change was not observed in the healthy maternal 
uncle of the proband or in 100 control chromosomes. 
At autopsy, the proband’s brain (weight 1,200 g) showed focal bilateral atrophy of the 
anterior temporal lobes, with only very mild frontal atrophy. Severe neuronal loss and 
gliosis were present in the temporal cortex, cingulate gyrus, entorhinal cortex, and 
hippocampus. The substantia nigra was not affected. A few Pick cells were seen in the 
temporal cortex. Bodian silver staining did not show any Pick bodies or neurofibrillary 
tangles. Immunohistochemical staining showed extensive tau pathology in the form of 
Pick-like bodies and more diffuse cytoplasmic staining in neurons of the frontal,  
temporal, and parietal cortices; the dentate gyrus of the hippocampus; the amygdala; 
and the ventral striatum (Fig. 1A-E). 
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Figure 1. Neuropathological findings in the proband’s brain 
 
(A,B) Immunostaining of frontal cortex with the phosphorylation-dependent anti-tau 
antibody AT8 shows multiple tau-positive inclusions (A), some of which resemble Pick 
bodies (arrow in B), while others show a more diffuse staining of the cytoplasm 
(arrowhead in B). (C) A small number of AT8-positive glial cells is seen in the frontal 
cortex. (D,E) The granule cells of the dentate gyrus of the hippocampus contain 
numerous inclusions resembling Pick bodies that are immunoreactive with AT8 (D), but 
not with the phosphorylation-dependent anti-tau antibody 12E8 (E). (F-H) Electron 
micrographs of tau filaments isolated from the proband’s brain show unlabelled straight 
 
 
(F) and twisted (G) filaments, as well as a twisted filament labelled by AT8 (H). Scale 
bars: 150 µm (A), 100 µm (B-E) and 80 nm (F-H). 
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Figure 2. Sarkosyl-insoluble tau and soluble tau from the proband’s 
brain. 
 
 
(A,B) Immunoblot of sarkosyl-insoluble tau before (A) and after (B) alkaline phosphatase 
treatment. (C) Immunoblot of soluble tau after alkaline phosphatase treatment. 
Immunoblotting was done using the phosphorylation-independent anti-tau antibody  
BR01. F = Frontal cortex; T = Temporal cortex;  P = Parietal cortex; C = Cerebellum; 
AD = Alzheimer’s disease, Rt = recombinant tau. 
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Figure 3. Effects of the S320F mutation on the ability of three-repeat 
htau37 (381 amino acid isoform of human tau) and four-repeat htau46 
(412 amino acid isoform of human tau) to promote microtubule 
assembly 
 
 
A. Polymerisation of tubulin induced by wild-type htau37 and htau37S320F. B. 
Polymerisation of tubulin induced by wild-type htau46 and htau46S320F. Microtubule 
assembly was monitored over time by turbidimetry. C. Optical densities for wild-type and 
mutant htau37 and htau46 at 2 minutes (expressed as percentages of wild-type htau37 
and htau46 taken as 100%). Each results is expressed as the mean ± the standard error 
of the mean (n = 5). 
The novel  mutation S320F 
77 
 
 
The Pick-like bodies were immunoreactive with all anti-tau antibodies tested, with the 
exception of antibody 12E8. A few glial cells, probably oligodendrocytes, in affected 
regions also contained tau-positive inclusions. Staining with β-amyloid and α-synuclein 
was negative. 
By immunoblotting, sarkosyl-insoluble tau ran as two major bands of 60 and 64 kDa 
(Fig. 2A). Following dephosphorylation, these bands resolved into four bands that 
aligned with human tau isoforms 4R0N, 3R1N, 4R1N, and 3R2N, except in the 
temporal cortex, where the 3R2N band was not observed (Fig. 2B). Following 
dephosphorylation, soluble tau gave a pattern similar to that seen in Alzheimer’s disease 
(AD; Fig. 2C), with a ratio of 3- to 4-repeat tau isoforms of 0.92 versus 1.01 in the 
control brain.  
Electron microscopy of preparations of sarkosyl-insoluble filaments showed filaments 
with two distinct morphologies (Fig. 1F,G). The major species (approximately 80% of 
filaments) was a straight filament, very similar to the filaments seen in AD brain. The 
minor species (approximately 20%) was an irregularly twisted filament with a cross-over 
spacing of 110-160 nm and a diameter of 6-8 nm in its narrow part. Both types of 
filament were decorated by BR01 and  AT8 antibodies (Fig. 1H). 
Recombinant 3-repeat htau37 and 4-repeat htau46 with the S320F mutation showed a 
markedly reduced ability to promote microtubule assembly when compared with the 
corresponding wild-type proteins (Fig. 3A, B). Thus, the S320F mutation led to a 90 to 
95% reduction in the rates of microtubule assembly when expressed as the optical 
density at 2 minutes (Fig. 3C). 
 
Discussion 
 
This study describes a novel mutation in exon 11 of the tau gene in a patient with 
presenile dementia. S320F is the first mutation to be described in exon 11 of tau. The 
initial clinical diagnosis was AD, but neuropathological findings closely resembled Pick’s 
disease (PiD). The inclusions in S320F brain were similar to those described in sporadic 
PiD8 and in some other cases with tau mutations, 9-14 except that they were undetectable 
with Bodian silver staining. They were immunoreactive with all anti-tau antibodies used, 
with the exception of antibody 12E8, which recognises tau phosphorylated at S262, or 
S356, or both. This 12E8-negative staining of Pick bodies has also been described in 
sporadic PiD,15 and in K257T, G272V, and K369I mutations, 9,11,14 indicating that these 
tau
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epitopes are not substantially hyperphosphorylated in most cases with Pick-like 
pathology. However, the 12E8-positive staining in G389R mutation suggests that 
nonphosphorylation of these sites is not required for the formation of Pick bodies.10 
Sarkosyl-insoluble tau extracted from S320F brain resolved into two major bands of 60 
and 64 kDa, like the pattern seen in sporadic PiD,8 and in K257T and G389R 
mutations.10,11,13 However, following dephosphorylation, the normally abundant band 
corresponding to tau isoform 3R0N was missing. Four major bands aligning with 
isoforms 4R0N, 3R1N, 4R1N, and 3R2N were observed instead. As the 60 kDa band 
corresponds to the 3R0N tau isoform in AD brain,6 the presence of a 60 kDa band in 
the absence of 3R0N tau in the case described herein implies that the isoform 
composition of sarkosyl-insoluble tau differed from that of AD. Previously, unexpected 
tau isoform patterns have been observed in the E342V mutation and in one of two 
families with a G389R mutation.12,13 As in the present case, it remains to be seen 
whether these patterns are a direct and general result of the tau mutations, or whether 
they are limited to the individual cases within each family studied so far. Soluble tau 
from S320F brain consisted of  all 6 isoforms, similar to that seen in AD and other 
missense mutations in tau. The two distinct filament morphologies, straight and twisted, 
have also been described in some cases of sporadic PiD and in some other cases with 
tau mutations and a Pick-like phenotype.8,10 
The S320F mutation is located within the highly conserved third microtubule-binding 
domain of tau. A serine residue is found at this position in all known tau sequences, as 
well as in related proteins MAP2 and MAP4. Accordingly, recombinant tau with the 
S320F mutation showed a greatly reduced ability to promote microtubule assembly, 
suggesting that this may be its primary effect. It is conceivable that this mutation has 
additional effects. It is located within the core region of the paired helical filament of AD, 
two residues amino-terminal of C322, which is known to be required for the 
dimerisation of tau.17,18 The S320F mutation removes a potential phosphorylation site in 
tau. In vitro studies have shown that microtubule-affinity regulating kinase, protein 
kinase N, and cyclic adenosine monophosphate-dependent protein kinase (in presence 
of heparin) can phosphorylate S320.19,20 It has even been suggested that 
phosphorylation of this site may inhibit the assembly of tau protein into filaments.19 
However, at present, there is no evidence to suggest that S320 is phosphorylated in 
either normal or pathological tau in vivo.  
In conclusion, the present study describes a novel tau mutation that causes a syndrome 
similar to Pick’s disease. It further underlines the relevance of tau protein dysfunction in 
the aetiology and pathogenesis of frontotemporal dementia in general, and Pick’s 
disease in particular. 
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Chapter  
4.2 
 
 
Variable phenotypic expression and extensive tau 
pathology in two families with a novel tau 
mutation L315R 
 
 
 
Abstract 
Mutations in the  gene cause familial frontotemporal dementia and parkinsonism 
linked to chromosome 17. Here we describe two Dutch families with frontotemporal 
dementia and the novel L315R mutation in exon 11 of . Both families showed a 
large variation in disease expression, which ranged from an age of onset of 25 years to 
no disease in a 82-year-old carrier. In affected individuals, extensive tau pathology was 
present in nerve cells (Pick-like inclusions) and astroglial cells, particularly in 
frontotemporal cortex and hippocampal formation.  Sarkosyl-insoluble tau extracted 
from cerebral cortex showed the presence of straight and twisted tau filaments and a 
pattern of pathological tau bands similar to that of Pick’s disease. Upon 
dephosphorylation, only five of the six brain tau isoforms were observed, with the 
shortest isoform being undetectable. All six tau isoforms were present in soluble brain 
tau. Recombinant tau proteins with the L315R mutation showed a reduced ability to 
promote microtubule assembly.  
 
tau
tau
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rontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-
17) is a neurodegenerative disease caused by mutations in tau.1-3 Where 
examined, these mutations lead to the assembly of the normally soluble tau 
protein into abnormal filaments.4-6 It follows that the pathway leading from 
soluble to filamentous tau protein is central to FTDP-17. Tau filaments are also 
characteristic of other neurodegenerative diseases, such as Alzheimer’s disease (AD), 
progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Pick’s disease 
(PiD), argyrophilic grain disease and the amyotrophic lateral sclerosis-Parkinsonism-
dementia complex. The study of FTDP-17 continues to throw light on these more 
common diseases, as exemplified by a clinical picture of PSP in cases with the recently 
identified R5L and ∆N296 mutations in tau.7,8 
Six tau isoforms are produced in the adult human brain by alternative mRNA splicing 
from a single gene.9 They differ from each other by the presence or absence of 29- or 
58-amino acid inserts located in the amino-terminal half, and an additional 31-amino 
acid repeat located in the carboxy-terminal half. Inclusion of the latter, which is encoded 
by exon 10, gives rise to the three isoforms with 4 repeats (4R) each; the other three 
isoforms have 3 repeats (3R) each. Similar levels of 3R and 4R tau isoforms are found in 
normal cerebral cortex.10 The repeats constitute the microtubule-binding domains of 
tau.11,12 
Known mutations in  are either missense, deletion or silent mutations in the coding 
region, or intronic mutations located close to the splice-donor site of the intron following 
exon 10. Most coding region mutations are located in the microtubule-binding repeat 
region or close to it and reduce the ability of mutant tau to promote microtubule 
assembly.13,14 Some of these mutations also stimulate the assembly of tau into filaments 
in vitro and lead to a reduced ability of mutant tau to bind to protein phosphatase 2A.15-
17 The intronic mutations and some exon 10 mutations have their primary effect at the 
RNA level and change the ratio of 3R to 4R tau. Where examined, this leads to the 
relative overproduction of 4R tau in human brain. 
Neuropathologically, filamentous tau deposits in nerve cells are characteristic of FTDP-
17.4-6 In addition, tau inclusions are also observed in glial cells in cases with mutations 
in exon 10 or in the intron following exon 10. The presence of both neuronal and glial 
tau inclusions thus correlates with either the expression of mutant 4R tau or the relative 
overproduction of 4R tau. By contrast, the presence of tau inclusions in nerve cells 
correlates with the expression of mutant 3R and 4R tau. However, the recently described 
mutations (R5H and R5L) in exon 1 of tau do not appear to fit into this scheme, since 
F 
tau
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they lead to a neuronal and glial tau pathology, despite all six tau isoforms being 
mutated.7,18 
Here, we report a novel missense mutation (L315R) in exon 11 of tau in two families 
with frontotemporal dementia. At autopsy, clinically affected individuals showed a severe 
neuronal and glial tau pathology. However, the penetrance of this mutation was 
incomplete, since some individuals with the mutation failed to develop clinical 
symptoms. The L315R mutation reduced the ability of recombinant tau proteins to 
promote microtubule assembly, while it had no significant effect on heparin-induced 
assembly of tau into filaments. 
 
Patient and methods 
 
Case reports 
The first five-generation family (Table 1 and Figure 1A) consisted of four affected 
members, and originated from a genetically isolated part of the Netherlands. Three 
patients (A V:1, A V:2, A V:3) presented with behavioural changes, memory problems or 
word-findings difficulties at ages 53, 55 and 56 years respectively. The mother of patient 
A V:1 (A IV:1) also suffered from a similar dementing illness and died at age 61. 
Perseverations, impaired executive function, and decreased attention and abstraction 
were found at neuropsychological testing in both of the tested patients (A V:1, A V:3). 
Neuroimaging showed asymmetric temporal atrophy in two patients (A V:2, A V:3), and 
frontotemporal atrophy in one patient (A V:1). Autopsy was performed in patient A V:1, 
who died after a disease duration of 8 years. The mother of two affected sibs (A IV:4) 
was cognitively normal at 82 years of age and CT-scanning did not reveal any 
abnormalities. 
The second four-generation family (Table 1 and Figure 1B) came from the same area as 
the ancestors of the first family, and consisted of five affected family members. Two 
patients (B III:3, B III:4) had frontal lobe symptoms at similar age (59 and 64 years) as 
the affected members of the first family, whereas three other patients (B III:1, B III:5, and 
IV:1) had a much earlier onset (25, 29 and 39 years). Depression with suicidal 
tendencies and apathy were the prominent features in patient B III:3. Patient B III:5 was 
not able to complete primary school (mental retardation) and developed word finding 
problems, dysarthria and apathy from the age of 25 years and died at the age of 33 
years. The parent of this patient (B II:5), according to the pedigree presumably the 
mutation carrier, died at age 70 without signs of dementia. The clinical presentation in 
patient B IV:1 consisted of impaired comprehension of language and depression, 
starting at the age of 39.  
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Figure 1. Pedigrees of the two families with haplotypes for the FTDP-17 
region 
                
Black bars indicate the shared alleles. Markers were obtained and ordered according to 
the Marshfield integrated linkage map and the April 2001 physical assembly of the 
Human Genome (http://genome.uc-sc.edu). 
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The pattern of atrophy on neuroimaging in all patients was temporal, frontotemporal or 
generalised. Little information is available on patient B III:1; at age 34 he died with a 
history of general brain atrophy. Individual B II:2, a possible carrier of the mutation 
according to the pedigree, died at age 85 without signs of dementia (see Table 1 for 
overview of patients and symptoms). 
 
Tau sequencing 
Genomic DNA of the patients was extracted and the tau exons were amplified and 
sequenced as described.19 Restriction enzyme digestion was used to investigate the 
presence of the base change in exon 11 in 100 control chromosomes. HpaII digests 
specifically the mutant allele of the exon 11 PCR product, whereas DdeI digests 
specifically the normal allele. Enzymes were used according to the manufacturer’s 
(InVitrogen) instructions. 
 
Tau haplotype analysis 
For the analysis we typed polymorphic short tandem repeat markers linked to the FTDP-
17 locus: D17S1824, D17S1880, D17S946, D17S1861, D17S934, D17S951, 
D17S791, D17S920, D17S930, D17S806, D17S1820, D17S787. The markers were 
obtained and ordered according to the Marshfield integrated linkage map and the April 
2001 physical assembly of the Human Genome (http://genome.uc-sc.edu). 
Fluorescently labelled markers were used as specified by the manufacturer and analysed 
using an ABI3100 automated sequencer with Genemapper 2.0 software (Applied 
Biosystems, Foster City, CA). 
 
Histology and immunohistochemistry 
Representative blocks through the brains of patients A V:1 and B III:5 were processed for 
histology and immunohistochemistry. Sections (4 µm) were cut and stained with 
hematoxylin and eosin (HE) and Bodian silver, or used for immunohistochemistry, as 
described.20 Anti-tau antibodies consisted of the conformation-dependent, 
phosphorylation-independent antibody MC1 and the phosphorylation-dependent 
antibodies AT8, AT180, AT270, 12E8 and PHF1. MC1 (a kind gift from Dr Peter 
Davies, Albert Einstein College of Medicine, Bronx, USA) recognizes amino acids 7-9 
and 312-322 of tau (in the numbering of the 441 amino acid isoform of human tau) 
and is sensitive to the conformation of tau. Antibodies AT8, AT180 and AT270 that 
recognize sites in tau phosphorylated, respectively, at S202/T205, T231 and T181 were 
obtained from Innogenetics (Ghent, Belgium). Antibody 12E8 (a kind gift from Dr P, 
Seubert, Elan Pharmaceuticals, San Francisco, USA) recognizes tau phosphorylated at 
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S262 and/or 356. Antibodies against α-synuclein, β-amyloid, ubiquitin and glial  
fibrillary acidic protein (GFAP) were also used as described.20 
  
Tau protein analysis and immunoblotting 
Soluble and sarkosyl-insoluble tau proteins were extracted from the cerebral cortex and 
cerebellum of patient A V:1, as described.21 Tau proteins extracted from the frontal 
cortex of an Alzheimer’s disease patient were used as a control. Dephosphorylation and 
immunoblotting using the phosphorylation-independent anti-tau antibody BR01 were 
done as described.22 
 
Microtubule assembly 
Site-directed mutagenesis was used to change L315 to arginine (in the numbering of the 
441-amino acid isoform of human tau) in the 3R 381-amino acid isoform and in the 4R 
412-amino acid isoform of human tau, expressed from cDNA clones htau37 and 
htau46, respectively. Wild-type and mutant tau proteins were expressed in E. coli 
BL21(DE3), as previously described.10 3R Tau with the K257T mutation and 4R tau with 
the ∆K280 mutation were expressed in parallel and used as controls. Tau proteins were 
purified and their concentration determined by densitometry, as described.13 Purified 
recombinant and mutant 3R tau (0.3 mg/ml) and 4R tau (0.1 mg/ml) were incubated 
with bovine brain tubulin (1 mg/ml, 20 µM; Cytoskeleton, Denver, CO) in assembly 
buffer at 37°C, as described.23 Assembly of tubulin into microtubules was monitored 
over time by a change in turbidity at 350 nm. In all experiments, wild-type and mutant 
tau proteins were expressed and purified in parallel. Numbers of separate experiments 
were as follows: htau37 and htau37L315R (n=5), htau46 and htau46L315R (n=5). 
 
Tau filament assembly 
Purified wild-type and L315R mutant forms of 3R tau (381 amino acid isoform) and 4R 
tau (412 amino acid isoform) (3 mg/ml) were incubated in the presence of 200 µg/ml 
heparin (British Drug House, Poole, U.K.) at 37° C for 48 h, as described (24). 3R Tau 
with the K257T mutation and 4R tau with the P301S mutation served as controls. 
Assembly was monitored semi-quantitatively by electron microscopy and quantitatively 
using thioflavin T fluorescence, as described.23 Each filament assembly experiment made 
use of newly prepared batches of recombinant wild-type and mutant tau proteins that 
had been purified in parallel. Numbers of separate experiments were as follows: htau37 
and htau37L315R (n=5), htau46 and htau46L315R (n=5). 
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Electron microscopy 
Aliquots of sarkosyl-insoluble, dispersed filament preparations and of synthetic tau 
filament assemblies were processed for electron microscopy, as described.21 Anti-tau 
antibody AT8 was used at a dilution of 1:100. Procedures for immunoelectron 
microscopy were as described.21 
 
Results 
 
Neuropathological examination of both brains, A V:1 and B III:5 (brain weight 818 g 
and 863 g resp.) showed severe atrophy of the frontal and temporal lobes. HE staining 
in brain A V:1 showed mild neuronal loss and reactive astrocytosis in the frontal cortex, 
but severe in the temporal cortex, as well as in hippocampus, substantia nigra, red 
nucleus, caudate nucleus and amygdala. The dentate gyrus of the hippocampus was 
almost completely degenerated, with only a few Pick bodies recognised by Bodian silver 
staining. Brain B III:5 (Figure 2) showed most severe neuronal loss and reactive gliosis in 
the frontal cortex and underlying white matter, and less severe involvement of the 
temporal cortex, hippocampus, substantia nigra, caudate nucleus and striatum. Staining 
with phosphorylation-dependent antibodies of brain A V:1 showed numerous Pick 
bodies of variable intensity and size in the frontal cortex, with some tau deposits in the 
dendrites of astrocytes. In contrast, the severely affected temporal cortex contained 
extensive tau deposits in the glial cells, probably of astrocytic origin, with only a few Pick 
bodies. The subiculum of the parahippocampal gyrus also showed numerous Pick 
bodies, stained positive with all tau antibodies, except for 12E8. Tau staining of brain B 
III:5 revealed severe  astrocytic tau deposits  and some Pick bodies in the frontal cortex, 
whereas  more  
numerous Pick bodies were present in the deeper layers of the temporal cortex, with less 
severe tau pathology in the underlying white matter. AT8 antibodies stained Pick bodies 
in nearly all granule cells of the dentate gyrus, and in neurons of the caudate nucleus, 
putamen, locus coeruleus, and olivary nuclei, but much less in the thalamus. Glial tau 
staining was intense in the substantia nigra, and less in the other nuclei. Notably, the 
AT180 and AT270 antibodies gave a weaker signal, especially in staining the astrocytic 
tau pathology. The staining with ubiquitin, β-amyloid and α-synuclein antibodies was 
negative in both brains. A detailed overview of the pathology of both autopsied patients 
can be found in Table 2. 
Sequence analysis of the genomic DNA of all affected family members revealed a T to 
G transition at the second base position of codon 315 (CTG to CGG), leading to a 
leucine to arginine amino acid substitution in exon 11 of the tau gene.  
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Figure 2 . Immunohistochemistry of brain of patient B III:5 
 
 
A. Immunostaining of the frontal cortex with the phosphorylation-dependent antibody 
AT8 shows some Pick bodies and multiple tau-positive reactive astrocytes. B. 
Immunostaining of the same area with the phosphorylation-dependent antibody AT180 
shows only the neuronal tau staining. C. Numerous AT8 positive glial cells are present in 
the white matter of the frontal cortex. D. Immunostaining of the temporal cortex with AT8 
shows only neuronal pathology. E. Typical Pick bodies in the subiculum, immunoreactive 
with AT8. F, G. Immunostaining of the dentate gyrus, showing immunoreactivity with 
AT8 (F) and AT180 (G) antibodies. 
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This base substitution was also observed in the unaffected 82-years old mother of two 
affected sibs. The base substitution was not observed in 200 control chromosomes. 
Haplotype analysis (Figure 1) showed a common allele in families A and B in the region 
of the tau gene, strongly suggesting a common ancestor for both families. 
Immunoblotting of sarkosyl-insoluble tau extracted from the brain of the proband of 
family A (A V:1) showed two major bands of 60 and 64 kDa and a minor band of 68 
kDa (Figure 3A). After dephosphorylation with alkaline phosphatase, these bands 
resolved into five bands that corresponded with human tau isoforms 4R2N, 3R2N, 
4R1N, 3R1N and 4R0N (Figure 3B). Immunoblotting of dephosphorylated sarkosyl-
soluble tau resolved into all six tau isoforms in a pattern identical to that found in AD 
and control brain, with a 4R to 3R ratio of 1.2 (Figure 3C). 
Electron microscopy of sarkosyl-insoluble material extracted from the frontal cortex 
showed a small numbers of filaments. The majority of filaments (~ 80%) were irregularly 
twisted filaments with a long periodicity of more than 130 nm and a diameter of 13-15 
nm, similar to the slender twisted filaments found in PiD. The minority (~ 20%) of the 
filaments were straight filaments. The phosphorylation dependent anti-tau antibody AT8 
decorated both types of filaments (Figure 3D1 and 2).  
Recombinant 3R and 4R tau proteins with the L315R mutation showed a reduced ability 
to promote microtubule assembly, when compared with the corresponding wild-type 
proteins (Figure 4 A,B). Thus, the L315R mutation led to a 20-30% reduction in the rates 
of microtubule assembly, when expressed as the optical density at 2 min (Figure 4C).  
The effects of the L315R mutation on filament assembly of recombinant 3R and 4R tau 
proteins were investigate by using heparin to induce assembly. Assembly was assessed 
quantitatively by thioflavin T fluorescence (Figure 4D) and semi-quantitatively by electron 
microscopy (not shown). Under the conditions of the experiments, no significant effect of 
the L315R mutation was detected (Figure 4D). 
 
Discussion 
 
The novel tau mutation L315R was found to lead to a variable clinical expression, 
including three cases of non-penetrance, an extensive tau pathology in nerve cells and 
astrocytes in clinically affected individuals, and a relatively small reduction in the ability 
of tau to promote microtubule assembly. The two families with the L315R mutation could 
not be linked genealogically, because relevant archive material pre-dating the year 
1800 was lost during the Second World War.  This notwithstanding, it appears likely that 
the affected members from both families shared a common ancestor. Thus, they 
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Figure 3. Sarkosyl-insoluble, sarkosyl soluble and electron microscopic 
analysis of patient A V:1 brain 
                              
A, B. Analysis of sarkosyl-insoluble tau before (A) and after (B) alkaline phosphatase 
treatment. C. Analysis of sarkosyl-soluble tau after alkaline phosphatase treatment. 
Immunoblotting was performed using the phosphorylation independent anti-tau antibody 
BR01. AD = Alzheimer’s disease; F = frontal cortex; T = temporal cortex; P = parietal 
cortex; C = cerebellum; Rt = recombinant tau. D,1-2. Electron microscopic images of 
tau filaments isolated from the frontal cortex of the patient’s brain show twisted filaments 
decorated by the phosphorylation dependent anti-tau antibody AT8. (Scale bar: 50 nm). 
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Figure 4. Effects of the L315R mutation in the tau on microtubule 
assembly and heparin-induced filament formation  
                               
A. Polymerisation of tubulin induced by 3R wild-type and 3R L315R recombinant tau 
protein. B. Polymerisation of tubulin induced by 4R wild-type and 4R L315R recombinant  
tau protein. Microtubule assembly was monitored over time by turbidimetry. C. Optical 
densities for wild-type and mutant 3R and 4R tau protein at 2 min (expressed as percent 
of wild-type 3R and 4R tau protein taken as 100%). The results are expressed as means 
± S.E.M. (n = 5). D. The effects of the L315R mutated 3R and 4R tau protein on 
filament assembly in the presence or absence of heparin. 
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originated from the same geographically and genetically isolated part of the 
Netherlands and haplotype analysis showed an allele shared by all the mutation carriers. 
The clinical phenotype of patients with the L315R mutation highlights the issue of 
variable penetrance. Thus, the presence of clinical symptoms in a 25 year-old mentally 
retarded patient with the mutation (B III:5) was in sharp contrast with the normal mental 
state of a 82 year-old mutation carrier (A IV:4). Previously, the P301S mutation was 
shown to lead to a similarly early age of onset of disease25,26 and the issue of non-
penetrance was raised in connection with several other mutations in tau.27-29 However, 
compared with this earlier work, we were able to provide much stronger evidence in 
favour of non-penetrance. Thus, two affected individuals (A V:2 and A V:3) and their 
mother (A IV:4) were carrying the same mutation. Despite this, the mother was 
neurological normal and had a normal CT scan without lobar atrophy.  Moreover, three 
additional cases of possible non-penetrance were present in  both families, where 
subjects A III:2, B II:2 and B II:5 died aged 92, 70 and 85 years respectively, without 
clinical signs of a dementing illness. 
Numerous Pick-like inclusions were present in cerebral cortex and hippocampus from 
both autopsied patients. They were stained by the Bodian silver stain and all 
phosphorylation-dependent anti-tau antibodies tested, with the exception of antibody 
12E8. Similar findings have previously been reported for a number of other mutations in 
tau.22,27,28,30-34 Unlike the latter, mutation L315R also resulted in a severe glial 
pathology, mainly astrocytic, in conjunction with the almost complete disappearance of 
nerve cells in some parts of the cerebral cortex. A similar neuronal and astrocytic 
pathology has recently been described for mutation L266V in exon 9 of tau34 (and M. 
Hutton and D. Dickson, personal communication). Neuronal and glial, mostly 
oligodendrocytic, tau inclusions are characteristic of mutations R5H and R5L in exon 1 
of tau.7,18 
The presence of astrocytic inclusions in cases with mutation L315R is unexpected, since 
abundant tau inclusions in glial cells are normally associated with mutations that only 
affect 4R tau or that increase the relative amount of 4R tau, with the glial deposits being 
made of 4R tau.4-6 Mutation L315R affects all six tau isoforms and does not  change the 
ratio of 3R/4R tau. In the two brains studied here, there appeared to be an inverse 
relationship between the relative numbers of neuronal and glial tau inclusions. Thus, in 
a given brain region, abundant neuronal inclusions were accompanied by a much 
smaller number of glial deposits. Conversely, abundant astrocytic tau inclusions were 
found in conjunction with few neuronal inclusions and extensive nerve cell loss. This 
suggests that astrocytic inclusions may develop later than neuronal deposits, or that they 
may be longer-lived. Phagocytosis of neuronal tau deposits by astrocytes is also 
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compatible with the observed staining pattern, which would imply the presence of 3R tau 
inclusions in astrocytes. Clarification will require the use of antibodies specific for 3R and 
4R tau.  
Sarkosyl-insoluble tau extracted from a L315R brain resolved into two major bands of 
60 and 64 kDa and a minor band of 68 kDa, similar to the pattern seen in sporadic 
Pick’s disease35 and in cases with the K257T, L266V, S320F and G389R mutations in 
tau. 22,27,28,32,34 However, following dephosphorylation, the band corresponding to tau 
isoform 3R0 was missing. Five bands aligning with isoforms 4R0N, 3R1N, 4R1N, 3R2N 
and 4R2N were observed instead. As the 60 kDa band from AD brain corresponds to 
isoform 3R0N,21,36 the presence of a 60 kDa band in the absence of 3R0N tau in the 
L315R case implies that the isoform composition of the sarkosyl-insoluble tau bands 
differed from that of AD. Previously, a similar tau isoform pattern was described in the 
cerebral cortex from a patient with the S320F mutation in exon 11 of tau.22 This raises 
the intriguing possibility that the absence of 3R0N tau from the sarkosyl-insoluble 
fraction may be a general characteristic of mutations in exon 11. The underlying 
mechanisms remain to be discovered. Soluble tau from L315R brain consisted of all six 
tau isoforms, similar to what is seen in AD and some cases of FTDP-17.6 Tau filaments 
similar to those present in sarkosyl-insoluble tau from the L315R brain have been 
described in some cases of sporadic PiD and cases with tau mutations and a Pick-like 
phenotype.22,27,35  
L315R is only the second mutation to be described in exon 11 of tau, the other being 
S320F.22 It is located in the third microtubule-binding repeat, where a leucine residue is 
present at this position in all known vertebrate proteins with tau repeats, indicating its 
functional relevance.37 Accordingly, recombinant tau with the L315R mutation showed a 
reduced ability to promote microtubule assembly, suggesting that this may be its primary 
effect. However, when compared with other mutations, the effect of the L315R mutation 
was relatively small, indicating a possible explanation for its reduced penetrance.  
Mutation L315R is located close to the hexapeptide sequence VQIVYK (residues 306-
311) that has been proposed to initiate tau filament assembly by forming local β-
structure.38 Despite this proximity, we failed to detect a significant effect of the L315R 
mutation on tau filament assembly. Of the known Tau mutations, L315R is only the third 
to increase the overall charge of the protein, the other two being N279K and G389R. It 
has been proposed that a reduction in charge is a positive determinant in the protein 
aggregation associated with human diseases.39 This appears unlikely in the case of tau, 
since most mutations do not affect its net charge. Of the 30 known mutations, only five 
(K257T, ∆K280, E342V, K369I and R406W) reduce the charge of tau. 
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In conclusion, the present study describes a novel mutation in exon 11 of tau, widening 
the spectrum of hereditary diseases that resemble Pick’s disease. The variable clinical 
expression, in conjunction with the small functional effect of the L315R mutation, 
emphasises the need to identify other factors (modifying genes or environmental 
precipitants) that influence the development of tauopathies. 
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Chapter  
4.3 
 
Coexistent tau and amyloid pathology in 
hereditary frontotemporal dementia with tau 
mutations 
 
Abstract 
Hereditary frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-
17) is associated with different mutations in the tau gene. Pathological changes consist 
of accumulation of hyperphosphorylated tau protein in frontal and temporal cortex, 
hippocampus, and some subcortical nuclei. We describe the neuropathological findings 
in five patients with P301L mutation, and in two affected sibs with R406W mutation. The 
P301L brains all showed a pretangle-type tauopathy of the frontal and temporal 
cortices. One of these patients, however, also showed an Alzheimer-type tauopathy with 
neurofibrillary tangles (NFT), neuritic plaques, and amyloid angiopathy of the temporo-
parietal cortex. Three tau bands (64, 68, and 72 kDa) were seen in the frontal cortex, 
while the temporal cortex revealed four bands (60, 64, 68, and 72 kDa), containing all 
six tau isoforms. The first R406W brain showed many neurofibrillary tangles in affected 
regions with only a few diffuse amyloid plaques. The second R406W brain contained a 
much higher density of NFT in affected regions, and an extensive amyloid deposition 
consisting of both diffuse and neuritic plaques with dense cores. An intriguing question is 
whether the FTD and Alzheimer’s disease changes are concomitant, or whether there is 
an interaction between tau and amyloid pathology. An acceleration of NFT formation 
due to amyloid deposition has been observed in non-demented aging and preclinical 
Alzheimer’s disease. The question whether this mechanism occurs in FTD with tau 
mutations remains to be elucidated. 
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he term frontotemporal dementia (FTD) covers a group of presenile dementias 
with progressive behavioural changes and often frontal or temporal atrophy on 
neuroimaging.1 Several mutations in the tau gene have been found in families 
with hereditary fronto-temporal dementia and parkinsonism linked to 
chromosome 17q21-22 (FTDP-17).2-8 These mutations explain the accumulation of 
hyperphosphorylated tau protein in neurons and glial cells in the cortex, hippocampus, 
and subcortical nuclei. Tau pathology shows considerable variation in the type and 
distribution of tau deposits, the physical structure of filaments, and tau isoform 
composition between the different FTDP-17 families.8-14   
 
Methods 
 
We have investigated tau pathology in five P301L and two R406W patients (Table 1). All 
brains showed moderate to severe atrophy of frontal and anterior temporal lobes. 
Sections from different cortical regions, hippocampus, substantia nigra, and other 
subcortical nuclei were processed for routine staining and for immunohistochemistry 
using phosphorylation-dependent (AT8, AT180, AT100, PHF1, 12 E8 and E10), 
phosphorylation-independent anti-tau (BR133, BR134, BR304, BR189), anti-β-amyloid 
(βA4), and anti-ubiquitin antibodies. Tissue sections were pre-treated with 90% formic 
acid for 5 minutes before immunohistochemistry with antibody against βA4 was 
performed. Sarkosyl-insoluble tau was extracted from fresh-frozen cortices and 
hippocampus, dephosphorylated as previously described, and run on 10% SDS-PAGE 
and blotted onto immobilon P [Millipore].15,16 Blots were incubated overnight at 4°C with 
antisera, BR134 and BR133, and stained using the biotin-avidin Vectastain system 
(Vector Laboratories). Sarkosyl soluble tau was extracted using 2.5% perchloric acid. 
Aliquots of sarkosyl-insoluble tau were processed for electron microscopy (EM).17 
 
Results 
 
P301L brains 
Neuronal loss and gliosis were moderate to severe in the frontotemporal cortex. The 
substantia nigra showed severe loss of pigmented cells. Tau deposits of the pretangle 
type were found in the frontal and temporal cortex, and to a lesser degree in the parietal 
cortex, the granular cells of dentate gyrus, and substantia nigra. In the first three P301L 
brains, no amyloid staining was observed, while in P301L brain 4, some diffuse plaques 
were seen, mainly in the temporal and occipital cortex; no neuritic plaques or amyloid 
angiopathy were found. In P301L brain 5, many neurofibrillary tangles (NFT), some 
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extracellular, and many diffuse and neuritic plaques with dense amyloid cores were 
present in all cortices, subiculum, and hippocampus, whereas some tau-positive glial 
cells were additionally found in grey and white matter. Immunoblots of sarkosyl-insoluble 
tau from P301L brain 5 showed two major bands (64 and 68 kDa) and a minor band of 
72 kDa in frontal cortex, and four bands of 60, 64, 68 and 72 kDa in temporal cortex 
and hippocampus. EM study of sarkosyl-insoluble tau preparations from P301L brain 5 
showed tau-containing filaments in hippocampal formation, which were structurally 
similar to paired helical filaments (PHFs) in Alzheimer’s disease (AD), and slender twisted 
filaments in frontal cortex, similar to the other P301L family that we have recently 
described.11 
 
R406W brains  
 In the first R406W brain, neuronal loss and gliosis were of variable intensity in frontal 
and temporal cortex. NFT were abundant in the frontal and temporal cortex, pyramidal 
layer of the hippocampus, and gyrus parahippocampalis. Substantia nigra showed only 
a few NFT and neuropil threads. Occasional tau-positive glial cells were seen in the grey 
and white matter. A few diffuse plaques and occasional classic plaques (stained by βA4 
antibody) were present.  The antibody against ubiquitin showed staining of numerous 
neurons and dystrophic neurites in cortices and hippocampus. The second R406W brain 
showed severe neuronal loss and gliosis in the frontal, temporal, and parietal cortex. 
Many NFT and extracellular tangles were present in all cortices (except for occipital), 
hippocampus, gyrus parahippocampalis, amygdala, and hypothalamus. The NFT 
density in this brain was much higher than in the R406W brain 2. Many diffuse and 
neuritic plaques with dense cores (stained by anti-βA4 antibody) were present in all 
cortices with moderate deposition of β-amyloid in blood vessels. Immunoblots of 
sarkosyl-insoluble tau from the  R406W brain 1 showed four bands of 60, 64, 68 and 
72 kDa, and after alkaline phosphatase treatment six immunoreactive bands 
corresponding to the six tau isoforms in AD. The pattern of soluble tau was similar to 
that from control brains. EM of sarkosyl-insoluble tau preparations from the R406W 
brain 2 showed tau-containing filaments in the frontal and temporal cortices and 
hippocampal formation, which were structurally similar to PHFs in AD, with a diameter 
of 8-20 nm and a cross-over spacing of approximately 80 nm. A minority of filaments 
consisted of straight filaments (SFs) of about 12 nm.  
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Discussion 
 
All seven brains of patients with tau mutations (five P301L, two R406W mutations) 
showed NFT or tau deposits of pretangle type. However, large numbers of neuritic 
plaques  and amyloid angiopathy were present in P301L brain 5 and in R406W brain 2. 
There are at least two other reports of diffuse or classic plaques in patients with presenile 
dementia and P301L or splice donor mutations.8,18.  
Tau-positive pretangles (mainly perinuclear deposits) were seen in the frontal and 
temporal cortex, and dentate gyrus of the P301L brains, and this is similar to the Dutch 
family (HFTD1) with this mutation.11 This P301L pathology is also supported by the 
presence of slender twisted filaments, two major bands of 64 and 68 kDa, and a minor 
band of 72kDa of extracted sarkosyl-insoluble tau from the frontal cortex, which is 
consistent with the pattern in other P301L families.8,12,13 However, NFT, diffuse and 
senile plaques, PHFs, and a pattern of four bands (60, 64, 68 and 72 kDa) of sarkosyl-
insoluble tau from the temporal cortex and hippocampus of the P301L brain 5 is 
consistent with the pathological diagnosis AD. This is further supported by the presence 
of all six tau isoforms following treatment with alkaline phosphatase. This implies that 
two different types of tau pathology coexist in the same brain, but were differently 
distributed in some brain regions. 
The presence of NFT in nerve cells with occasional tau deposits in glial cells in both 
R406W brains is in agreement with studies carried out in another R406W family.19 NFT, 
extracellular NFT, PHFs and SFs are found when all six tau isoforms are mutated, as in 
cases with coding mutations outside exon 10. Interestingly, the R406W brain 2 showed 
both a higher density of NFT and a higher number of diffuse and neuritic plaques than 
the R406W brain 1.  
An intriguing question is whether the FTD and AD changes are concomitant, or whether 
there is an interaction between tau and amyloid pathology. An acceleration of NFT 
formation due to amyloid deposition has recently been observed in nondemented aging 
and preclinical AD.20 The question, therefore, whether this mechanism occurs in FTD 
with tau mutations remains to be elucidated in future studies. 
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Total tau and phospho-tau 181 in CSF of 
patients with frontotemporal dementia due to 
P301L and G272V tau mutations 
 
 
 
 
 
 
Abstract 
In this study, we analysed total tau, phosphotau 181, and amyloid-β1-42 in CSF of 26 
FTD patients, including nine with tau mutations (seven P301L, two G272V). Although 
CSF total tau was mildly increased in FTD (p=0.05), this increase was not seen in the 
subgroup with tau mutations. Furthermore, CSF phospho-tau 181 and Aβ1-42 levels were 
not different compared with non-demented controls. Therefore, we conclude that the tau 
pathology present in P301L and G272V brain does not appear to be associated with an 
increase in either CSF total tau or phospho-tau 181.  
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rontotemporal dementia (FTD) is a neurodegenerative disorder of the 
frontotemporal cortex, presenting with presenile onset of behavioural changes 
and cognitive decline.1 Mutations in the tau gene have been identified in 
some, but not all patients with familial FTD, and are associated with the 
accumulation of hyperphosphorylated tau protein in the brain at neuropathological 
examination.2,3 In contrast, only about 20% of cases with sporadic FTD show 
accumulation of tau protein, usually in the shape of classical Pick bodies. The remaining 
cases are characterised by neuronal loss, spongiosis and gliosis with or without 
ubiquitin-positive, but tau-negative inclusions in the frontotemporal cortex, and may 
occur in sporadic as well as in familial form.4     
Because cerebrospinal fluid (CSF) is in direct contact with the extracellular space of the 
central nervous system, many studies have focussed on CSF in search of biomarkers with 
diagnostic significance in dementia. Most studies with FTD patients show a modest 
increase of total tau protein concentration in CSF.5,6 However, the level of tau protein in 
CSF has not yet been investigated in FTDP-17 patients with tau mutations. Therefore, we 
measured levels of CSF total tau (t-tau), CSF tau phosphorylated at Thr181 (Ptau-181), 
and CSF-amyloid-β1-42  (Aβ1-42) in 26 FTD patients, nine of whom showed missense 
mutations in the tau gene. We compared our findings with a group of patients with 
tauopathy due to Alzheimer’s disease (AD) as well as non-demented controls. Our 
hypothesis was that CSF Ptau-181 levels would be elevated in FTDP-17 patients with tau 
mutations, as all known tau mutations lead to the deposition of hyperphosphorylated tau 
protein in neurons and/or glial cells, and these deposits are known to be 
phosphorylated at Thr181 in P301L and G272V brain.7 
 
Methods 
 
Subjects 
Twenty-six patients with FTD (12 women, 14 men, mean age 54.7 ± 7.0 years [± 
standard deviation]) were recruited for CSF analysis from the outpatients clinic of the 
departments of Neurology of the Erasmus Medical Centre of Rotterdam and the VU 
University Medical Centre of Amsterdam, the Netherlands between January 1997 and 
December 2001 (Table 1). Tau mutations were identified in nine FTD patients with a 
positive family history: seven with the P301L mutation and two with the G272V 
mutation.8 Family history of dementia was negative in the remaining 17 FTD patients. In 
addition to these patients, we included 18 patients with AD (seven women, 11 men, 
mean age 66.0 ± 7.5 years), and 13 non-demented controls (eight women, five men, 
mean age 57.3 ± 12.6). Non-demented controls were subjects who visited the 
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outpatients clinic for thunderclap headache without subarachnoidal haemorrhage, 
neuritis vestibularis, or non-progressive subjective memory complaints without cognitive 
impairment on extensive psychometric evaluation or imaging abnormalities.  
The diagnosis probable FTD was made according to the Lund-Manchester criteria1 and 
the diagnosis probable AD was made in accordance with the NINCDS-ADRDA criteria.9 
All patients underwent thorough clinical investigation, including detailed medical and 
family history, neurological examination, psychometric evaluations and neuroimaging, 
consisting of CT, MRI, and/or single-photon emission computed tomography (SPECT) 
scanning with 99mTc-hexamethyl propyleneamine oxime (HMPAO). In case of a 
diagnostic lumbar puncture and CSF examination, patients were asked to consent to the 
collection of additional 4 ml for research purposes. The study protocol was approved by 
the Medical Ethics Committee of Erasmus Medical Centre, Rotterdam, and the VU 
University Medical Centre, Amsterdam, the Netherlands.  
 
CSF analysis 
CSF samples were obtained by lumbar puncture  and stored in  polypropylene tubes at 
-80°C until biochemical analysis. CSF t-tau was determined by sandwich ELISA using the 
monoclonal antibody (Mab) AT120 as capturing antibody, and two Mabs (HT7 and 
BT2) as detection antibodies, recognising different epitopes (INNOTESTTM hTAU-Ag, 
Innogenetics, Gent, Belgium).10 CSF Ptau-181 was determined by sandwich ELISA 
(INNOTESTTM PHOSPHO-TAU (181P), Innogenetics), using Mab HT7 as capturing 
antibody and biotinylated Mab AT270 as detection antibody, which is specific for a 
phosphotau-Thr181 epitope.11 CSF Aβ1-42 was determined by sandwich ELISA, using 
Mab 21F12 specific for the C-terminus of Aβ1-42 as capturing agent, and a biotinylated 
Mab anti- Aβ1-42 N-terminal antibody (3D6) for detection (INNOTESTTM β-amyloid (1-42), 
Innogenetics).12  
 
Statistics 
Statistical procedures were performed using Statistical Package of Social Sciences (SPSS) 
software. Data are presented as medians (25 and 75 percentiles) since CSF t-tau, CSF 
Ptau-181, and CSF-Aβ1-42 were not distributed normally. For group comparisons, the 
Mann-Whitney U-test and the Kruskal-Wallis tests were used depending on the number 
of groups. Correlations were calculated using Spearman’s rank correlation coefficient 
test with respective two-sided correlation. 
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Results 
 
The age at examination in  patients with FTD was similar to that of non-demented 
controls (p=0.4), while the AD patients were significantly older (p<0.001). The mean 
age of the nine FTD patients with tau mutations (52.3±7.0 years) did not differ from that 
of the remaining FTD patients (56.0±6.9 years, p=0.2). The mean duration of disease 
at lumbar puncture in both FTD and AD patients was 3.0 years. CSF t-tau, CSF Ptau-
181, and CSF Aβ1-42 levels were similar in men and women. There was no significant 
correlation between CSF t-tau, CSF Ptau-181 or CSF Aβ1-42, and age at lumbar 
puncture or duration of disease in any of the patient groups. The correlation between 
CSF t-tau and CSF Ptau-181 was high in all groups.  
CSF t-tau in FTD patients was slightly higher than in non-demented controls (p=0.05), 
whereas CSF t-tau in the subgroup of FTD patients with tau mutations did not differ 
significantly from that in controls (Figure 1). CSF t-tau levels were increased in patients 
with AD (p<0.001) compared with non-demented controls . CSF Ptau-181 in the total 
FTD group, as well as in the two subgroups separately, did not differ from that in 
controls, while CSF Ptau-181 levels in AD patients were significantly higher than in non-
demented controls (p<0.001). The ratio of CSF Ptau-181 over CSF t-tau was not 
different in any of the groups. There was no correlation between the duration of the 
symptoms in patients with tau mutations and CSF t-tau or CSF Ptau-181 (Table 2). FTD 
patients, including patients with tau mutations, had similar levels of CSF Aβ1-42 
compared with non-demented controls, in contrast to AD patients, who had  lower levels 
of CSF Aβ1-42 compared with non-demented controls (p< 0.001).   
 
Discussion 
 
To our knowledge, this study is the first to address CSF tau levels in FTD patients with tau 
mutations. Although CSF t-tau was slightly higher in FTD patients than in non-demented 
controls, this elevation was not found in the subgroup of patients with P301L or G272V 
tau mutations. CSF Ptau-181 was not increased in FTD patients, neither in FTD with tau 
mutations or in sporadic FTD. At the same time, we confirmed previous findings of 
increased CSF t-tau and CSF Ptau-181 levels, and lowered CSF Aβ1-42  in AD patients. 
The observation of mildly increased levels of CSF t-tau in the total FTD group is similar 
to findings in previous studies regarding FTD.5,6 Increased CSF t-tau has also been 
found in a variety of other neurological disorders, including AD, corticobasal 
degeneration, Creutzfeldt-Jakob disease and acute stroke.13,14 Therefore, these elevated 
levels probably   
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Figure 1. Scatterplots of CSF analyses  
 
                             
 
A. Total-tau, B. CSF Ptau-181, C. CSF Aβ1-42, per diagnostic category (bar represents 
median). 
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Table 2. Characteristics of patients with tau mutations 
 
    Sex  Age*  Duration*   t-tau   Ptau-181  Aβ1-42  
               (pg/ml)  (pg/ml)  (pg/ml) 
 
P301 L tau mutation 
  1.  F   49   0.5    266   27    528 
  2.  M   58   2.0    345   44    674 
  3.   M   52   0.8    569   42    725 
  4.  F   62   5.0    214   34    475 
  5.  F   53   1.1    332   31    692 
6.  M   63   2.0    155   28    324 
  7.  F   45   2.3    331   28    478 
G272V tau mutation 
8.  M   45   3.2    330   42    748 
  9.  M   45   2.2    123   20    343 
 
* years. T-tau = total tau; Ptau-181= tau phosphorylated at Thr. 181; Aβ1-42 = β-
amyloid1-42 protein, F = female, M = male.      
 
 
reflect aspecific neuronal and axonal degeneration, and are not merely a consequence 
of neurofibrillary tau pathology. It has been proposed that hyperphosphorylated tau 
protein, which is the neuropathological substrate that all tauopathies have in common, 
may be more specific in differentiating tauopathies such as AD and corticobasal 
degeneration from other neurodegenerative disorders. Indeed, studies regarding CSF 
phospho-tau using antibodies directed against different phospho-epitopes (Threonine-
181, Serine-199, and Threonine-231) have all shown an increase in CSF phospho-tau, 
specifically in AD.15-17  
Surprisingly, CSF Ptau-181 levels in the present study were not increased in FTD patients 
with tau mutations. These findings indicate that accumulation of phosphorylated tau in 
brains of patients with tauopathy does not necessarily lead to an increase in CSF 
phospho-tau. Additional factors are probably involved in determining why certain other 
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tauopathies, such as AD, are indeed associated with an increase in CSF phospho-tau. A 
possible explanation for this observation may be that the tau deposits in P301L and 
G272V brain are located intracellulary (in the shape of pretangles or Pick-like inclusions 
respectively) and might not reach the CSF, while the extracellular ghost tangles found in 
AD are not seen.18 It will be interesting to examine CSF of patients with R406W tau 
mutations, as the neurofibrillary pathology found in this mutation closely resembles 
AD.19  
In the current study, CSF was only available from patients with P301L and G272V 
missense mutations, which both reduce the ability of mutant tau protein to interact with 
microtubules and other molecules.20 Intronic and some coding region mutations in exon 
10 have a primary effect at the mRNA level, resulting in a change in ratio of 3- to 4-
repeat tau isoforms, without affecting the binding-properties of the protein. Because of 
the different mechanisms by which tau mutations lead to neurodegeneration, it is 
unpredictable whether CSF t-tau or CSF Ptau-181 levels may be altered in patients with 
tau mutations that affect the alternative splicing of exon 10. Analysis of CSF of patients 
with different types of tau mutations, as well as various other types of tauopathy, may 
contribute to our understanding of which factors determine the selective increase of 
different CSF proteins in neurodegenerative disorders in general. 
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Chapter  
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Familial frontotemporal dementia with ubiquitin-
positive inclusions is linked to chromosome 
17q21-22 
 
 
Abstract 
Hereditary frontotemporal dementia (FTD) is an autosomal dominant neurodegenerative 
disorder that is associated with mutations in the tau gene and with the pathological 
accumulation of hyperphosphorylated tau protein in affected brain cells in about a 
quarter of cases. However, most FTD families have no demonstrable tau mutations. 
Here we describe the clinical and neuropathological features of a large family with 
hereditary FTD. Genetic analysis showed strong evidence for linkage to chromosome 
17q21-22 (maximum lod score 3.46, θ=0 for marker D17S950), but mutations in the 
tau gene were not found. Clinical symptoms, neuropsychological deficits, and 
neuroimaging findings of affected family members were similar to sporadic and tau-
related FTD. The mean age at onset was 61.2 years, with initiative loss and decreased 
spontaneous speech as the most prominent presenting symptoms. Pathological 
examination of the brains of two affected family members showed non-specific neuronal 
degeneration with dense cytoplasmic ubiquitin-positive inclusions in neurones of the 
second layer of the frontotemporal cortex and dentate gyrus of the hippocampus. In a 
number of neurones these inclusions appeared to be located inside the nucleus, 
although due to the small number of these inclusions this localisation could not be 
confirmed by electron microscopy. The inclusions were not stained by tau, α-synuclein, 
or polyglutamine antibodies. Biochemical analysis of soluble tau did not reveal 
abnormalities in tau isoform distribution and analysis of mRNA showed the presence of 
both three- and four-repeat transcripts. This is the first report of ubiquitin-positive, tau-
negative inclusions in an FTD family with significant linkage to chromosome 17q21-22. 
Further characterisation of the ubiquitin-positive inclusions may clarify the 
neurodegenerative pathways involved in this subtype of FTD.  
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ereditary frontotemporal dementia (FTD) is a genetically heterogeneous 
disorder. Tau mutations were first identified in several families with FTD and 
parkinsonism linked to chromosome 17 (FTDP-17),1-4 and subsequently in 
patients presenting with other clinical phenotypes, including progressive 
supranuclear palsy and corticobasal degeneration.5-7 All families with tau mutations 
have in common the accumulation of hyperphosphorylated tau protein in affected 
neurones or glial cells.8,9 However, at least three FTDP-17 families have not shown tau 
mutations, despite significant linkage to the tau-containing region on chromosome 
17q21-22.10-12 Linkage to another locus on the centromeric region of chromosome 3 
has been reported previously in a single Danish FTD kindred.13 Recently, locus 
heterogeneity in FTD has been emphasised by the identification of a new locus on 
chromosome 9q21-22 in families with amyotrophic lateral sclerosis and FTD-type 
dementia.14 
Two FTD families have shown ubiquitin-positive, tau-negative inclusions, which suggests 
an alternative pathophysiological mechanism.15,16  Ubiquitin-positive inclusions have 
classically been associated with FTD with motor neurone disease, although recent 
studies have shown similar inclusions in sporadic cases of FTD without motor neurone 
disease,17 and in semantic dementia.18 These ubiquitin-positive cytoplasmic inclusions 
are present consistently in the superficial layers of the frontotemporal cortex and dentate 
gyrus of the hippocampus, and have to be distinguished from the ubiquitinated neurites 
that can be found in nearly all cases of FTD.19,20  
Here we describe the clinical and neuropathological features of a large Dutch FTD 
family (family HFTD3) reported earlier,10 which is characterised by ubiquitin-positive, 
tau-negative inclusions. Genetic analysis revealed strong evidence for linkage to the tau-
containing region of chromosome 17q21-22, but mutations in the tau gene were not 
identified.  
 
Methods 
 
Clinical data 
This four-generation FTD family with 32 affected members (19 women, 13 men) shows an 
autosomal dominant pattern of inheritance (Figure 1) and has been reported briefly.10  
Clinical information was obtained by interviewing relatives of patients, neurological 
examination of living patients (six patients), and reviewing the medical records (including 
hard copies of neuroimaging studies). The diagnosis of FTD according to the criteria of the 
Lund and Manchester groups21,22 was established in 10 patients, and unspecified dementia 
was diagnosed in the remaining 22 patients because of limited clinical information.  
H 
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Figure 1. Pedigree of family HFTD3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extensive psychometric testing was done at our department in two patients, and included 
the assessment of language functions, intelligence, attention and concentration, 
memory, executive functions, abstract thinking, and visuoconstructive abilities. 
Neuropsychological evaluation was done earlier elsewhere in five patients. CT was 
available in six patients, MRI in one patient, single-photon emission computed 
tomography (SPECT) scanning with 99mTc-hexamethyl propyleneamine oxime (HMPAO) 
in three patients, and with 123I-iodobenzamide (IBZM) scanning in one patient. Brain 
autopsy with neuropathological verification of the clinical diagnosis was performed in 
two patients. The Medical Ethics Committee of the University Hospital of Rotterdam 
approved the study. The spouse or a first-degree relative of each patient gave informed 
consent for blood sampling for DNA studies. 
 
Genetic studies 
We have reported mildly positive lod-scores for chromosome 17 markers for this family 
previously, but these scores did not reach significance.10 After ascertainment of 
additional affected relatives, we repeated the analysis on all available family members.  
Genomic DNA was isolated from peripheral blood as described by Miller et al.23 The 
short tandem repeat polymorphisms D17S945, D17S953, D17S946, D17S934, 
D17S951, D17S950, and D17S791 for chromosome 17q21-22 were selected based 
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108 9 12 20
48 51 61
1
I 
 
II 
 
III 
 
IV 
 
 
 
 
II 
 
III 
 
IV 
Chapter 5.1 
120 
 
 
on previous linkage results,10 and D3S1598, D3S3695, D3S3681, D3S1603, and 
D3S3574 for the pericentromeric region of chromosome 3 were selected on the basis of 
a report of linkage in familial FTD.13 Genomic DNA (25 ng) was amplified in  10 µl 
polymerase chain reactions (PCR) containing 1X GeneAmp PCR Gold Buffer, 1.5 mM 
MgCl, 25 ng of fluorescent forward primer, 25 ng unlabelled reverse primer and 0.4U 
of AmpliTaq Gold DNA polymerase. Initial denaturation was 15 min at 95°C followed 
by 32 cycles of 30s denaturation at 95°C, 30s annealing at 55°C and 90s extension at 
72°C. Reactions were prepared using a Beckman Biomeck 2000 robot system and 
performed in 384-well plates covered with sealing lids (Costar 6557; 6555). A 
GeneAmp PCR System 9700 (Applied Biosystems, Foster City, Calif., USA) equipped 
with dual 384-well plates was used for amplification. PCR products were pooled and 
loaded on an ABI 377 automated sequencer (filterset D; 5% denaturing FMC 
LongRanger acrylamide gel), data were analysed using ABI GeneScan 3.1 and ABI 
Genotyper 2.1 software.  
Two-point linkage analysis was performed using the Mlink and Ilink programs of the 
Linkage package, version 5.1.24 Maximum lod and location scores were calculated for 
each marker using an affected only analysis. Unaffected family members were typed as 
unknown. A gene frequency of 1 : 10 000, no phenocopies and equal allele 
frequencies of the genotyped markers were used in the calculations. Changing allele 
frequencies of the polymorphic markers did not alter the lod and location scores 
significantly. Multipoint analysis was performed by subsequent three-point linkage 
analysis on all markers tested. 
Exons 1, 2, 3, 4, 5, 7, 9, 10, 11, 12, and 13 of the tau gene were amplified using 
specific primers derived from the 5' and 3' intronic sequences.25 The annealing 
temperature for all primer pairs was 58ºC. Amplification conditions were as follows: 
reaction volume was 50 µl with a final concentration of 10mM Tris-HCl, pH 8.3, 50mM 
KCl, 1.5mM MgCl2, 200µM dNTPs, Taq polymerase at 1.5 U/50 µl, primers at 25 
pmol/µl, and 50 ng of template genomic DNA. The PCR reactions were analysed on a 
2% agarose gel to verify the size and quantity of the PCR product. PCR products were 
analysed subsequently by direct sequence analysis of the PCR products on an automated 
DNA sequencer (ABI 377) using the BigDye terminator cycle sequencing kit (Applied 
Biosystems).  
 
Neuropathology 
A brain autopsy was performed by the Netherlands Brain Bank on two patients (IV:10 
and IV:60). Informed consent was obtained from the patients’ next of kin before autopsy 
for use of the tissue for diagnostic purposes as well as for scientific research. After fresh 
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dissection of various brain regions, tissue blocks were either frozen rapidly in liquid 
nitrogen and stored at -80°C (Patient IV:60 only) or fixed in formalin and embedded in 
paraffin. Sections from all cortical regions, the hippocampus and parahippocampal 
gyrus, amygdala, substantia nigra, basal ganglia, thalamus, cerebellum, and brainstem 
were processed for routine staining (haematoxylin and eosin, Bodian silver, 
methenamine silver, and congo red) and immunohistochemistry. A conventional avidin-
biotin-peroxidase complex method (Zymed Laboratories, San Francisco, Calif., USA) 
was used, with diaminobenzidine as the chromogen. Slides were counterstained with 
Mayer’s haematoxylin and mounted in Entellan.  
We used monoclonal (MC) and polyclonal (PC) antibodies raised against tau protein, 
both phosphorylation dependent [AT8 (MC), 1:40, Innogenetics, Gent, Belgium; AT180 
(MC), 1:500, Innogenetics;  AT270 (MC), 1:500, Innogenetics; PHF1 (MC), 1:500, gift 
from Peter Davies, Albert Einstein College of Medicine, New York, NY, USA; MC1 (MC), 
1:25, gift from Peter Davies], and phosphorylation independent [T14 (MC), 1:100, 
Zymed Laboratories; BR01 (MC), 1:500, Innogenetics; Tau2 (MC), 1:100, Sigma, St 
Louis, Mo., USA), as well as antibodies against ubiquitin (PC, 1:500, Dako, Glostrup, 
Denmark),  polyglutamine (1C2 (MC), 1:1000, Chemicon, Temecula, Calif., USA), 
human leucocyte antigen DR (HLA-DR)(MC, 1:100, Dako),  αΒ-Crystallin (PC, 1:500, 
Novocastra Laboratories, Newcastle-upon-Tyne, UK), β-amyloid (βA4, MC, 1:100, 
Dako), α-, β-, and γ-synuclein (PER 4, 3 and 5, 1:500, M.G.Spillantini, Cambridge, 
UK26), β-tubulin (TUB 2.1, MC, 1:500, Sigma), glial fibrillary acidic protein (GFAP)(MC, 
1:500, Dako), synaptophysin (PC, 1:100, Dako), microtubule associated protein 
(MAP2)(MC, 1:100, Boehringer, Mannheim, Germany), neurofilament (SMI-32, 
1:1000, Sternberger Monoclonals, Lutherville, Md., USA), neuroserpin (1:500, 
M.G.Spillantini), actin (MC, 1:25, Dako), neurogranin (1:500, Chemicon), strathmin 
(1;500, Calbiochem, San Diego, Calif., USA), heparan sulphate (1:250, Seikagaku 
Amerika, Rockville, Md., USA), parkin (1:500, Chemicon). Heat-induced antigen 
retrieval was performed by heating slides at 80°C for 30 minutes in 0.1M sodium citrate 
buffer at pH 7.7 for several antibodies (polyglutamine, HLA DR, β-tubulin, 
synaptophysin, MAP2, GFAP, T14, BR01, and Tau2). Tissue sections were pretreated 
with 90% formic acid for 5 min before incubation with βA4 antibody.  
 
Biochemical studies 
Soluble tau was extracted using 2.5% perchloric acid as described previously27 and 
blotted onto Immobilon P (Millipore, Bedford, Mass., USA). Blots were incubated 
overnight at 4°C with phosphorylation-independent anti-tau antibodies (BR133 and 
BR1348) and stained using the biotin-avidin Vectastain system (Vector laboratories, 
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Burlingame, Calif., USA). Sarkosyl-insoluble extracts were run on 10% SDS-PAGE 
(sodium dodecylsulphate-polyacrylamide gel electrophoresis) gels and blotted onto 
Immobilon P (Millipore) and processed for immunoblotting as indicated above. Electron 
microscopy was used to evaluate the presence of sarkosyl-insoluble tau filaments as 
described previously.28  
Total RNA was isolated from frontal cortex tissue of Patient IV:60 and two healthy 
control brains using RNAzolB kit (Campro Scientific, Berlin, Germany) according to 
manufacturer’s specifications. Reverse transcription (RT)-PCR was performed using the 
Superscript Preamplification System (Life Technologies, Gaithersburg, Md., USA) on 5 
µg of brain RNA with both oligo(dT) and random hexamer primers. PCR was performed 
between exon 9 (forward, 5’-ATCGCAGCGGCTACAGCAG-3’) and exon 11 (reverse, 
5’-TGGTTTATGATGGATGGATGTTGCCT-3’). PCR products (30 cycles) were resolved 
on 2% agarose gel and visualised with ethidium bromide. 
 
Results 
 
Clinical features 
The mean age at onset of symptoms in the 10 patients with probable FTD was 61.2 
years (range 53 - 71 years). The mean duration of symptoms until time of death was 8.6 
years (n=9), one patient was still alive at the time of investigation. The average age at 
death of all affected family members (n=30) was 69.1 years. There was no difference 
between the age at death of men (69.7 years) and women (68.6 years), or evidence of 
anticipation in consecutive generations.  
Loss of initiative and decreased spontaneous speech were the most prominent clinical 
features. The patients withdrew socially and lost interest in their family and environment. 
Restlessness and agitation were often reported at late stages of the disease. Patients did 
not show any concern or insight as to their illness, except at the earliest stage in one 
patient. Memory problems were inconsistent and often related to decreased attention 
span. Focal neurological deficits were absent, whereas primitive reflexes were seen at a 
late stage in all patients examined. Bradykinesia and cogwheel rigidity were found in 
three patients, in one at a very late stage of the disease. The two patients with early 
symptoms (IV:20 and V:1) were both treated with levodopa, which resulted in only a 
partial and transient response in Patient V:1. Signs of motor neurone disease, such as 
muscle weakness, hyperreflexia, and fasciculations, were absent. No epileptic seizures or 
myoclonic movements were observed or mentioned in the medical records of any of the 
patients. The main clinical features and neuroimaging findings are summarised in Table 
1.  
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Extensive neuropsychological evaluation in two patients (1 and 2 years after onset, 
respectively) showed evidence for cognitive impairment compatible with the diagnosis 
FTD. Both patients were co-operative, but lacked insight about their performance and 
were easily distracted as a result of decreased attention and stimulus-bound behaviour. 
Reduced word fluency, impaired abstract thinking, perseverations, and reduced mental 
flexibility were also evident. Except for mild naming difficulties, no evident signs of 
language disturbance were apparent. Memory and visuospatial functions were both 
relatively spared. Neuropsychological results of the other patients, using various test 
batteries, were also consistent with frontal lobe dysfunction.  
Structural neuroimaging, available in six patients, showed mild atrophy (frontotemporal 
in three, temporal in one) in four patients (1, 2, 3, and 3 years after onset), and 
moderate to severe atrophy in two patients (1 and 5 years after onset). Two of these 
patients showed mild asymmetry of atrophy. An HMPAO-SPECT scan was available for 
three patients and showed anterior hypoperfusion in all three, with a mildly asymmetrical 
pattern in two patients. IBZM-SPECT was performed in one patient (V:1) and showed an 
asymmetric reduction in dopamine D2 receptors in the striatum. 
 
Illustrative cases 
 
Patient IV:60 This patient became unable to manage his farm at age 70 and his son 
had to take over. He showed lack of initiative and did not respond adequately in difficult 
situations. Spontaneous speech decreased and he lost interest in family and friends. He did 
not care sufficiently for his handicapped wife and quarrelled with her about trivialities. He 
spent most of his time at home sitting in a chair and tapping the armrest with his fingers 
continuously. He showed no signs of disinhibition and his eating habits remained 
unchanged. Neuropsychological evaluation 2 years after onset showed mild naming 
difficulties, problems with abstract thinking, perseverative and impulsive behaviour, mild 
visuospatial impairment and relatively intact memory functions.  
A CT scan at that time showed mild atrophy of both the frontal and temporal lobes, which 
was slightly more prominent in the left hemisphere (Fig. 2A). HMPAO-SPECT showed 
evident hypoperfusion of anterior parts of both cerebral hemispheres, which was more 
pronounced on the left than on the right. His condition deteriorated during the next 3 
years. He developed mutism, bradykinesia, rigidity without resting tremor, and swallowing 
difficulties. A second CT scan 5 years after disease onset showed moderate to severe 
atrophy of the same regions (Fig. 2B). The patient died  at the age of 76 years, probably 
from ischaemic heart disease, and an autopsy was done. 
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Figure 2. CT scans of patient IV:60 
 
 
A. Transverse image 2 years after onset showing mild frontotemporal atrophy, which is 
slightly more prominent on the left than on the right. B. Transverse image showing 
progression of atrophy 5 years after onset of symptoms. 
 
Patient V:1 This 53-year-old woman complained of memory problems and difficulty in 
scheduling her work as a specialised nurse. Her colleagues found her alertness reduced 
in complicated situations. Her husband noted social withdrawal by neglecting telephone 
calls and appointments with friends. She called her daughter several times a day with 
identical questions. She was restless and made long trips on foot (several miles a day) or 
by bicycle (up to 40 miles a day) without losing her way. She was caught twice for 
shoplifting in a supermarket. An MRI scan of the brain showed symmetric frontotemporal 
atrophy (Fig. 3A and B), with corresponding anterior hypoperfusion on SPECT scan. 
Psychometric evaluation showed decreased attention and concentration, perseveration, 
impairment of abstract thinking and concept-shifting, and relatively intact memory and 
visuospatial functions. One year after onset, the patient still showed some insight as to 
her illness, and felt depressed about her deficits. Furthermore, she complained of fatigue 
and stiffness in both legs and her right hand. Neurological examination showed a 
masked face, mild bradykinesia and cogwheel rigidity in both extremities, without 
postural instability. IBZM-SPECT showed a reduction of striatal dopamine D2 receptors, 
greater on the left than on the right (Fig. 3C). The symptoms showed a subjective partial 
and transient response to levodopa treatment. 
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Figure 3. Neuroimaging of patient V:1 
 
 
A. T1-weighted transverse image showing moderate frontotemporal atrophy 1 year after 
disease onset. B. T2-weighted coronal image at the same time as that illustrated in A, 
showing additional mild atrophy of the temporal lobes. C. Reduction in striatal 
dopamine D2 receptors on IBZM-SPECT. The reduction is greater on the left than on the 
right.  
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Genetic studies 
Positive lod scores for all chromosome 17 markers were obtained, with a maximum lod 
score of 2.5 with marker D17S950 (θ = 0). Multipoint analysis resulted in a maximum 
lod score of 3.46 at D17S950 (θ = 0). Haplotype analysis revealed recombination 
events with markers D17S945 and D17S953, but not with marker D17S791. Therefore, 
the microtubule-associated protein tau gene is located within the critical region for this 
family. Mutation analysis of the complete coding region and intron-exon boundaries did 
not reveal a pathogenic mutation in this gene. Two-point lod scores for all chromosome 
3 markers did not support linkage to this region, although none of the markers definitely 
excluded linkage. 
 
Neuropathology 
Atrophy of both frontal and temporal lobes and severely dilated ventricles were present 
in the brain of patient IV:10 (1170 g), whereas only frontal atrophy was seen in the 
brain of Patient IV:60 (930 g). The brains of the two patients showed similar pathology: 
severe neuronal loss and gliosis in the second and third cortical layers of the frontal and 
temporal cortex (Fig. 4A), although the temporal cortex of brain IV:60 was relatively 
spared compared to the frontal cortex. Furthermore, neuronal loss was seen in the cornu 
ammonis of the hippocampus and the entorhinal cortex of both brains. A few 
neurofibrillary tangles in the pyramidal cells of the entorhinal cortex (no more than five 
per section) were present in brain of Patient IV:60, as can be expected at the age of 76.  
Both brains showed normal occipital cortex and cerebellum. Severe loss of pigmented 
neurones was seen in the substantia nigra, and the thalamus, caudate nuclei and 
putamen were also affected. The nucleus hypoglossus of both patients and the cervical 
spinal cord (only available for brain IV:60) were normal. Neuritic or diffuse plaques, 
ballooned cells, Pick bodies and Lewy bodies were absent in both brains.  
Staining with anti-ubiquitin antibody showed small, dense intracytoplasmic inclusions in 
neurones of the second layer of the frontal and temporal cortex of both brains, and also 
to a lesser extent in the parietal cortex of  brain IV:10. The highest density of inclusions 
was present in the cingulate gyrus of both brains. The inclusions were not visible with 
conventional hematoxylin-eosin, Bodian or methenamine-silver staining, and were 
located preferentially in the perikaryal space directly next to the nucleus. The inclusions 
were sharply circumscribed and usually round- or crescent-shaped (Fig. 4B). A few 
ubiquitin inclusions, apparently located within the nucleus, were identified at thorough 
examination. These inclusions had a cat’s eye or target shape and were occasionally 
grouped together in small fields (Fig. 4C).  
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Figure 4.  Microscopic findings in patient IV:60 
 
 
A. Hematoxylin and eosin staining of frontal cortex, showing severe neuronal loss and 
microvacuolation. B. Ubiquitin immunostaining of frontal cortex, showing cytoplasmic 
inclusions in neurones of layer 2 (arrows). C. Same region and staining as B, showing a 
small field of inclusions that appears to be located inside the nucleus (arrows). D. 
Dentate gyrus of hippocampus, showing ubiquitin-positive cytoplasmic inclusions 
(arrows). Scale bars = 240 µm (A) and 100µm (B-D). 
 
Furthermore, some granular cells of the dentate gyrus contained cytoplasmic ubiquitin-
positive inclusions, which were round and less dense than the inclusions found in cortical 
regions (Fig. 4D). Ubiquitin-positive neurites were also present in the affected cortical 
layers in both patients. The subcortical regions did not contain any inclusions. The 
nucleus hypoglossus of the midbrain of both patients, as well as the spinal chord (only 
available for Patient IV:60) did not show any ubiquitin inclusions.  
Phosphorylation-dependent and independent antibodies against tau protein and 
antibodies against α-synuclein, neurofilament (SMI-32), β-tubulin , MAP2, and 
polyglutamine (1C2) did not stain the inclusions. No amyloid plaques or ballooned cells 
were detected with βA4 antibody or αB-crystallin, respectively. In brain IV:10, staining 
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with GFAP antibody showed very severe reactive astrocytosis in all frontal and temporal 
cortical layers, whereas in brain IV:60 astrocytosis was moderate and restricted to the 
frontal and temporal subcortical white matter, with relatively mild changes in the cortex. 
 
 
Biochemical studies 
Analysis of soluble tau showed the presence of all six tau isoforms in affected  regions of 
brain IV:60 (Fig. 5). The distribution of isoforms appeared normal, with similar amounts 
of three- and four-repeat tau isoforms. No sarkosyl-insoluble filaments could be 
detected by electron microscopy, in agreement with the fact that no sarkosyl-insoluble 
tau was found by immunoblotting. RT-PCR revealed the presence of both three- and 
four-repeat tau transcripts in frontal cortex of Patient IV:60 (data not shown). 
 
 
Figure 5.  Biochemical studies of patient IV:60 
 
 
 
Immunoblot of dephosphorylated soluble tau protein (BR134) from the frontal cortex of 
Patient IV:60 (lane 3) and a control patient with Alzheimer’s disease (lane 2). All six tau 
isoforms are present and align with the six recombinant human brain tau isoforms (lane 
1). 
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The present study describes the clinicopathological features of a large family with 
autosomal dominantly inherited FTD. Ubiquitin-positive, tau-negative neuronal 
inclusions were the most characteristic neuropathological finding. The significant linkage 
to chromosome 17q21-22 in this family was not associated with either mutations in the 
tau gene or tau deposition in the brain, as can be found in a subset of families with FTD.  
The clinical symptomatology of the present family is consistent with the diagnosis of FTD 
according to the Lund and Manchester criteria, and fits within the wide spectrum of the 
clinical phenotype in hereditary tau-related FTD.9,29-31 In the absence of disinhibition, the 
diagnosis in our family was based on the presence of initiative loss, reduced 
spontaneous speech and frontal deficits on neuropsychological testing (reduced 
concept-shifting and word fluency, mental inflexibility and impaired abstract thinking) 
and was supported by selective atrophy of the frontal and temporal cortex. However, 
there was great variation in the age at onset – from 53 to 71 years. This differs from that 
seen in most families with tau-related FTD.30 An age at onset of > 65 years (which was 
found in two of the affected family members) is also uncommon in other hereditary 
forms of FTD. Other symptoms typical of FTD, such as disinhibition, obsessive-
compulsive behaviour, and signs of motor neurone disease, were not observed, 
although they are found in other FTD families with ubiquitin inclusions.15,32 The reduction 
in striatal dopamine D2 receptors in one of our patients with early parkinsonism 
indicated a similar pathophysiological mechanism of a postsynaptic defect, as found in 
an FTD patient with P301S mutation in the tau gene.33 
The presence of cytoplasmic ubiquitin-positive inclusions in neurones of the frontal and 
temporal cortices in the present family may be a first clue in elucidating the aetiology of 
this form of FTD. These tau- and α-synuclein-negative inclusions are similar in 
appearance and distribution to those described in FTD with motor neurone disease, 
some cases of semantic dementia and in a few other families with FTD.15-18 A small 
fraction of inclusions appeared to be located inside the nucleus of neurones, but may be 
located within the inward invaginations of the nuclear membrane, giving the false 
impression of intranuclear localisation. These intranuclear-like inclusions were seen in 
only a few microscopic fields after thorough inspection and were too rare to be 
considered as a main pathological substrate in our family. Their exact localisation can 
only be determined by electron microscopic studies, which were hampered by the 
scarcity of the lesions and the altered morphology of post-mortem tissues. It would be 
interesting to look for their presence in other familial and sporadic FTD cases.  
Discussion 
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other triplet repeat diseases,34,35 and has not been observed in FTD with tau pathology. 
It is unlikely that FTD in the present family is a triplet repeat disorder, as the inclusions 
did not stain with a polyglutamine antibody and anticipation in consecutive generations 
was not observed. As in other neurodegenerative diseases, the protein in the inclusions 
had probably been ubiquitinated in an attempt at degradation. Purification of the 
proteins in the inclusions and subsequent amino acid analysis of the isolated peptides 
may help to identify the genetic defect responsible for the disease.  
Our study confirms for the first time significant linkage to the chromosome 17q21-22 
region in a family with FTD showing neuronal ubiquitin-positive, tau-negative inclusions, 
and lacking mutations in the coding regions and exon-intron boundaries of the tau 
gene. Tau pathology was absent in both cases autopsied, except for a very few 
neurofibrillary tangles in the entire entorhinal cortex of Patient IV:60, consistent with the 
age of death of this patient (76 years). The presence of only a few neurofibrillary tangles 
in the entorhinal cortex of patient IV:60 was insufficient for the detection of sarkosyl 
insoluble tau. Interestingly, Zhukareva et al. have found reduced levels of sarkosyl-
soluble tau protein in sporadic FTD cases and in a family with hereditary dysphasic 
disinhibition dementia (HDDD2), which has shown linkage to the same chromosomal 
region and absence of tau mutations.36 However, we did not find a striking qualitative 
difference in the amount and ratio of three- versus four-repeat isoforms as compared 
with control brain. However, more patients are needed to determine the exact ratio’s.  
Kertesz et al. also found positive lod scores for the chromosome 17q21-22 region in 
one of the two other FTD families with ubiquitin-positive, tau-negative inclusions, but no 
mutations in the tau gene.15 Although an obligatory recombinant with an intragenic 
marker in the tau gene was found in one patient, only the 3’-end of the tau gene can be 
definitely excluded in this family as the marker is located within intron 9. Linkage to 
chromosome 17q21-22 or another genetic locus has not yet been demonstrated in the 
other FTD family with ubiquitin-positive inclusions and no tau mutations.16,32 It is 
interesting that a similar distribution of neuronal degeneration, most prominent in the 
second and third layers of the frontal and temporal cortices, is associated with two 
different pathological phenotypes, characterised either by abnormal tau deposition or by 
ubiquitin-positive inclusions.  
The critical region of linkage in this family contains a number of interesting candidate 
genes.11 GFAP is one of the genes within the critical region. The severe reactive 
astrocytosis seen upon GFAP antibody staining in the affected cortices of the brain IV:10 
and in the underlying white matter of brain IV:60 is similar to that described in the other 
The intranuclear-like appearance of some of the inclusions was different from the 
consistently intranuclear localisation of inclusions found in Huntington’s disease and 
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astrocytosis is an non-specific phenomenon and only reflects severe neuronal loss. 
Another candidate gene might be the nerve growth factor receptor gene,11 which may 
play a role in the induction of apoptotic cell death in the absence of nerve growth factor. 
However, evidence for apoptosis in FTD is inconsistent.37,38 We are currently 
investigating other candidate genes by sequence analysis. 
In summary, the present study of a family with FTD (family HFTD3) showing linkage to 
chromosome 17q21-22 initiates a new search for an alternative pathway of 
neurodegeneration in FTD, since ubiquitin-positive inclusions in neurones were found in 
the absence of both pathological tau deposition and mutations in the tau gene. The 
prevalence of ubiquitin-positive, tau-negative inclusions in both sporadic and familial 
FTD cases is unclear at present, and should be investigated systematically as they are a 
distinguishing feature and may be the hallmark of a specific subgroup of FTD cases. 
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lthough frontotemporal dementia (FTD) is the second most common cause of 
presenile dementia after Alzheimer's disease (AD), it is still a relatively rare 
disorder. Taking into account recent epidemiological studies (chapter 2.1),1 
we expect there to be less than a thousand patients in a population like the 
Netherlands of about 15.5 million inhabitants. Nevertheless, research in this field has 
evolved enormously over the past decade, especially after the delineation of the first 
clinical and neuropathological criteria for FTD by the Lund and Manchester groups in 
1994.2 However, it was not until the identification of the first mutations in the tau gene 
in 1998,3-5 that the major importance of this disorder was recognised by specialists in 
other neurodegenerative fields. Tauopathy is the hallmark of a number of related 
disorders, including progressive supranuclear palsy (PSP) and corticobasal degeneration 
(CBD), and elucidation of the pathophysiological pathways leading to 
neurodegeneration in these disorders may ultimately lead to therapeutic and preventive 
action. 
 
Further research regarding FTD is of importance for a number of reasons. First of all, 
accurate diagnosis of FTD at an early stage of the disease is necessary to improve the 
value of clinical studies. Knowledge regarding both epidemiology and the spectrum of 
clinical manifestations resulting from this disease is indispensable in this respect, as well 
as the development of novel diagnostic tools, such as biomarkers. This presenile 
disorder invariably has great impact on close family members, as the severe behavioural 
and personality changes often lead to distressing situations at home. Early diagnosis is 
therefore also of great importance for the family to understand and accept the changes 
in behaviour in the patient. Secondly, although much has been learnt over the past few 
years regarding the tau gene, identification of new tau mutations may give more insight 
into the different mechanisms through which tau dysfunction can lead to 
neurodegeneration. Subsequent development of functional studies and animal models 
yields invaluable information on the pathophysiological mechanisms involved in each 
type of mutation. Thirdly, little is known regarding the aetiology of FTD in patients 
without tau mutations, over 80% of the FTD population. Other genetic and possibly 
environmental causes still have to be identified.  
 
In this chapter the studies described in this thesis are discussed in the context of our 
current knowledge regarding neurodegeneration in general and FTD in particular. After 
some methodological considerations, the implications of the main findings are 
discussed, and suggestions for future research are made. 
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Methodological considerations 
 
Epidemiological studies 
Because FTD is a rare disorder, the patients in this study were collected from throughout 
the Netherlands, which has a population of more than 15 million inhabitants. We 
regularly requested all hospital-based neurologists and psychiatrists, as well as nursing 
home physicians, to refer patients with suspected FTD to us. In this way we hoped to 
ascertain all patients in the Netherlands with FTD. Unfortunately, as shown in chapter 
2.1, this approach was not entirely successful, with estimated prevalences in Zuid-
Holland being twice as high as in other provinces. As there is no evidence for familial 
clustering in Zuid-Holland, this difference is probably due to underascertainment in 
other provinces. As is discussed in chapter 2.1, explanations for underascertainment 
may be found in either misdiagnosis or non-referral, both of which occurred in our 
study.  
The only other study regarding the prevalence of FTD used a different approach and 
investigated all patients with presenile dementia in a small, but well-defined population 
in Cambridge, United Kingdom (UK).1 Underascertainment is less frequent in such a 
study, with misdiagnosis only occurring if a dementia syndrome is not recognised by the 
primary physician. However, there are also drawbacks to this study. First of all, 
neuropathological verification was not available, making it impossible to determine the 
accuracy of clinical diagnosis. A second drawback is the fact that this population was 
small, and may not be representative for the general UK population. For instance, the 
prevalence of Huntington's disease was extremely high in the Cambridge area, because 
of the presence of a specialised nursing home. Environmental factors may also affect 
prevalence estimates in a small population. The extreme overrepresentation of men in 
the Cambridge study (14 men, three women) may point in the direction of occupational 
risk factors, e.g. mining or exposure to chemicals in factories, which may be more 
common within specific populations.  
The province of Zuid-Holland is suitable for epidemiological studies, because of the 
population size (over 2 million inhabitants), density (relatively small area) and diversity 
(occupations, ethnic backgrounds). To improve the degree of ascertainment in our 
study, multiple sources of case ascertainment should be employed to minimise non-
referral. On top of the approaches already taken, general practitioners should be 
regularly requested to participate, so that patients not referred by their primary specialist 
or patients referred to hospitals outside the province would still be identified. 
Psychological practices and psychiatric hospitals should also be involved, as many 
patients are mistakenly diagnosed with psychiatric disorders such as depression. Finally, 
in order to reach patients and family directly, information regarding the study should be 
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and application of the capture-recapture technique propagated by Laporte,6 an estimate 
of the degree of under-ascertainment and subsequent correction may be attempted. 
Ideally, to completely resolve the issue of underascertainment in our study, a more 
rigorous approach to patient ascertainment would have to be pursued. Indeed, an 
epidemiological study regarding the prevalence of PSP in the U.K. investigated the effect 
of different methods of case ascertainment, a so-called ‘Russian doll’ design.7 Best 
results were achieved with an active method of case ascertainment, in which all 
computerised records of general practitioners were screened for PSP in a community 
based setting. However, this approach would be extremely time-consuming if applied to 
a large population such as Zuid-Holland, and may not be as efficient as in PSP, as 
relatively objective physical findings or therapeutic options are absent in FTD. In my 
opinion the amount of time and labour involved in obtaining an accurate estimate of the 
prevalence should be carefully weighted against the relevance of the information 
gained.  
 
Temporal variant of FTD 
Ascertainment of patients with the temporal variant of FTD in the current study has been 
difficult due to the fact that the clinical criteria were not established until 1998.8 The 
temporal variant of FTD may present as primary progressive aphasia or semantic 
dementia, depending upon the distribution of temporal atrophy on neuroimaging,9,10 
and patients with either of these syndromes were not included into our study until 1999. 
Patients who had been seen before that time were re-evaluated, and a number were 
included retrospectively. However, the percentage of patients not referred to us prior to 
1999 due to the atypical presentation of FTD, is unknown. 
Alternatively, recently an increasing number of patients with language difficulties were 
referred because of suspected FTD. However, language difficulties may also be 
prominent in other neurodegenerative diseases, such as Alzheimer's disease (AD), 
making the clinical distinction quite difficult.11,12 Typical in FTD patients, including those 
with the temporal variant, is the focal and often asymmetric aspect of atrophy on 
neuroimaging.13 If the atrophy tends to generalise, other disorders as AD are more 
likely. The chance of misdiagnosis is higher in the temporal variant of FTD, as AD also 
may present with atrophy of the medial temporal lobe, possibly resulting in an 
overestimation of the prevalence of FTD. Our approach, using strict criteria for focal 
and asymmetric atrophy, was found to be  successful, as shown by the fact that the 
diagnosis FTD was confirmed in all 13 patients with the temporal variant of FTD who 
came to autopsy during the course of the study.  
available on the internet. By  comparing the degree of ascertainment for each method 
General discussion 
139 
 
 
 
Genetic studies 
During the nineties, linkage to chromosome 17q21-q22 was found in a number of large 
pedigrees with an autosomal dominant pattern of inheritance of variable dementia 
syndromes. Remarkable names were used for these syndromes, such as disinhibition-
dementia-parkinsonism-amyotrophic complex (DDPAC),14 pallido-ponto-nigral 
degeneration (PPND),15 familial progressive subcortical gliosis,16 familial multiple system 
tauopathy,17 rapidly progressive familial frontotemporal dementia,18 and others. In 
1997, at a consensus meeting in Ann-Arbor, the similarities between these syndromes 
induced the collective term frontotemporal dementia and parkinsonism linked to 
chromosome 17 (FTDP-17).19 In 1998 mutations in the tau gene were identified in a 
large number of these families, confirming the common origin of these syndromes.3-5 
However, the great clinical diversity, both within families and between families, has 
complicated ascertainment of suitable patients for genetic studies.  
During this study, we regularly requested participating physicians to refer patients with 
suspected FTD. However, as can be derived from the names of above mentioned 
syndromes, familiar FTD may present with a variety of clinical features not typical of 
FTD. Indeed, the novel S320F mutation described in chapter 4.1 was found in a patient 
initially diagnosed with AD. Only after neuropathological examination showing 
tauopathy without any amyloid deposition, mutation analysis of the tau gene was 
performed. This clearly shows how other familial FTD cases with atypical presentation 
may have been missed. Indeed, the virtual absence of intronic tau mutations in the 
Dutch population may be explained non-referral or exclusion of patients with prominent 
parkinsonian features. However, intronic mutations were also absent in the French 
population.20,21 Furthermore, sequencing of the tau gene in a series of patients with AD 
did not reveal any mutations, making the S320F patient probably an exception.22 
In establishing the frequency of tau mutations in the Dutch FTD population, we were 
faced with the problem of referral bias. FTD patients with a positive family history are 
more likely to be referred, as family members are more keen to gain information and to 
contribute to research for future generations. This bias leads to an overestimation of 
familiar forms of FTD, and is even present in pathology series, as next-of-kin are often 
more willing to consent to autopsy in familial disorders. Most studies report similar 
findings of positive family history in about 40% of FTD patients, but the percentage of 
tau mutations ranges considerably.23-25 Both the Dutch and the Swedish FTD population 
have a positive family history of dementia in about 35 to 40% of patients, but mutations 
were found in 14% in the Dutch (chapter 2.1) and in none of the Swedish patients.25 
Although population-dependent factors cannot be excluded (founder effect of common 
mutations), this difference may also be due to application of stringent diagnostic criteria 
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in our study, as well as the evaluation of family history. We considered the family history 
only to be positive if a first degree relative developed signs of dementia before the age 
of 80, in order to exclude FTD patients with a family member with AD at old age. The 
criteria used in the Swedish population are unclear and may be less strict.25 
A final methodological consideration concerns the evaluation of the pattern of 
inheritance in familiar cases. Up to date, nearly all mutations in the tau gene have an 
autosomal dominant effect with a high degree of penetrance. Only one pedigree has 
been reported with PSP patients homozygote for a tau mutation (∆N296), with 
heterozygotes being less severely affected (late onset parkinsonism).26 Recessive forms of 
FTD may exist and consanguinity of parents may point in this direction. However, the 
finding of non-penetrance in the family with the L315R mutation (chapter 4.2) 
emphasises that family history should be extensively evaluated. If multiple siblings are 
affected and both parents reached old age without dementia, this may be due to non-
penetrance in the parents due to a dominant mutation. Further evaluation of second 
degree relatives may reveal which type of inheritance it concerns if DNA is not available.   
 
Main findings and their implications 
 
The tau gene in hereditary frontotemporal dementia 
At the present, over 20 different tau mutations have been identified in patients with 
familiar FTD (chapter 1.3).27 Although much has been learnt since 1998 regarding the 
effect of tau mutations, it is currently still unknown how they lead to neuronal cell death. 
The complexity of tau function, effects of mutations and involvement in 
neurodegeneration is reviewed amongst others by Shahani et al.28 
Most mutations cluster around the 5’-end of the tau gene in exons 9 to 13, although 
mutations in a single codon in exon 1 have been reported.29,30 Mutations may affect the 
alternative splicing of exon 10 (measured by exon-trapping and resulting in an altered 
ratio of 3 to 4 repeat tau), alter the binding properties of tau with respect to tubulin 
(resulting in a decreased microtubule assembly rate), or enhance the self-aggregation of 
tau into filaments. Functional studies are available to measure all three effects in vitro, 
and are frequently used to evaluate whether an observed base-change may be 
pathogenic. Unfortunately, the severity of the effect of the mutation does not correlate 
well with the observed phenotype in patients. For instance, the R406W mutation causes 
a severe reduction of microtubule assembly rate,31 while patients with this mutation have 
a relatively late age at onset and longer duration of disease.32 
The two novel tau mutations reported in chapter 4.1 (S320F) and 4.2 (L315R) are the 
only two mutations found to date in exon 11 of the tau gene. Both mutations were 
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associated with extensive tau pathology with Pick-like inclusions, although the astrocytic 
tau pathology observed in L315R was not present in S320F. These mutations are only 5 
amino acids separated from each other, but have a very different effect on the binding 
properties of the tau protein. The amino acid change in S320F is located within the 
microtubule binding domain of the protein and subsequently results in a large (95%) 
reduction of the microtubule assembly rate. The L315R mutation, however, is located 
outside the microtubule binding domain and the microtubule assembly rate was reduced 
by only 20 to 25%. The filament assembly rate was also mildly affected in L315R, with 
just a 15% increase in only the 4 repeat isoforms. Together with the extreme variance in 
age at onset in patients with the L315R mutation, this suggests that other mechanisms 
probably play a role in the pathogenic effect of tau mutations in general. 
Mutations in most dominant disorders usually result in a gain of function of the mutated 
protein. Loss of function of the tau protein due to a dominant tau mutation is less likely, 
as experimental studies with tau knock-out mice do not reveal a severe phenotype.33 The 
fact that tau mutations lead to a neurodegenerative disorder with onset at adult age is 
also more consistent with a slow accumulation of a toxic process over time. A gain of 
function of mutated tau protein may be found in a toxic effect of either the unbound tau 
protein itself (for instance in hyperphosphorylated state), tau aggregates (dimers, 
oligomers or  filaments), or degradation products of the mutated tau protein. The 
different mechanisms by which tau mutations may lead to neurodegeneration are 
schematically represented in Figure 1. Identification of the correct pathway to 
neurodegeneration may lead to the development of functional studies that measure an 
effect of tau mutations which shows more correlation to the clinical phenotype. 
Neuropathologically, all tau mutations are characterised by the accumulation of 
filamentous tau in the cytoplasma of affected neurons and glial cells. Aggregation of tau 
into insoluble filaments may however be a mechanism by which neurons neutralise 
mutant tau protein. Similar observations have been made in experimental models of 
polyglutamine disease, where interruption of inclusion formation by mutant 
polyglutamine results in enhanced toxicity.34 Recently, excessive accumulation of proteins 
(such as synucleins, serpins, amyloid and tau) became recognised as a common cause 
for stress of the endoplasmic reticulum (ER), and subsequent cellular malfunction and 
apoptosis. This interesting observation might explain part of a common pathogenic 
pathway of accumulation of apparently heterogeneous proteins in different 
neurodenerative disorders.35-37  
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Interaction between tau and other proteins, such as beta-amyloid (Aβ1-40 and Aβ1-42), is 
also subject of much research at this moment. AD is neuropathologically characterised 
by both deposition of Aβ and tau in affected brain regions. Mutations found in 
hereditary AD (amyloid precursor protein gene (APP), presenilin 1 and 2 genes) all lead 
directly to increased production of Aβ, making this probably one of the first steps in the 
cascade to neurodegeneration in AD, with tau deposition playing a secondary role. FTD 
patients with tau mutations rarely develop Aβ deposition (amyloid plaques), suggesting 
that these mutations intervene at a later stage and that the cascade to 
neurodegeneration is a one-way street.38 Induction of tau pathology by Aβ has been 
observed in experimental studies. Lewis et al. showed that double mutant tau/APP 
transgenic mice have a much more severe phenotype and degree of tau pathology than 
transgenic mice with only tau mutations.39 This observation is especially interesting when 
one takes into account that APP transgenic mice show only Aβ deposition and never tau 
pathology, unlike AD patients. Secondly, Aβ injected into the cortex of mice transgenic 
for the P301L tau mutation showed a severe increase in tau deposition.40 This increase 
was not found at the cortical injection site, but in the amygdala from where the axons 
project. In light of this knowledge, the Aβ deposition in FTD patients with tau mutations 
(chapter 4.3), probably due to an unrelated cause such as old age or co-occurrence of 
AD, may well have accelerated tau deposition in these patients, resulting in more severe 
pathology than in other patients with the same mutation and comparable disease 
duration. 
 
FTDP-17 without tau mutations 
Tau mutations account for only 10 to 50% of all cases of familiar FTD23,24,41 with the 
genetic cause for the remaining patients still unknown at this point in time. A number of 
families with linkage to the tau-containing region of chromosome 17q21-22 show 
neither tau mutations, nor tau pathology at neuropathological examination.42-44 
Although this is in sharp contrast to all of the patients with known tau mutations, it 
cannot be excluded that these patients have a novel type of tau mutation (for instance in 
the regulatory region of the gene) which may lead to neurodegeneration through a 
different mechanism. Zhukareva et al. reported that patients from one of these families 
(HDDD2), as well as a number of sporadic FTD patients with Dementia Lacking 
Distinctive Histology (DLDH), were characterised by loss of normal brain tau protein.45 
Although this observation might explain the lack of tau deposition in these patients, it is 
hard to imagine that a dominant mutation (present in only one of the two tau gene 
copies) may lead to less than 50% production of tau protein. Furthermore, transcription 
of the tau gene in these patients was normal, making mutations in the regulatory regions 
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unlikely. The authors suggest that the problem would therefore be post-transcriptional, at 
the level of translation or messenger RNA stability.45 Remarkably, the loss of brain tau 
was found both in brain regions with and without neurodegeneration. This is in contrast 
to FTD patients with tau mutations, in whom tau deposition takes place only in the 
regions with neurodegeneration, mainly the frontotemporal cortex. So far, the 
observation of reduced levels of tau protein in subgroups of FTD patients has not been 
reproduced by other groups.46 In my opinion, it is more likely that a second gene, 
located close to the tau gene, is involved in this type of FTD. 
The Dutch HFTD3 family (chapter 5.1) shows ubiquitin-positive inclusions, which are not 
found in DLDH, and normal levels of normal brain tau, suggesting a different aetiology. 
A family with similar pathological features, also from the Netherlands, has been reported 
by Rademakers et al.47 Linkage to chromosome 17q21-q22 was also found in this 
family, with a maximal lod-score of 5.5. When we combine genetic information of both 
of these families, assuming a common genetic defect, linkage is restricted to a 4 Mbp 
region containing about 130 genes, including the tau gene. Before mutations in the tau 
gene were identified, a number of candidate genes were sequenced in the search for 
pathogenic mutations in FTDP-17. The gene for Glial fibrillary acidic protein (GFAP), is 
still located within the critical region of linkage, but was sequenced by Isaacs et al. 
without mutations being found in a number of FTD families, including HFTD3 and 
HDDD2.48 Two other genes which were sequenced at this time, NIK protein kinase and 
C17orf1, now lie outside the critical region of linkage.49 However, a number of 
interesting candidate genes remain. 
First of all, a recently discovered gene named Saitohin is located within intron 9 of the 
tau gene.50 A single nucleotide polymorphism that results in an amino acid change 
(Q7R), in complete linkage disequilibrium with the well-defined extended tau haplotype, 
was associated with late-onset AD (RR genotype).50 Although this could not be replicated 
in two subsequent studies with larger AD populations,51,52 a trend towards an association 
between the QQ genotype and FTD was found.51 The saitohin Q allele can be 
considered as a novel determinant of the tau H1 haplotype, which has previously also 
been implicated in FTD,53 as well as a number of tauopathies such as PSP and CBD.54,55 
The function of the saitohin gene is largely unknown, although it’s expression profile is 
similar to that of tau. The reported association might be due to the influence of the tau 
gene, and more work is clearly needed to clarify the association.   
One of the most promising candidate genes within the region of linkage on 17q21-q22 
is the Gamma-tubulin gene. The protein is probably a universal component of the 
microtubule organising centers and although gamma-tubulin is present at less that 1% 
of the level of alpha- and beta-tubulin, it is limited to the centrosome.56 In particular, it is 
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associated with the pericentriolar material, the microtubule-nucleating material of the 
centrosome. This is of particular interest with respect to the localisation of the ubiquitin-
positive inclusions found in the HFTD3 family, which are preferentially located directly 
adjacent to the nucleus. Another interesting candidate gene is the Proteasome activator 
subunit 3 (PSME3) gene.57,58 The corresponding protein is part of the proteasome 
activator 28 (PA28) complex, which is an alternative proteasome activator that does not 
employ the use of ubiquitin in protein degradation. Hypothetically, mutations in this 
gene may lead to disruption of the PA28 complex, resulting in excessive use of the 
ubiquitin-dependent pathway of protein degradation, which may ultimately lead to 
accumulation of ubiquitinated proteins in inclusions or stress on the ER. 
 
Other forms of hereditary frontotemporal dementia 
Genetic heterogeneity is further emphasised by the identification of three additional loci 
in pedigrees of patients with FTD and related disorders. First of all, linkage to the 
pericentromeric region of chromosome 3 was found in a large Danish pedigree 
described by Brown et al.59 The clinical features in this family fulfil the Lund-Manchester 
criteria for probable FTD, although involvement of the parietal lobes was quite 
prominent on neuroimaging.60 In contrast to our HFTD3 family (chapter 5.1), the 
neuropathological changes in the Danish family are compatible with the diagnosis 
DLDH, without tau- or ubiquitin-positive deposits. The region of linkage is about 23.6 
Mbp, but contains only about 125 genes, mostly of unknown function making it difficult 
to identify a good candidate gene. However, some of the genes with known function 
show some promise. For instance, the gene for the serotonin receptor, as reduced levels 
of post-synaptic serotonin have been found in post-mortem studies of FTD patients.61-64 
Furthermore, a partial treatment response to SSRIs was found in a small sample of FTD 
with behavioural problems.65  
Hosler et al. found linkage to a 12 Mbp locus on chromosome 9q21-q22 in a group of 
22 families with both FTD and amyotrophic lateral sclerosis (ALS).66 Linkage to this locus 
was not found in a subset of families with only ALS, suggesting a specific phenotype for 
this locus. Features of ALS or motor neurone disease (MND) occurred in only about 4% 
of our total population, although six of these patients came from families with autosomal 
inheritance of both dementia and ALS. Unfortunately, it is difficult to obtain DNA for 
linkage analysis in these families, as patients with ALS or MND have a very rapid disease 
progression. Neuropathologically, FTD with MND is characterised by ubiquitin-positive 
inclusions, similar to those found in family HFTD3 (chapter 5.1), although none of the 
family members had any signs of MND. The region of linkage on chromosome 9q21-
q22 contains 94 genes, none of which show any functional similarity to the candidate 
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genes discussed for chromosome 17q21-q22. It may be interesting to compare genes 
with unknown function in both regions of linkage for homology.  
Finally, linkage to another region on chromosome 9 (9p13.3-p12) was found by 
Kovach et al. in four families with autosomal inheritance of a unique syndrome: 
premature FTD, inclusion body myopathy (IBM), and Paget's disease of bone.67 
Neuropathological features from these families are incompletely established, making it 
difficult to classify the dementia into one of the subgroups. The association with IBM is 
however very interesting, as deposition of both tau and amyloid has been described in 
muscle biopsies of patients with sporadic IBM, accentuating the similarity to 
neurodegenerative disorders such as AD.68,69 Mutations in the UDP-N-
acetylglucosamine-2-epimerase/N-acetyl-mannosamine kinase (GNE) gene, located 
within the critical region of linkage, have recently been found in recessive forms of IBM 
without FTD.70 It is possible that different types of mutations within the same gene may 
lead to different phenotypes (allelic variants), making the GNE gene also a good 
candidate for this autosomal dominant disorder. 
 
Suggestions for future research 
 
The Lund-Manchester criteria (in combination with neuroimaging and psychometric 
evaluation) are very accurate in distinguishing FTD from other neurodegenerative 
disorders, reaching a sensitivity and specificity of about 97%.71 However, it is difficult to 
accurately diagnose FTD at early stages of the disease, even with the aid of new 
functional imaging techniques. In light of the progression made regarding new 
therapeutic interventions, it is of the utmost importance to identify biological markers 
that can differentiate early signs of FTD from both psychiatric and other 
neurodegenerative disorders. Much attention is currently being paid to the analysis of 
CSF, with promising results for AD with respect to the application of total tau, phospho-
tau and amyloid measurement in a diagnostic setting.72,73 CSF analysis in patients with 
FTD has lead to some contrasting results. For instance, increased CSF total-tau has 
been found by some groups, but not by others.25,74,75 This is not very surprising, given the 
fact that FTD is a clinical syndrome that may be caused by a number of different 
neuropathological disorders. Unfortunately, there are currently no accurate ways to 
predict the subtype of pathology based on clinical or radiological features. As shown in 
chapter 4.4, patients with tau mutations (known to be associated with deposition of tau 
protein in affected brain regions), did not have an increase in either total tau or 
phospho-tau181 in CSF. Therefore, it is of importance that findings from CSF analyses 
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are related to the post-mortem diagnosis, as the relationship between neuropathology 
and subsequent protein changes in CSF is more complex than previously expected.    
The novel tau mutation L315R (chapter 4.2) is associated with a very variable 
phenotypic expression, with one carrier dying at the age of 33 of Pick's disease and 
another carrier being cognitively intact at age 82. This is in contrast to most other tau 
mutations, which show a high degree of penetrance and less variation in the age at 
onset of FTD.31 Therefore, this family is extremely interesting with respect to identification 
of possible modifying factors, either of genetic or environmental origin. Identification of 
protective or detrimental modifying factors will lead to more understanding regarding 
the effect of tau mutations on neuronal cell loss, and may eventually lead to 
development of new therapeutic interventions. 
Regarding family HFTD3 (chapter 5.1), if sequencing of candidate genes does not yield 
any new information, it will be important to identify which proteins accumulate within the 
ubiquitinated inclusions. New techniques for analysing protein composition of tissue, for 
instance mass spectrometry, may be of value in the identification these proteins. Because 
fresh-frozen brain tissue from this family is very scarce, it may be prudent to analyse 
brain tissue from unrelated patients with FTD with ubiquitin inclusions, as the pathology 
of both subtypes is remarkably similar.  
Finally, the main question which arises when studying neurodegenerative disease is: why 
are specific cell populations more vulnerable in specific disorders? The fact that different 
diseases present with typical clinical symptoms is largely related to the subgroup of 
neurons which are affected by the disease. The neurons of the frontal and anterior 
temporal lobes progressively degenerate in FTD, with relative sparing of the parietal and 
occipital lobe at even late stages of the disease. Although we have learnt much 
regarding tau function and dysfunction, it is currently still unclear why a germ-line 
mutation in a gene coding for a protein expressed in neurons throughout the brain, 
should lead to problems is such specific groups of neurons. Although this will be a 
difficult question to answer, with the development of microchip arrays we have a 
powerful tool to screen for a large number of transcription factors and proteins in 
different brain regions, giving more insight in the differences between specific cell 
populations, and possibly resolving this enigma.  
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Summary 
 
Frontotemporal dementia (FTD) is a neurodegenerative disorder of mainly presenile 
onset, characterised by progressive behavioural disturbance, aphasia, and a decline in 
frontal cognitive functions. Although FTD is a relatively rare disorder compared to the 
more common Alzheimer’s disease, research regarding FTD is of importance for a 
number of reasons. First of all, accurate diagnosis of FTD at an early stage of the 
disease is necessary to improve the value of clinical studies, especially in light of future 
therapeutic interventions. Secondly, elucidation of the pathophysiological pathways 
leading to neurodegeneration in FTD may yield knowledge regarding a number of 
related neurodegenerative disorders. The identification of mutations in the tau gene in 
hereditary FTD is an important example in this respect. 
This aim of this thesis was to describe epidemiological and clinical characteristics of the 
FTD patient population in the Netherlands, with emphasis on hereditary forms of FTD. 
This study was part of an ongoing population-based genetic-epidemiological study on 
FTD in the Netherlands, which was started in 1994 at the Erasmus University Rotterdam. 
Chapter 1.1 gives an general introduction to the thesis. This is followed by an 
introduction to FTD in general in chapter 1.2, and an introduction to hereditary forms 
of FTD in chapter 1.3. 
Chapter 2 describes two epidemiological studies on FTD. Chapter 2.1 presents 
prevalence estimates on FTD in the Netherlands, with emphasis on the prevalence in the 
province Zuid-Holland where the study centre is located. FTD was diagnosed in 245 
patients (51% female), the largest FTD patient population described to date. The 
prevalence of FTD in the province Zuid-Holland was higher than reported in previous 
studies, with a maximum of 9.4 per 100.000 inhabitants at age 60 to 69 years. Tau 
mutations were found in 34 patients, all with a positive family history for dementia (14% 
of the total population; 32% of patients with a positive family history). Chapter 2.2 
concerns a retrospective case-control study with 80 patients with the sporadic form of 
FTD and 124 age, sex, and surrogate informant matched control subjects, regarding 
various medical and environmental risk factors. Head trauma was associated with a 3.3 
times increased risk of FTD (95% confidence interval: 1.3 to 8.1) and thyroid disease 
with a 2.5 times increased risk (95% CI: 0.9 to 7.9). This study is the first to address 
non-genetic risk factors for sporadic FTD, and further studies will be important to 
confirm the observed associations. 
Chapter 3 focuses on FTD patients with mainly temporal atrophy, a clinical subgroup 
of FTD not formally recognised until the new criteria for FTD in 1998. Chapter 3.1 
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investigates the correlation between complex compulsive behaviour (CCB) and the 
distribution of atrophy in a group of 90 FTD patients. Logistic regression analysis 
showed that temporal lobe atrophy (p<0.005), as well as asymmetry of atrophy 
(p<0.05) were independently associated with CCB, after adjusting for age at onset, 
gender, duration of symptoms at the time of imaging, severity of atrophy, and bicaudate 
and bifrontal ratio. This suggests that temporal lobe atrophy may mediate CCB in 
patients with FTD, especially if asymmetry of atrophy is present. Chapter 3.2 is a letter 
on the association between the apolipoprotein E4 allele and distribution of atrophy in 
FTD patients. Although the frequency of the ApoE4 allele was not increased in FTD 
patients compared with non-demented controls, in the subgroup of FTD patients with 
temporal atrophy the ApoE4 allele was significantly more common, suggesting that 
apoE genotype may be involved in determining the distribution of atrophy in FTD. 
The role of the tau gene in hereditary FTD is explored in Chapter 4. In chapter 4.1 
and 4.2 we describe families with presenile dementia due to novel missense mutations 
in exon 11 of the tau gene, namely S320F and L315R. To our knowledge, they are the 
first mutations to be described in exon 11 of tau. Clinical, pathological, biochemical 
data are presented, as are functional studies regarding the effect of the mutations on tau 
function in vitro. These mutations highlight the importance of variable clinical 
penetrance and the need to develop functional studies which measure effects of tau 
mutations which correlate with the clinical phenotype. Chapter 4.3 describes the 
neuropathological findings in five patients with P301L and in two patients R406W tau 
mutations. Amyloid pathology is observed in two patients (one P301L and one R406W), 
both with deposition sarkosyl-insoluble tau protein, consisting of four bands (60, 64, 68, 
and 72 kDa) and containing all six tau isoforms, in the temporal cortex. Although the 
FTD and Alzheimer’s disease-type changes are probably concomitant, there may be an 
interaction between tau and amyloid pathology, in the form of acceleration of tau 
pathology due to amyloid deposition. In chapter 4.4 we analysed total tau, 
phosphotau 181, and amyloid-β1-42 in CSF of 26 FTD patients, including nine with tau 
mutations (seven P301L, two G272V). Although CSF total tau was mildly increased in 
FTD, this increase was not seen in the subgroup with tau mutations. Furthermore, CSF 
phospho-tau 181 and Aβ1-42 levels were not different compared with non-demented 
controls. Thus, we conclude that the tau pathology present in P301L and G272V brain 
does not appear to be associated with an increase in either CSF total tau or phospho-
tau 181, and that the relationship between neuropathological changes in the brain and 
subsequent protein alternations in CSF is more complex than expected.  
Chapter 5 deals with hereditary forms of FTD that do not show any tau mutations. In 
chapter 5.1 we describe the clinical and neuropathological features of a large family 
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with hereditary FTD. Genetic analysis showed strong evidence for linkage to 
chromosome 17q21-22 (maximum lod score 3.46, θ=0 for marker D17S950), but 
mutations in the tau gene were not found. Pathological examination of the brains of two 
affected family members showed non-specific neuronal degeneration with ubiquitin-
positive inclusions in neurones. Biochemical analysis of soluble tau did not reveal 
abnormalities in tau isoform distribution. Therefore, we suggest that the FTD in this 
family may be caused by a gene other than the tau gene itself, located within the same 
region on chromosome 17q21-q22.  
In chapter 6 methodological considerations of these studies are presented, focussing 
mainly on different aspects of study design in epidemiological studies. The most 
important findings of the study are also reviewed and finally suggestions for future 
research are made. 
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Samenvatting 
 
Frontotemporale dementie (FTD) is een neurodegeneratieve aandoening met een 
voornamelijk preseniele presentatie, gekarakteriseerd door progressieve 
gedragsstoornissen, afasie, en een teloorgang van de frontale cognitieve functies. 
Hoewel FTD een relatief zeldzame aandoening is vergeleken met de veel vaker 
voorkomende ziekte van Alzheimer, is onderzoek naar FTD van belang voor een aantal 
redenen. Ten eerste, een betrouwbare diagnose van FTD in een vroeg stadium van de 
ziekte is belangrijk voor de verbetering van de betrouwbaarheid van klinische 
onderzoeken, vooral met het oog op toekomstige therapeutische opties. Ten tweede, 
verheldering van de pathofysiologische mechanismen van neurodegeneratie in FTD kan 
leiden to inzicht in een groot aantal andere verwante aandoeningen. De identificatie van 
mutaties in het tau gen in erfelijke FTD is hier een belangrijk voorbeeld van.  
Het doel van dit proefschrift was het beschrijven van epidemiologische en klinische 
eigenschappen van de Nederlandse FTD populatie, met nadruk op de erfelijke vormen 
van FTD. Deze studie is onderdeel van een lopende genetisch-epidemiologische studie 
naar FTD in Nederland, welke in 1994 is opgezet aan de Erasmus Universiteit 
Rotterdam. 
Hoofdstuk 1.1 is een algemene inleiding van het proefschrift. In hoofdstuk 1.2 
wordt een introductie over FTD in het algemeen gegeven, terwijl hoofdstuk 1.3 zich 
richt op met name de erfelijke vorm van FTD 
Hoofdstuk 2 beschrijft een tweetal epidemiologische studies naar FTD. Hoofstuk 
2.1 presenteert prevalentie schattingen van FTD in Nederland, met nadruk op de 
prevalentie van FTD in Zuid-Holland, de provincie waar de Erasmus Universiteit 
Rotterdam zich bevindt. De diagnose FTD werd gesteld in 245 patiënten (51% vrouwen), 
de grootste FTD populatie tot op heden beschreven. De prevalentie van FTD in Zuid-
Holland was hoger dan eerder werd gerapporteerd, met een maximum van 9.4 per 
100.000 inwoners in de leeftijd van 60 tot 69 jaar. Tau mutaties werden gevonden in 
34 patiënten, allen met een positieve familie anamnese voor dementie (14% van de 
totale populatie, 32% van de patiënten met een positieve familie anamnese). 
Hoofdstuk 2.2 betreft een retrospectieve case-control studie met 80 patiënten met de 
sporadische form van FTD en 124 leeftijd, geslacht en heteroanamnese gematchde 
controle personen, aangaande diverse medische en omgevingsfactoren. Hoofdtrauma 
was geassocieerd met een 3.3 maal verhoogde kans op FTD  (95% betrouwbaarheids 
interval: 1.3 to 8.1) en schildklier aandoeningen met een 2.5 maal verhoogde kans 
(95% BI: 0.9 to 7.9). Deze studie is tot op heden de eerste die zich richt op non-
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genetische risico factoren voor FTD, en verder onderzoek zal van belang zijn om de 
gevonden associaties te bevestigen.   
Hoofstuk 3 betreft FTD patiënten met vooral temporale atrofie, een klinische subgroep 
die pas sinds de nieuwe criteria van 1998 officieel wordt herkend. Hoofdstuk 3.1 
onderzoekt de correlatie tussen complex dwangmatig gedrag en de verdeling van atrofie 
op structurele beeldvorming in een groep van 90 FTD patiënten. Met logistische 
regressie analyse werd aangetoond dat met name temporale atrofie (p<0.005), maar 
ook asymmetrische atrofie (p<0.05) onafhankelijk van elkaar zijn geassocieerd met 
dwangmatigheid, na aanpassing voor beginleeftijd, geslacht, duur van de symptomen 
tijdens beeldvorming, ernst van de atrofie, bicaudatus ratio en bifrontale ratio. Dit 
suggereert dat de temporaal kwab een rol speelt bij het ontstaan van dwangmatigheid 
in FTD, vooral als er sprake is van asymmetrische atrofie. Hoofdstuk 3.2 is een brief 
over de associatie tussen het apolipoproteïne E4 allel en de verdeling van atrofie in FTD 
patiënten. Hoewel de frequentie van het ApoE4 allel niet verhoogd was bij patiënten met 
FTD vergeleken met niet-dementerende controle personen, was in de subgroep van FTD 
patiënten met temporale atrofie het ApoE4 allel significant vaker aanwezig. Dit 
suggereert dat het ApoE genotype een rol speelt in het bepalen van de distributie van 
atrofie in FTD. 
De rol van het tau gen in de erfelijke vorm van FTD wordt bestudeerd in Hoofdstuk 4. 
In hoofdstuk 4.1 en 4.2 beschrijven we een aantal families met preseniele dementie 
ten gevolge van nieuwe mutaties in exon 11 van het tau gen, namelijk S320F en L315R. 
Tot op heden zijn dit de enige mutaties gevonden in exon 11 van tau. Klinische, 
pathologische en biochemische bevindingen worden beschreven, als ook functionele 
studies die het effect van de mutaties in vitro meten. Deze mutaties benadrukken het 
belang van variabiliteit in klinische penetrantie en de noodzaak om functionele 
testmethoden te ontwikkelen die effecten van mutaties meten die correleren met het 
klinisch fenotype. Hoofdstuk 4.3 beschrijft neuropathologische bevindingen in vijf 
patiënten met P301L en twee patiënten R406W tau mutaties. Amyloid pathologie werd 
gevonden in twee patiënten (een P301L en een R406W), beiden met depositie van 
sarkosyl-onoplosbaar tau eiwit, bestaande uit vier banden (60, 64, 68, en 72 kDa) die 
alle zes de tau isoformen bevatten, in de temporale cortex. Hoewel deze FTD en AD-
achtige veranderingen waarschijnlijk concomitant zijn, is het mogelijk dat er een 
interactie tussen tau en amyloid pathologie optreedt in de vorm van een acceleratie van 
de tau pathologie door amyloid depositie. In hoofdstuk 4.4 analyseerde we totale 
tau, phosphotau 181, and amyloid-β1-42 concentraties in liquor cerebrospinalis van 26 
FTD patiënten, waarvan negen mutaties in het tau gen hadden (zeven P301L, twee 
G272V). Hoewel de totale tau concentratie licht verhoogd was in de FTD groep, bleek 
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deze toename niet aanwezig te zijn in de subgroep van patiënten met tau mutaties. 
Bovendien, phospho-tau 181 en Aβ1-42 concentraties in de liquor cerebrospinalis waren 
niet verschillend vergeleken met niet-dementerende controle personen. Hierdoor 
concluderen wij dat de tau pathologie die gevonden wordt in hersenen van patiënten 
met P301L en G272V mutaties niet gepaard gaat met een toename van totale tau of 
phospho-tau 181 in de liquor, en dat de relatie tussen neurodegeneratie en de 
daaropvolgende eiwit veranderingen in de liquor meer complex is dan verwacht.  
Hoofdstuk 5 richt zich op de erfelijke vormen van FTD waarbij geen mutaties in het 
tau gen worden gevonden. In hoofdstuk 5.1 beschrijven we de klinische en 
neuropathologische kenmerken van een grote familie met FTD. Genetisch onderzoek 
leverde bewijs voor koppeling aan het tau-bevattende deel van chromosoom 17q21-
q22 (maximale lod score 3.46, θ=0 voor marker D17S950), maar mutaties in het tau 
gen werden niet gevonden. Pathologisch onderzoek van de hersenen van twee 
aangedane familieleden toonde aspecifieke neuronale degeneratie met ubiquitine-
positieve inclusies in neuronen. Biochemisch onderzoek van oplosbaar tau eiwit liet 
geen afwijkingen zien in de distributie van de tau isoformen. Het is daarom goed 
mogelijk dat de FTD in deze familie wordt veroorzaakt door een ander gen, dat gelegen 
is in de nabijheid van het tau gen zelf.  
In hoofdstuk 6 worden methodologische aspecten van deze studie besproken, met 
nadruk op de verschillende technieken in epidemiological studies. De belangrijkste 
bevindingen van de studie worden doorgenomen en als laatste worden suggesties voor 
toekomstig onderzoek gemaakt.  
 
 160 
 
 
Dankwoord 
 
Dit proefschrift zou niet tot stand zijn gekomen zonder de betrokkenheid van velen. 
Naast alle artsen die onmisbare FTD patiënten hebben verwezen, wil ik vooral de 
patiënten zelf en hun familieleden bedanken voor hun onbaatzuchtige deelname.  
Een aantal mensen wil ik in het bijzonder bedanken. Ten eerste mijn co-promotor John 
van Swieten, de stuwende kracht achter het FTD project sinds 1993. Beste John, hoewel 
je me - toen we elkaar net leerde kennen - waarschuwde voor je ‘moeilijke’ karakter, 
heb ik geen moment spijt gehad dat ik aan dit onderzoek ben begonnen. Ik heb erg 
gewaardeerd dat je me zoveel vrijheid hebt gegeven om diverse terreinen te ontdekken: 
de kliniek, het laboratorium en de microscoop. De afgelopen vier jaar zijn daardoor 
geen moment saai geweest en dat straalt hopelijk van dit boekje af. Ik hoop dat we 
komende jaren nog veel zullen samenwerken. Daarnaast mijn tweede co-promotor Peter 
Heutink. Beste Peter, jouw deur stond altijd open voor mij als ik weer eens vast zat met 
lastige genetische vraagstukken. Zelfs als ik je buiten tegen kwam - ‘s avonds in de 
supermarkt! - had je tijd om uitgebreid met me te discussiëren over FTD. Ik hoop ten 
zeerste dat onze samenwerking nog lange tijd mag blijven bestaan nu je vertrekt naar 
‘de grote stad’! 
Mijn beide promotoren, Prof.dr. P.A.E. Sillevis Smitt en Prof.dr. W.F. Niermeijer. Beste 
professor Sillevis Smitt, het was vast voorbestemd dat u mijn promotor zou worden, daar 
precies 50 jaar geleden één van mijn weinige voorgangers in Nederland, J. van 
Mansvelt, promoveerde bij een andere Prof.dr. Sillevis Smitt op het onderwerp Ziekte 
van Pick (1953). Hoewel onze samenwerking nog maar van korte duur is, hoop ik dat ik 
komende zes jaar nog veel van u kan leren. Beste professor Niermeijer, over de 
afgelopen vier jaar heb ik van niemand zulke heldere (en vaak ook uitgebreide!) 
correcties op manuscripten ontvangen als van u. Gelukkig kunt u nu van een 
welverdiende pauze genieten en deze laatste versie zonder pen in de hand door te 
lezen! 
Ook de overige commissieleden ben ik zeer dankbaar: Prof.dr. P.J. Koudstaal, Prof.dr. 
C.M. van Duijn, Prof.dr. B.A. Oostra en Dr. J.M. Kros. Beste professor Koudstaal, 
zonder u stond ik mogelijk nog steeds niet op het rooster voor de kliniek. Nu is aan u de 
zware taak om van deze onderzoekster een goede dokter te maken: sterkte! Professor 
van Duijn, beste Cock, hartelijk dank voor de fijne samenwerking en de genetisch-
epidemiologische kennis van de afgelopen jaren; ik hoop die nu ook zelfstandig in de 
praktijjk te kunnen gaan brengen! Beste professor Oostra, hartelijk dank voor de goede 
commentaren op mijn discussie. Ik hoop dat ik u een fijne vlucht heb bezorgd. Dr. J.M. 
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Kros, beste Max. Mijn wetenschappelijk carrière begon bij jou vele jaren geleden (een 
goede start is het halve werk!) en ik ben dan ook erg blij dat onze samenwerking zich 
heeft voortgezet en je nu in de commissie plaats wilt nemen.  
Deze studie is het gevolg van samenwerking tussen vele verschillende afdelingen binnen 
en buiten het Erasmus MC. Ten eerste, The Brain Repair Centre, Cambridge, United 
Kingdom. Dr. M.G. Spillantini, dear Maria. Thank you so much for inviting me to 
Cambridge to try to solve the riddle of the ubiquitin inclusions in family 3. Although I 
only managed to isolate GFAP, I enjoyed the time at your lab and learned so much from 
your enormous enthousiasm for science. Dr. M. Goedert, Dear Michel, thank you also 
for your kind hospitality, your collaboration with the microtubule binding assays, and 
your amazingly quick and thorough comments on several manuscripts. Cambridge 
would not have been the same without Yolanda, Claudia, Bridget and Giorgios: thank 
you for making me feel so welcome! 
Ook de samenwerking met andere universiteiten is erg belangrijk geweest bij het 
verzamelen van onze grote FTD populatatie. Met name het VU Medisch Centrum, 
Amsterdam (Philip Scheltens, Yolande Pijnenburg, Niki Schoonenboom), Academisch 
Medisch Centrum, Amsterdam (Pim van Gool, Gerard Walstra), St. Radboud Medisch 
Centrum, Nijmegen (Berry Kremer, Daniëlle de Jong), en het Academisch Ziekenhuis 
Maastricht (Frans Verhey). Hartelijk dank voor jullie inspanningen voor het FTD 
onderzoek en de warme ontvangst in jullie ziekenhuizen. 
De bijdrage van de Nederlandse Hersen Bank is ook onmisbaar geweest. Dr. R. Ravid, 
beste Rivka, hartelijk dank dat ik altijd (vaak onverwacht) grote hoeveelheden coupes 
mocht komen snijden, en vooral ook dank voor de gezellige samenwerking. Helaas is 
heb ik het filmfestival dit jaar gemist vanwege dit proefschrift, maar volgend jaar ben ik 
er weer bij! Dr. W. Kamphorst, beste Wouter,  wat een ongelofelijke luxe was het om 
hele dagen met u achter de microscoop door te mogen brengen en te genieten van de 
vele ‘wonderbollen’ die de hersenen rijk zijn! Daarnaast ben ik natuurlijk ook José 
Wouda en Michiel Kooreman erg dankbaar voor hun hulp als ik weer eens vol statische 
electriciteit een poging wilde doen om - even snel - coupes te snijden. 
Ook binnen de Erasmus Universiteit is gelukkig veel samengewerkt met andere 
afdelingen. De samenwerking met de Klinische Genetica is op meerdere terreinen erg 
vruchtbaar gebleken. Esther, niet alleen zijn we een goed team als het om samen 
publiceren gaat, ook je vriendschap is me erg waardevol geworden en ik hoop dat die 
nog vele jaren blijft bestaan. Patrizia, thank you for teaching me immunohistochemistry. 
Thanks to your good instructions I’m now able to help you with your slides! Rob 
Willemsen en Lies-Anne Severijnen, hartelijk dank voor de gastvrijheid op het lab als ik 
weer eens grote series coupes kwam kleuren. Dennis Dooijes, zonder jou hadden we de 
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twee belangrijjke mutaties niet gevonden. Ook Marijke Joosse, Bianca de Graaf, Wout 
Deelen, Guido Breedveld, Leon Testers, Raoul van de Graaf, Esther de Graaf en Jeltje 
van Baren (cyber-hulp!) ben ik zeer dankbaar voor hun samenwerking. De Medische 
Psychologie, Aad Tibben en Jacqueline Mourik, en de Genetische Epidemiologie, Cock 
van Duijn, Gerwin Roks, Kristel Sleegers: hartelijk dank voor de plezierige 
samenwerking! 
Dan mijn collega’s van de Neurologie! Nu ik (al) vier weken in de kliniek aan het werk 
ben, kijk ik met veel heimwee terug naar de gezellige dagen op de 22e. Beste 
Annemarie, vier jaar hebben we samen boven gezeten, en ik hoop dat we nog zes jaar 
samen door zullen brengen ‘beneden’ in de kliniek. Ik ben erg blij dat je naast me wilt 
staan (zitten?) de 26e, want jij kan me vast tot rust manen! Beste Laura, Esther, Bregje, 
Karin, Monica, Dragan, Marcel, Liesette, Mary-Lou, Ilse, Kris, Hanneke, en Nazia: ik mis 
jullie!!! Dat zegt denk ik voldoende over hoe ik het naar mijn zin heb gehad op de 22e! 
Martijn Stevens, mijn voorganger, hartelijk dank voor al je inspanningen voor het 
onderzoek in de begin jaren. Ook de studenten die zich in hebben gezet voor het FTD 
onderzoek de afgelopen vier jaar; Timo Baks, Marieke Gieteling, EriK-Jan Landweer, en 
Mariëlle Houterman: hartelijk dank! De neuropsychologie is van groot belang geweest 
voor dit onderzoek. Beste Inge, dank je voor je fantastische beoordelingen van patiënten 
en je bereidheid afspraken te plannen wanneer het anderen goed uit kwam. Mijn 
collega’s van de kliniek wil ik ook alvast bedanken voor hun begrip de afgelopen 
weken: het is niet makkelijk als er weer een onervaren onderzoeker de afdeling op komt 
met tien-duizend onnozele vragen.  
Naast de vriendschappen op het werk, zijn natuurlijk ook de vrienden buiten het werk 
van levensbelang voor het promoveren zonder burn-out! Lieve Astrid, we kennen elkaar 
al vele jaren en ik ben je vooral dankbaar dat we altijd (maakt niet uit hoe lang we 
elkaar niet hebben gesproken) even goed contact hebben. Het is heerlijk om te weten 
dat je er altijd voor me bent en ook naast me zult staan op 26 maart! Ook de ‘meiden 
van het squash’ (het is de afgelopen jaren zoveel meer geworden dan alleen dat!), lieve 
Rascha, Aagje, Gysele, Annemiek en Mirjam: dank jullie voor het begrip deze afgelopen 
maanden van promotie-stress! Ik beloof beterschap na de 26e!  
Mijn familie, in het bijzonder mijn vader, lieve papa: hartstikke bedankt voor je 
onvoorwaardelijke steun de afgelopen (30) jaren. De wetenschap dat jij aan mijn kant 
staat geeft me het gevoel dat ik alles kan bereiken! Lieve Moon, ik ben trots op je! Toch 
ooit een duo-praktijk? Lieve Diederik, jouw afwezigheid het afgelopen half jaar was van 
doorslaggevend belang voor het tijdig afronden van dit boekje. Maar dat benadrukt 
vooral hoe belangrijk je AANwezigheid voor mij is!  
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